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Summary
Osteosarcoma (OS) is the most common malignant tumor of bone, affecting predominantly
children and young adults. Even though modern treatment regimens including pre- and
postoperative multidrug chemotherapy and surgical resection, have additional improved 5
year survival rates to currently 60-70%, no significant improvements have been achieved
in the past decades. Furthermore, the systemic chemotherapy applied lacks specificity and
can lead to severe adverse effects. New targeted cancer treatment approaches, informed by
genomic analysis, aim to exploit molecular properties specific to the neoplastic cells. However,
the genomic landscape of OS is complex and is characterized by chromosomal instability,
which has historically confounded driver gene discovery. While few and small previous
genomic studies exist, a higher sample number and state of the art analysis methods can
contribute to a more complete picture of recurring and driving events. To this end, we first
characterized the genomes of OS using high-throughput sequencing and single nucleotide
polymorphism arrays. We found features of TP53 intron 1 rearrangements suggesting a
highly specific mechanism correlated with transcription. Screening of 288 OS and 1'090 other
tumor types revealed evidence for TP53 rearrangements in 46 (16%) OS, while none were
detected in residual tumors, indicating high specificity to OS. Further, we identified a TP53
intron 1 rearrangement as the causal aberration in a four-generation Li-Fraumeni syndrome
family and showed that this rearrangement can at least partially explain the diagnostic
gap of formerly classified “TP53 wild-type” Li-Fraumeni syndrome. We then sequenced the
exomes of 31 OS and integrated the findings with the corresponding sequencing and single
nucleotide polymorphism array data from a replication set of 92 tumors. We identified 14
main driver genes, including some which were formerly unknown in the context of OS. More
than 80% of analyzed tumors furthermore exhibited a specific combination of single-base
substitutions, LOH, or large-scale genome instability signatures which are characteristic of
BRCA1/2-deficient tumors. These BRCA-like traits might be of therapeutic potential since
they could render the tumor cells susceptible to PARP inhibitor treatment, which might
constitute a novel therapeutic strategy to support current chemotherapy regimens. Last,
we screened 337 OS patients for germline alterations and identified bona fide pathogenic
mutations in the RET proto-oncogene in 2% of cases. These mutations appear to combine
functional kinase activity with dysfunctional ligand binding and expose affected individuals
to an increased risk of developing OS when compared to the normal population (odds ratio
9.12). Our findings add OS to the spectrum of RET associated diseases and highlight RET as
a potential target for multi-targeted tyrosine kinase inhibitors.
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1 Introduction
1.1 Osteosarcoma
Osteosarcoma (OS) is the most common primary malignancy of bone and mainly affects
children and young adults. OS can occur in any bone, but is most frequently observed in the
long bones around the knee (distal femur, proximal tibia, proximal fibula, 71% of all OS) and
in the proximal humerus (12%) [1], where it generally arises near the metaphyseal growth
plates. OS in the axial skeleton (skull, ribs, vertebrae, and pelvis) is rare and associated with
higher age and poor prognosis [1]. Sarcomas are neoplasms which originate from cells of
mesenchymal lineage. Besides OS, sarcomas can be divided into other subclasses, such as
chondrosarcoma (consisting of cartilage producing cells), Ewing sarcoma, and soft tissue
sarcomas. OS, chondrosarcoma, and Ewing sarcoma together make up 75% of all malignant
bone tumors [2].
1.1.1 Epidemiology
Based on data collected by the American National Cancer Institute (NCI) from 1992 to 2004,
the incidence rate of OS in children and adolescents is reported as 4.7 per million population
per year [3]. OS contributes with 35% to the incidence of primary malignant bone tumors,
followed by chondrosarcoma (25%) and Ewing sarcoma (16%) [4]. Overall, OS is the eight
most frequent tumor in children and adolescents [5]. However, OS rarely occurs in very
young children below the age of 5, which make up only 2% of described patients in the
Cooperative German-Austrian-Swiss Osteosarcoma Study Group (COSS) [6]. Children of
African American, Asian or Hispanic ethnicity are more often affected than Caucasians [7].
The age at OS diagnosis shows a bimodal distribution with a first peak in the second decade
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Figure 1 – Incidence of osteosarcoma per million population. Data was derived from
the Surveillance, Epidemiology, and End Results (SEER) program on the US population. Modified
from Savage et al. [9].
of life and a second smaller peak in the seventh and eighth decade (see figure 1 on page 2).
In elderly individuals a higher incidence of OS in combination with Paget disease is observed.
Likewise, secondary OS is more frequent in older persons, at least partially due to previous
radiation treatment [8].
1.1.2 Etiology
Compared to other malignant tumors, the etiology of OS is not well understood. In accordance
with the age distribution, skeletal growth has been found to be a host factor for OS. The
disease mainly occurs at the metaphyses of the femur and tibia, where the growth plates
are located. The first peak of the bimodal age distribution at the onset of puberty coincides
with the adolescent growth spurt. This growth spurt is earlier in girls, which is also reflected
in an earlier first incidence peak when compared to boys [10, 11]. In canines, giant breeds
are more at risk to develop OS than small-sized breeds [12]. Conflicting reports exist on the
connection between overall height and OS incidence [13, 14]. The only described exogenous
risk factor is exposure to ionizing radiation, both as a result of a therapeutic intervention or
environmental exposure. Of all pediatric cancers, patients with Ewing sarcoma are reported
to be at highest risk to develop OS as a second primary neoplasm, due to the high irradiation
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doses used in the treatment of these patients [15]. However, radiation induced OS appears
to be rare and develops after a long interval of 10-20 years [16]. Accordingly, environmental
radiation likely plays no major role in the etiology of pediatric OS. Paget disease was identified
as a risk factor for secondary OS development [17].
1.1.3 Cell of Origin in Osteosarcoma
Unlike for other neoplasms, such as the basal subtype of breast and prostate cancer for
which the cell of origin was experimentally identified as a luminal and basal progenitor cell
[18], respectively, the cell of origin in OS has not been identified conclusively. Accumulating
results from lineage-specific inducible mouse models have shown that various cell types of the
osteogenic lineage can give rise to OS, when the archetypical cancer driver genes TP53 and RB1
are targeted with a cell type specific Cre-Lox knockout system. Mesenchymal stem cell (MSC)
which attained osteoblast-specific lineage commitment seem to possess higher sarcomagenic
potential than less committed cells; TP53−/−/RB−/− mutations in mesenchymal progenitors
induced OS with an incidence of 30-60% and in osteoblast precursors in 50-100% of mice
[19]. Accordingly, bone marrow derived MSCs with a knockout of TP53 and RB1 require some
degree of osteogenic differentiation to induce OS, otherwise leiomyosarcoma-like tumors,
which usually arise from smooth muscle tissue, were observed [20]. The unsolved question
of the originating cell in OS has several implications for research and drug development.
Differential gene expression or methylation analysis of cancer cells, for example, require the
assumption of a normal cell for comparison and can therefore be difficult to perform in OS
studies.
1.1.4 The Clinical Picture of Osteosarcoma
Clinical Presentation
Patients with OS usually experience pain, often during the night, which may increase in
intensity when the growing tumor is penetrating the bone cortex (hard outer layer). Due
to the coincidence with the adolescent growth spurt, these symptoms might be mistaken
as “growing pains” [21], which can lead to a delay in diagnosis. These circumstances can
increase the chance of developing metastases before the treatment can be initiated. Physical
examination often shows local swelling and occasionally pathologic bone fracture.
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Diagnosis
The diagnosis is initially suspected clinically and further substantiated by imaging, such as
plain x-ray radiographs, as well as computed tomography (CT), and magnetic resonance
imaging (MRI) scans. Radiographs can reveal patterns of aggressive growth, such as an
elevated periosteum which gets dislocated from the bone surface by the growing tumor
(Codman triangle) or periosteal spikes extending into the surrounding soft tissue (sunburst
appearance) [22]. MRI is usually performed to investigate the exact position and extent of the
tumor, which is crucial for planning of subsequent biopsy and surgery. Also, other aggressive
features such as soft tissue infiltration and skip lesions can be observed. CT of the thorax
can reveal possible macroscopic lung metastases [23]. In some cases, increases in alkaline
phosphatase (AP) and lactic dehydrogenase can be found [24]. These measurements are,
however, of limited diagnostic value since they are also observed in other skeletal diseases,
but can correlate with adverse outcome in OS [23].
Tumor Biopsies
To confirm the diagnosis of OS, a biopsy and histopathologic assessment is required. The
necessary material can be collected either by an open or core needle biopsy. While the latter
method has the advantages of minimal invasiveness, lower costs, and reduced morbidity, core
needle biopsies can only capture small amounts of tissue that might not be sufficient to make
the diagnosis and generally leave no material for subsequent scientific studies. This makes
pretherapeutic OS samples a scarce and precious resource for biomedical studies.
The Histology of Osteosarcoma
OS belongs to the group of osteogenic tumors, which by definition are neoplasms that produce
an osteoid or bony matrix [25]. A general categorization of OS can be made according to
the site where the tumor arises in the bone and includes intramedullary or central (arising
inside the medullary canal) and surface-related types (arising from the bone surface or
periosteum) [22]. Histopathology allows the further classification into several subgroups,
based on the features of the neoplastic cells and the amount and type of osteoid or other
matrix they produce (see figure 2 on page 5). Intramedullary OS, which constitute 80-90%
of all OS, include the conventional, telangiectatic, and small cell subtypes [23, 26, 27]. The
tumor cells produce bony, cartilaginous, or fibrous matrix and based on the predominant
type of extracellular matrix and cell types, conventional OS is divided into osteoblastic,
chondroblastic, and fibroblastic subtypes [22]. Unlike conventional OS, the small cell subtype
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Figure 2 – Classification of primary osteosarcoma. The most common subtypes of OS are
shown. General classifications can be made based on the site of origin within the bone. Further histo-
logic subclassifications are defined according to the predominant cellular component and composition
of the produced bone matrix.
Figure 3 – Subtypes of conventional high-grade osteosarcoma (hematoxylin-eosin stain-
ing). A, osteoblastic subtype. B, fibroblastic subtype. C, chondroblastic subtype.
is rare and accounts for only 1-2% of cases. It is characterized by atypically small nuclei with
scant amounts of cytoplasm. Small cell OS has a slightly worse prognosis than conventional
OS [25]. Histologic differences notwithstanding, current clinical protocols treat all subtypes
of high-grade OS identically (see section 1.2.2 on page 6).
Histological Grading
In OS, low- and high-grade tumors based on cellularity, variations in size and shape of nuclei
(nuclear pleomorphism), number of mitoses and distinct growth patterns can be distinguished.
Some authors also use a three- (G1-G3) or even four-tiered (G1-G4) grading system but
the clinically relevant decision has to be made between low- and high-grade. As mentioned
above, 80-90% of OS represent conventional or surface associated high-grade lesions. The
residual types include low-grade central (G1), parosteal (G1) and periosteal (G2) tumors.
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1.1.5 Metastasizing Potential
At the time of diagnosis, 20% of OS cases show detectable metastases, most frequently in the
lungs (85-90%) or other bones (8-10%) [28, 29, 30]. Regional metastases affecting the same
bone or situated across an adjacent joint are designated as skip lesions [21]. The remaining
80% of cases are considered to have localized disease, although it is know from historical
observations (before the introduction of chemotherapy) that 80-90% of these patients die
of subsequent systemic spread nevertheless and despite immediate tumor resection. OS
is therefore considered to represent a systemic disease already at the time of diagnosis
[31]. Even with current treatment protocols, 30-40% of patients with localized OS develop
metastases or local recurrences, most of which occur within the first 2-3 years [32].
1.2 Treatment Strategies for Osteosarcoma
1.2.1 The Rise of Chemotherapy
Until the 1970s, the treatment options for OS were limited mainly to amputation, which
was associated with very poor survival of 5-20% [33]. Chemotherapy was introduced to OS
treatment in the mid 1970s, when doxorubicin and methotrexate were shown to be effective
in OS and a combination treatment using the two agents was used in some clinics [34, 35].
While initially controversial, a large multi-institutional trial later showed that the use of
bleomycin, cyclophosphamide, dactinomycin, methotrexate, doxorubicin and cisplatin as
postoperative multi-agent chemotherapy increased 5-year survival rate to 60-70% [36, 37],
whereas patients treated with amputation only showed the historically reported 20% survival
[24].
1.2.2 Current Treatment Approaches for Localized Osteosarcoma
Current treatment protocols for localized, high-grade OS are based on surgical resection
of the primary tumor and systemic pre- and postoperative multidrug chemotherapy. With
this strategy, long-term disease-free survival (DFS) can be achieved in 60-70% of pediatric
cases [38] (see figure 4 on page 7). Preoperative (neoadjuvant) chemotherapy can eradicate
micrometastases [21] and help to predict treatment response. The response to chemotherapy
is analyzed by investigating a complete section through the largest tumor diameter histologi-
cally by assessing the percentage of viable tumor. It is still regarded as the gold-standard in
prognostic prediction and distinguishes good and poor responders defined as having less or
more than 10% viable tumor residues [39]. Low-grade OS are generally only resected and
no chemotherapy is applied. Commonly combined agents are methotrexate, doxorubicin,
6
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Figure 4 – 5-year overall survival of localized osteosarcoma. A meta-analysis of 5-year
survival derived from 264 OS patient series from various clinical institutions over the time span
from 1920s to the 2000s is depicted. The numbers of included patients per decade are indicated
in parenthesis (47'227 in total). A steep rise in 5-year survival coincides with the introduction
of doxorubicin and methotrexate as standard treatment in the 1970s and 1980s. Since then, no
statistically significant improvement in survival was recorded. Figure adapted from Allison et al. [44].
and cisplatin (MAP regimen). MAP is sometimes extended with ifosfamide and/or etoposide
(IE), however, this does not seem to improve patient survival, but increases hematologic
toxicity [40]. The recent EURAMOS-1 trial further showed that even patients who responded
poorly to preoperative MAP treatment did not benefit when MAP was extended with IE during
the adjuvant treatment phase [41, 42]. Reduction of the treatment regimen to two drugs
significantly reduces the rate of good responders [43]. Today, surgical resection aims to resect
the complete tumor with a wide margin to avoid local recurrence, while conserving the limb.
Amputation is always the last considered option due to its invasiveness and the psychological
and cosmetic consequences [27].
1.2.3 Current Treatment Approaches for Metastatic Osteosarcoma
In contrast to localized OS, the success in treating (overt) metastatic OS remains limited. Only
a few studies that include OS patients with metastatic disease have been reported and patients
across different treatment facilities often do not receive consistent treatment. Frequently,
patients who qualify for surgical resection are treated with the same chemotherapeutic
7
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protocols as localized OS patients. Resection of lung metastases can prolong survival [45] and
is therefore performed whenever possible. However, even complete resection in combination
with chemotherapy is generally associated with a poor prognosis and two-thirds of patients
relapse due to the development of new lung metastases [46], resulting in a current 5-year
survival rate of less than 20% [38].
1.2.4 Prognostic Factors for Survival
Response to preoperative chemotherapy is an important prognostic factor for localized OS,
as was demonstrated in a retrospective study assessing 5-year event-free survival of 789
patients [43]. Patients with OS are classified into good and bad responders to preoperative
chemotherapy by histologic examination of necrosis in multiple tissue samples of the resected
primary tumor. Good responders show necrosis attributable to the chemotherapy of more
than 90% of their mass [47]. 63% of patients showed good response to various chemotherapy
regimens and 37% responded poorly. Interestingly, the fraction of good responders seems to
be significantly correlated to the histologic subtype of OS (63.9% for osteoblastic tumors:
50.6% for chondroblastic tumors, 25% for small-cell tumors, and 61.7% for fibroblastic
tumors) [43]. Poor responders have a 5-year overall survival rate of 45-55%, which is
substantially lower than the survival rate of 60-70% of good responders [38, 41]. An other
study which analyzed an American cohort of 2'849 patients with high-grade OS of all types
found that metastatic disease at presentation was an additional strong prognostic factor for
decreased survival. Furthermore, axial tumor location, large tumor size of more than 10 cm
as well as patient patient age over 25 and male sex were identified to confer poor prognosis
[48].
1.3 From Chemotherapy to Targeted Cancer Therapies
The introduction of chemotherapy has greatly improved the survival of patients diagnosed with
OS. Nonetheless, unlike other cancers, treatment of OS has not seen any major improvement
for several decades (see figure 4 on page 7). Moreover, the principle of systemic chemotherapy
bears some intrinsic disadvantages which will be discussed below.
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1.3.1 Chemotherapy Lacks Specificity and Results in Adverse Effects
Cytotoxic chemotherapy regimens, like the ones currently used for the treatment of patients
with OS, have the disadvantage of being non-specific and can lead to severe side effects. The
cause of this becomes clear when looking into the mechanisms with which the used agents
achieve their therapeutic effect. Generally, cytotoxic drugs inhibit one of the steps in the
process of cell reproduction. This is supposed to affect primarily cancer cells, since one of
the hallmarks of cancer is the ability to maintain chronic proliferation [49] but is still toxic
for normal cells which also undergo cell division. Methotrexate is a small molecule which
inhibits dihydrofolate reductase (DHFR) by competing with folate. Folate is the substrate of
DHFR and serves as a cofactor in the de novo synthesis of the thymine nucleotides, purine and
pyrimidine bases. In these synthesis processes folate is oxidized. DHFR subsequently reduces
folate and therefore enables another synthesis cycle. When the activity of DHFR is blocked
by methotrexate no thymine nucleotides, purine and pyrimidine bases can be produced and
therefore desoxryribonucleic acid (DNA) and ribonucleic acid (RNA) synthesis in the cell are
halted, resulting in cell death [50, 51].
Cisplatin introduces DNA damage and interferes with DNA replication. Inside the cell the
concentration of chloride is lower than in the extracellular fluid, which leads to a slow
replacement of the cisplatin chloride ligands with water. This results in highly reactive
aquated cisplatin which covalently cross-links DNA and leads to single-strand DNA breaks
and eventually apoptosis [52].
Doxorubicin is a topoisomerase II inhibitor, which can also intercalate with DNA. The resulting
enzyme-doxorubicin-DNA complex blocks topoisomerase progression and therefore blocks
DNA replication and induces DNA damage, which eventually leads to cell death [53]. The
three mechanisms of action described above target mainly DNA replication and synthesis;
processes which are most frequently active in - but importantly are not restricted to - fast
dividing neoplastic cells, as they do evidently also occur in normal cells. The lack of specificity
to cancerous cells can cause a plethora of adverse effects. This is further amplified by the prop-
erties of bone tissue. Due to the poor permeability and low blood flow, the chemotherapeutics,
which are usually delivered as systemic infusions, need to be administered in relatively high
doses to reach a sufficient concentration in the tumor, which can lead to severe toxicity [54].
Toxicity data of 599 OS patients enrolled in the recent EURAMOS-1 trial reported adverse
events to chemotherapy in 95% of cases [41].
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1.3.2 Resistance to Chemotherapy
As in other malignant tumors, chemotherapy resistance is responsible for the majority of
treatment failures in OS [55]. Drug resistance can be either intrinsic or acquired during
the course of treatment. The subpopulation of cancer cells which has acquired a mutation
leading to increased resistance might possess a growth advantage over non-resistant cells.
Several examples of mutations conferring chemotherapy resistance have been described in
OS. Firstly, chemoresistance can be achieved by decreasing the intracellular accumulation
of the drug. Methotrexate for instance passes through the cell membrane by the reduced
folate carrier (RFC). Acquired mutations as well as reduced expression of RFC are associated
with Methotrexate resistance and metastases in OS patients [56, 57]. Another way in which
neoplasms can decrease intracellular drug concentration is through non-specific removal
of the compounds by the membrane efflux pump P-glycoprotein (P-GP), which is encoded
by the multidrug-resistance gene MDR1. Cell line experiments have shown that high levels
of P-GP might be responsible for doxorubicin resistance but attempts to use high P-GP
levels as a predictor for survival in OS patients remain inconclusive [58]. Other reported
resistance mechanisms are based on enhanced repair of the DNA damage which is inflicted
by therapeutics such as cisplatin. Apurinic endonuclease 1 (APE1) is a key player in the base
excision repair (BER) pathway and high APE1 expression levels in OS patients are correlated
with reduced survival times [59]. Similar observations have been made with members of the
excision repair associated (ERCC) set of proteins which are involved in the nucleotide excision
repair pathway; several polymorphisms in ERCC genes, on the other hand, are associated
with a good response to cisplatin treatment [60].
1.3.3 Improvements of Existing Chemotherapy Drugs
Different strategies have been tried to tackle the problems of adverse effects and resistance
to chemotherapy. Existing chemotherapeutics and their mode of delivery can be modified
to increase specific targeting of neoplastic cells. A recent innovation is the use of drug
nanocarriers and liposomes which, based on surface moieties recognizing specific tumor
antigens, the particle size or geometry, can be designed to introduce tropism to tumor
cells [61]. While these approaches show encouraging results in animal studies [62] and
nanoparticle-based formulations have been approved for breast and ovarian cancers [63, 64],
they have not had any impact on OS treatment yet.
Attempts are also made to modify existing chemotherapeutics to circumvent chemoresistance
mechanisms found in OS. In one approach, doxorubicin is directly delivered to mitochondria,
where it can lead to mitochondrial impairment and cell death. To this end, the drug is
conjugated to a hydrophobic peptide with tropism to the mitochondria [65]. This limits
10
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the time the compound remains in the cytoplasm and within reach of the P-GP membrane
efflux pump, and therefore increases the drug efficacy. While cell line results have been
promising, these insights have also not translated into clinical use, yet. A last notable avenue
was explored by a recent animal study, in which the antitumor immune response modulator
interleukin-2 (IL-2) was delivered to tumor cells via overexpression in the attenuated and
facultative anaerobic Salmonella typhimurium strain and showed antitumoral activity against
primary OS and lung metastases [66]. Salmonella bacteria preferentially replicate in tumors
due to their affinity for a hypoxic or anaerobic environment. IL-2 can enhance an antitumoral
immune response and has long been used in the treatment of metastatic melanoma, but
toxicity is limiting the dose which can be administered systemically. Again, despite promising
animal studies no clinical utility has been reported so far.
1.3.4 Principles and Notable Examples of Targeted Cancer Treatment
In contrast to systemic chemotherapy, a targeted approach to cancer treatment aims to target
individual molecular properties which are specific to the neoplastic cells. With the advent
of molecular analysis methods and the burgeoning of the related fields of genomics and
proteomics, new tools came to the disposal of cancer research. These methods allow the
characterization of tumors beyond classical pathology, which is largely based on morphologic
observations. Ideally, by finding the molecular Achilles' heel of a tumor, drugs can be
developed which specifically exploit this property of the tumor cells while sparing normal
cells.
One point of attack for targeted cancer therapeutics are pathways which are deregulated in
neoplasms. Often, this dysregulation leads to sustained proliferative signaling, a fundamental
hallmark of cancer [49]. For example, growth factors and other ligands normally bind to
receptor tyrosine kinase (RTK) located on the cell membrane, which in turn activate diverging
intracellular signalling pathways. These pathways eventually control vital processes such
as cell cycle progression, cell survival, and energy metabolism. Cancer driving mutations in
members of these signalling pathways can lead to constitutive activation and thus continuous
proliferation. Thus not surprisingly, many drugs have been developed which try to coun-
teract activating mutations of oncogenes or the resulting pathway activation. Conversely,
deactivating mutations in tumor suppressor genes are not as easily actionable as oncogenes.
However, due to regulatory feedback loops, loss of tumor suppressor gene function can lead
to an overall activation of signalling pathways, which then in turn can potentially be targeted
by an inhibitor.
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Already before the rise of genomics and next-generation sequencing (NGS) a few break-
throughs have been made in the area of targeted cancer treatment. In 1985, all-trans retinoic
acid (ATRA) was reported to be effective in targeting the PML-RARA fusion protein, a driver
in acute promyelocytic leukemia (APL) [67]. This fusion protein is the result of a balanced
reciprocal translocation between the chromosomes 15 and 17 and is present in 70-90% of
APL cases [68]. Not unlike in OS, the treatment success of APL with chemotherapy alone had
reached a plateau, whereby only 35 to 45% of patients could be cured. Introduction of ATRA
in combination with chemotherapy as the first-line treatment increased 6-year DFS to 86 %
[67]. Another big success story is the development of imatinib for the treatment of chronic
myeloid leukaemia (CML). In 98% of CML patients, the disease is driven by the archetypical
BCR-ABL1 gene fusion, which eventuated from a reciprocal translocation involving chro-
mosomes 22 and 9. As a result of this genomic rearrangement, the non-receptor tyrosine
kinase ABL1 is retained in the cytoplasm and is constitutively activated. This leads to the
dysregulation of the MAPK, JAK-STAT and PI3K pathways and subsequent uncontrolled cell
division. Based on this knowledge, a rational drug discovery program lead to the development
of the first therapeutically used kinase inhibitor imatinib and its approval for the treatment of
CML [69]. As compared to the previous regimen consisting of interferon-α and chemotherapy,
targeted treatment with imatinib increased 5-year survival rates from 30% to 89% and still
remains the first-line treatment. The indications have since been extended to primary acute
lymphoblastic leukaemia, where 20% of patients harbor the BCR-ABL1 fusion and therefore
are responsive to imatinib, and to gastrointestinal stromal tumors (GIST) due to the ability
of imatinib to also inhibit the c-KIT tyrosine kinase [70]. A third prominent example of
a targeted cancer drug is the tyrosine kinase inhibitor (TKI) vandetanib. While originally
developed as a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor-
2, the drug was later shown to be an effective multi-kinase inhibitor which is also active
against the EGF receptor, the RET oncoprotein and other kinases [71, 72]. As a consequence,
vandetanib was approved for the treatment of late-stage medullary thyroid carcinoma (MTC)
patients ineligible for resection. Also for targeted cancer therapy, resistance to treatment is
a major problem. Common examples are imatinib and the other tyrosine kinase inhibitors
which are currently used in the treatment of CML. Resistance is arising primarily due to point
mutations in the drug target, which in CML is the kinase domain of the constitutively active
ABL1. These mutations interfere with the drug-protein interaction. For ABL1 alone, more
than 100 different resistance mutations have been cataloged so far [73]. This resistance can
either be intrinsic or acquired during treatment. Various studies have shown that more than
10% of patients do not show any response to imatinib at all, suggesting that resistant cells
already existed prior to treatment. Even though more seldom, ATRA treatment for APL also
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occasionaly fails, due to PML and RARA mutations and both intrinsic and acquired resistance
has been reported. Taken together, targeted cancer treatment is a promising paradigm, ideally
mediating its toxic effect specifically to an individual neoplasm. However, this specificity can
also be prone to developing resistance, e.g. due to secondary mutations.
1.3.5 Translational Research Enables Targeted Treatments
Becoming apparent from the examples described above, molecular classification and analysis
of tumors precedes the development and implementation of targeted treatment strategies.
This is even more emphasized by our growing understanding of intra- and inter-tumoral
heterogeneity which mandates in-depth analysis of as many cancer subtypes as possible.
Recent advances in the field of massively-parallel NGS along with the computational resources
and algorithms needed for storing and interpreting the copious amounts of data facilitate the
genomic characterization of tumors and the identification of genomic aberrations which lead
to tumorigenesis. Since the completion of the human genome project in 2001 [74] much
effort was put into cancer genomics and with projects such as The Cancer Genome Atlas
(TSGA) [75] and the Catalogue of Somatic Mutations in Cancer (COSMIC) [76] they start to
bear first fruits. Cancer genomics now play an integral part in finding and selecting molecular
targets for novel and innovative anticancer drugs [77]. The work presented here aims to
leverage current genomic approaches to characterize OS and to identify new actionable
mutations with potential clinical utility.
1.3.6 Genomic Aberrations and Available Analysis Methods
In this thesis, several methodologies for the analysis of genomic aberrations have been used
and a brief overview over these techniques will be given in this section. Generally, genomic
aberrations can be classified into single nucleotide variations, InDels and structural variations
(see figure 5 on page 16). Structural variation (SV) include copy number neutral (= balanced)
rearrangements such as inversions and translocations, and unbalanced copy number alteration
(CNA), such as deletions, insertions, tandem duplications, and unbalanced translocations.
Recurring SV have been implicated in various diseases and phenotypes. Prominent examples
are a 20 kb deletion upstream of the IRGM gene in Crohn's disease [78] or the recurrent
11;22 chromosomal translocation between the EWS and FLI1 genes in Ewing sarcoma [79].
Before the development of NGS and DNA arrays, the available methods for analyzing single
nucleotide variation (SNV) and structural changes were very limited. SNV and InDels were
detectable with conventional Sanger sequencing, which is still used in routine diagnostics
since it is reliable, easy to use and cost effective. Because of the principle of the technique
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which only allows the probing of one short genomic region at a time, Sanger sequencing
is not scalable to exploratory genomic studies, where multiple genes or complete tumor
genomes are to be analyzed. Gross structural anomalies were detected by karyotyping and
chromosome banding [80]. With the rather low resolution achieved by these approaches only
gross numerical aberrations such as trisomy 21 [81] or subchromosomal SV of several Mb in
size can be detected. More sensitivity can be achieved by fluorescence in situ hybridization
(FISH). Rather than relying on banding patterns to visually identify chromosomal regions,
FISH uses fluorescently labeled DNA probes designed specifically against the locus of interest.
While offering more resolution than classical DNA banding, the resolution of FISH is still
limited by the size of the bacterial artificial chromosome (BAC)-probes which is usually
between 100-300 kb, as well as by optical limitations of microscopy. Small insertions and
deletions in the kb range, for example are difficult to identify. Still, low costs and high
throughput opportunities make FISH a useful screening tool. A big technological leap for
chromosome diagnostics came with the introduction of array-based comparative genomic
hybridization (aCGH) in the early 1990s [82, 83]. This technique measures hybridization
ratios between test samples and normal DNA, from which CNA can be inferred [84]. A
limitation of CGH-based methods lies in the fact that they are not able to detect copy-number
neutral regions of loss of heterozygosity. To detect these, single nucleotide polymorphism
(SNP) -based arrays can be used. In SNP arrays not only the amount of genetic material
from a given locus is assessed, but also the genotype of predefined SNP probes distributed
across the genome. Newer iterations of commercially available SNP arrays several millions of
probes (e.g. 1.9 million copy number + 750'000 SNP probes in Cytoscan HD), whereby SNP
are positioned at specific sites in the genome and the non-polymorphic copy number probes
fill the gaps to allow high density coverage. Current arrays have a probe spacing of ∼880 bp
in most genes and 400-660 bp in known disease-related genes. Typically, SNP arrays can be
used to confidently call CNA or loss of heterozygocity (LOH)-segments of ∼50 kb.
With the advent of massively parallel NGS, a new tool became available for the study of both
SV and SNV. The basic principle of NGS shall not be explained here as it has been done
abundantly in the literature [85]. Of note, however, are conceptual varieties in regard to SV
detection. With classical single-end sequencing, CNA can be inferred using read depth, which
after normalizing for biases introduced by genomic context such as GC-content, reflects the
abundance of a given genomic site in the original sample material. Single-end reads are
also used to identify copy-number neutral SV. In this case, two parts of the same sequencing
read can map discordantly to the reference genome, and orientation and positioning of the
mapping allow for conclusions about the underlying rearrangements to be drawn. With
paired-end sequencing a similar principle applies but with each read of a pair being located
at the ends of the sequenced fragment [86]. This allows for a better mappability, due to
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generally longer read length when compared to split reads as well as for higher physical
coverage. This advantage is even further increased in so-called mate-pair or DNA-paired-end
tag (PET)-sequencing, in which the sequenced pairs originate from genomic sites which can
be spaced by several kb (see figure 12 on page 132). This increases physical coverage and,
importantly, is able to cross large repeats which are present at many SV breakpoints but are
notoriously hard to map to a unique genomic location. Yet another big advancement in SV
analysis, and sequencing in general, is currently being introduced in the form of long-read
technologies, such as single-molecule real-time sequencing by PacBio [87] and nanopore
based systems by Oxford Nanopore [88]. With promised average read-lengths of over 15 kb
and 5 kb, respectively, both systems are able to span long and complex SV can be spanned in
one read.
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Nucleotide Variations
Copy-Number NeutralCopy Number Alterations (CNAs)
SNVs InDels
Figure 5 – Genomic aberrations in cancer. Three classes of genomic aberrations found in
cancer genomes are depicted: small nucleotide variations, structural copy number alterations (bottom
left box), and copy number neutral structural variations (bottom right box). SNV are of three basic
types: substitutions (transversions and transitions); insertions; and deletions (InDels). Copy Number
Gains: The two homologous chromosomes are shown with a gain (blue bar) of two additional copies
of region A on the paternal chromosome. Copy number losses: Regions A and B on the paternal
chromosome are shown with a red bar highlighting the deleted region. The three most common types
of genomic structural variations (SV) are shown. Inversions on the same chromosome results in a
change of the orientation of DNA sequences. The inverted regions in the tumor are highlighted with red
letters. Translocations can be reciprocal or nonreciprocal and typically occur between nonhomologous
chromosomes (depicted in green and blue). Recombination between sister chromatids can result in
copy number neutral LOH. A, adenine; C, cytosine; cnLOH, copy number-neutral loss of heterozygosity;
G, guanine; LOH, loss of heterozygosity; T, thymine. Adapted from Watkins et al [89].
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1.4 Current Knowledge of the Genomic Landscape of Osteosar-
coma
As highlighted in the previous section, knowledge about genomic aberrations can not only
help in understanding the etiology and pathogenesis of a disease but can also be used to
derive targeted therapies. Several studies have therefore begun to unravel the genome of
OS in the past [90, 91]. However, many of these studies are based on cell lines or mouse
models, or include only a limited number of clinical samples. Additionally, early studies could
not benefit from the technological advancements in sequencing and array technologies and
therefore were more constrained in their scope than the genomic cancer studies of today.
Nevertheless, important observations about OS driver genes, chromosomal instability and
other aspects were accrued.
1.4.1 Sporadic Osteosarcoma
In contrast to other sarcoma subtypes, no canonical genomic rearrangement or genetic
mutation has been identified for OS. Nonetheless, causal roles of the tumor suppressor
genes TP53 and RB1 have been demonstrated in some tumors already some decades ago
and were later confirmed in several species [92, 93, 94]. Aberrations in these driver genes
are thought to induce chromosomal instability (see figure 6 on page 18). RB1 blocks the
G11/S phase transition in the cell cycle by binding to E2F family transcription factors, thereby
preventing cell cycle progression. During mitosis, the E2F/RB1 interaction is reversed through
phosphorylation of RB1 by CDK4. Loss of function mutations in RB1 therefore remove this
cell cycle checkpoint and can lead to increased proliferation. CDK4 in turn is inhibited by
p16, a protein which is encoded by the CDKN2A gene. The archetypical tumor suppressor
p53 is a transcription factor and a critical regulator of DNA damage response, cell cycle
progression and apoptosis [95]. In the absence of stress signals, p53 protein is kept at low
levels through continuous degradation by MDM2. The p53 pathway can be activated by
ARF, which can sequester MDM2 and therefore prevent the degradation of p53. ARF, like
the above-mentioned p16, is encoded by CDKN2A. Recent studies have shown that TP53
mutations are present in OS with high frequency and can be caused by both SNV and SV
[96, 97].
That being said, the clinical utility of TP53 and RB1 mutations to date are limited. Beyond OS,
TP53 is recognized as one of the most mutated genes in human malignancies [98] and germline
mutations in TP53 can lead to the Li-Fraumeni cancer predisposition syndrome. Therefore,
drugs which are able to restore the p53 pathway are an active area of research. While
compounds like APR-246 show promising preclinical results in restoring p53 transcriptional
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Figure 6 – Classical Model of osteosarcoma pathogenesis. In the classical view of tumor
initiation and progression in OS, mutations in the P53 or RB1 tumor suppressors in an undetermined
cell of origin leads to chromosomal instability. The resulting deletions, amplifications and rearrange-
ments contribute to tumor progression and development of drug resistance. P53, Cellular tumor
antigen P53; RB1, Retinoblastoma. Adapted from Chou et al [55].
activity of selected missense mutations, no drugs to counter other aberrations like deletions,
truncating mutations or disrupting rearrangements are currently available [99]. Strategies
for wildtype TP53 reconstitution in tumors (gene therapy) via introduction of an intact
complementary DNA (cDNA) copy of the gene for example using viral vectors are being
tested, but have not yet lead to clinical success. Other genomic studies have identified
additional OS driver candidates. ATRX, which is involved in telomere maintenance and
chromatin remodelling, has been reported as mutated in 10– 50% of tumors; the oncogene
MDM2 which suppresses TP53 is amplified in 4-5% [96, 97]; and MYC-amplifications were
described in 15% [97], amongst others. Further, deletions of the phosphatase and tensin
homolog (PTEN) tumor suppressor were found in 44% of cases [100]. For a comprehensive
list of additional driver genes which have been reported with lower frequency, the interested
reader may refer to a review by Rickel et al. [90].
The emerged consensus of the existing studies paints the picture of a highly complex and
rearranged genome. OS is generally characterised by high levels of genomic instability [91].
Genomic instability can be divided into several types: Microsatellite instability, which is
attributed to deficiency in DNA mismatch repair and which has mainly been described in
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colorectal- and bladder cancer, results in the accumulation of SNV and InDels as a consequence
of replication errors [101]. The second type is chromosomal instability and represents an
increase in the rate of genomic rearrangements as well as deletions and gains [102]. Whereas
OS generally appear to be microsatellite stable, chromosomal instability has been observed
in most genomic studies and is thought to be primarily induced by p53 deficiency [90, 103].
Moreover, ploidies of haploid to hexaploid have been described in OS [104]. Two of the
most recent genomic studies with comprehensive cohorts by Chen et al. and Perry et al.
underline the importance of chromosomal instability in OS and report an average of 317
and a median of 230 somatic rearrangements per tumor, respectively. Chen and colleagues
further described catastrophic genomic events in form of chromothripsis in several OS cases.
In chromothripsis, a cell acquires tens to thousands of rearrangements in a one-off event, as
a result of chromosome shattering and error-prone repair [105]. Interestingly, like “classical”
chromosomal instability, chromothripsis has been linked to TP53 mutations [106].
1.4.2 Familial Osteosarcoma
Most cases of OS are sporadic, yet there are several known heritable syndromes which
predispose patients to develop OS. Germline mutations in the TP53 tumor suppressor cause
Li-Fraumeni syndrome (LFS), a rare autosomal dominant disorder with a wide spectrum
of early-onset tumors, including OS, soft tissue sarcomas, breast cancer, and tumors of the
central nervous system. The majority of the causal alterations are missense mutations which
are mostly located in exons 3 to 11, but rarer rearrangements (mostly deletions) have been
described [107]. Germline mutations in the cell cycle regulator RB1 have also been shown to
increase the incidence of OS significantly [108], as well as mutations in the RecQ protein-like
4 helicase, which causes Rothmund-Thomson syndrome and leads to development of OS in
up to 32% of affected individuals [109]. BLM and WRN are two other members of the RecQ
family in which germline mutations lead to syndromes associated with OS.
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2 Results
2.1 Rationale and Aims of the Thesis
The work presented in this thesis aimed to leverage current genomic approaches to better
characterize OS and to identify new actionable mutations of potential clinical utility. A better
understanding of the genomic basis of the disease is crucial to improve the prognosis of
patients and may lead to more individualized treatment approaches. The number of patients
with refractory or recurrent disease remains high and underlines the clear need for innovative
and novel therapies. By analyzing a large set of OS samples using state of the art techniques
for exome-, whole genome-, and targeted panel-sequencing, as well as copy number arrays,
we therefore aimed to contribute to the expanding knowledge of OS genomics. Even though
few studies on OS genomics have been reported, many are based on cell lines or mouse
models or include only a limited number of tumor samples. Since OS is a rare disease and
commonly used biopsy methods often result in insufficient sample material for research,
the extensive pretherapeutic sample collection of the Basel Bone Tumor Reference Center
represents a highly valuable resource for this undertaking.
21
Chapter 2. Results
2.1.1 Publications and Manuscripts Arising from this Work
In Publication No 1 (“TP53 intron 1 hotspot rearrangements are specific to sporadic osteosar-
coma and can cause Li-Fraumeni syndrome”, page 23) we started to disentangle the chaotic
genomic landscape of four pretherapeutic OS. Using whole-genome DNA-PET sequencing, we
found rearrangements with breakpoints in intron 1 of the tumor suppressor gene TP53 as a re-
current aberration.Using FISH analyses, we demonstrated such rearrangements to be specific
to a subset of OS and not to occur in an extended cohort of 1'090 bone-producing and bone-
unrelated tumors. We further showed that intron 1 rearrangements can cause Li-Fraumeni
syndrome in a four-generation family with previously unidentified TP53 mutations.
In Publication No 2 (“Exome sequencing of osteosarcoma reveals mutation signatures remi-
niscent of BRCA deficiency”, page 63) we analyzed SNVs and CNAs of a large cohort consisting
of 123 pretherapeutic OS samples using next-generation sequencing and SNP-based copy
number arrays. By combining the data we found that 47% of tumors could be explained by
clonal TP53 and RB1 aberrations and an additional 40% by clonal aberrations in 12 other
well-described cancer-driver or -susceptibility genes. We further showed that the majority
of analyzed cases revealed genomic signatures similar to BRCA-deficient tumors (so-called
BRCAness), indicating homologous recombination repair deficiency which might be therapeu-
tically exploitable. In fact, PARP-inhibitors targeting this impairment in double strand repair
are currently tested in several other malignant tumors. At least in OS cell lines also showing
BRCAness, we could demonstrate PARP-inhibitors to significantly reduce cell viability.
In Manuscript No 3 (“RET Germline Mutations and Susceptibility to Osteosarcoma“, page
75) we picked up on our observations of recurrent TP53 rearrangements in Li-Fraumeni
syndrome and further investigated the role of germline alterations in the context of inherited
OS, beyond the known susceptibility genes TP53, RB1, BLM, WRN, and RECQL4. Based on
the findings in an index case with a pathogenic germline variant in the RET tyrosine kinase
and a family history of medullary thyroid cancer, we analyzed whole-genome, exome, and
targeted sequencing data of 336 OS patients. We discovered seven patients with bona fide
pathogenic RET germline variants and four patients with germline variants of unknown
clinical significance. We compared mutation burden, somatic mutation signatures and copy
number profiles and showed that the genomic landscapes of these tumors resemble previously
described OS. When comparing these findings to the frequency in the population, we could
show that patients carrying disease-associated germline RET mutations are at a significantly
increased risk of developing OS. Taken together, these data suggests the inclusion of OS to
the spectrum of RET-associated disorders and encourages the consideration of tyrosine kinase
inhibitors as a treatment option in appropriate cases.
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2.2 Publication No 1
TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can
cause Li-Fraumeni syndrome.
Ribi S*, Baumhoer D*, Lee K*, Edison, Teo AS, Madan B, Zhang K, Kohlmann WK, Yao F, Lee
WH, Hoi Q, Cai S, Woo XY, Tan P, Jundt G, Smida J, Nathrath M, Sung WK, Schiffman JD,
Virshup DM, Hillmer AM.
*These authors have contributed equally to this work
Oncotarget. 2015 Apr 10;6(10):7727-40.
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ABSTRACT
Somatic mutations of TP53 are among the most common in cancer and 
germline mutations of TP53 (usually missense) can cause Li-Fraumeni syndrome 
(LFS). Recently, recurrent genomic rearrangements in intron 1 of TP53 have been 
described in osteosarcoma (OS), a highly malignant neoplasm of bone belonging 
to the spectrum of LFS tumors. Using whole-genome sequencing of OS, we found 
features of TP53 intron 1 rearrangements suggesting a unique mechanism correlated 
with transcription. Screening of 288 OS and 1,090 tumors of other types revealed 
evidence for TP53 rearrangements in 46 (16%) OS, while none were detected in other 
tumor types, indicating this rearrangement to be highly specific to OS. We revisited 
a four-generation LFS family where no TP53 mutation had been identified and found 
a 445 kb inversion spanning from the TP53 intron 1 towards the centromere. The 
inversion segregated with tumors in the LFS family. Cancers in this family had loss 
of heterozygosity, retaining the rearranged allele and resulting in TP53 expression 
loss. In conclusion, intron 1 rearrangements cause p53-driven malignancies by 
both germline and somatic mechanisms and provide an important mechanism of 
TP53 inactivation in LFS, which might in part explain the diagnostic gap of formerly 
classified “TP53 wild-type” LFS.
Chapter 2. Results
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INTRODUCTION
Germline mutations in the TP53 tumor suppressor 
gene cause Li-Fraumeni syndrome (LFS), an autosomal 
dominantly inherited predisposition syndrome to various 
cancers, including osteosarcoma (OS) [1, 2]. TP53 
coding mutations can be identified in 70% of classic 
LFS families [3] leaving a significant proportion of LFS 
cases with an unknown genetic basis. The vast majority 
of TP53 mutations in LFS, OS and other tumors are point 
mutations dominated by missense mutations [4]. Larger 
germline deletions encompassing the entire TP53 gene 
together with neighboring genes have been described to 
correlate with developmental delay [5]. Partial deletions 
of TP53 have been found to be associated with LFS 
suggesting that the partial loss of TP53 has a different 
functional outcome than the entire deletion of the gene 
[5]. Some genomic structural variations (SVs) have been 
described that can affect TP53 function. These SVs are 
either deletions, which were identified by PCR based 
methods or comparative genome hybridization, that affect 
the TP53 gene in LFS patients [5, 6], or rearrangements 
in intron 1 of TP53 which initially have been identified 
by Southern blot in OS [7–9]. Recently, whole-genome 
sequencing of tumors from 32 OS patients showed cancer-
specific TP53 rearrangements in > 50% of patients [10].
p53 is a DNA-damage response protein [11] and its 
inactivation could be expected to result in further genomic 
instability [12]. Mutations of TP53 are among the most 
common defects associated with human cancer in general. 
Given the large number of TP53 point mutations which have 
been identified in the majority of cancer types, it is surprising 
that TP53 intron 1 rearrangements have only been found 
in OS [7–10]. Since exome sequencing does not allow the 
identification of copy number neutral genome rearrangements 
with intergenic or intronic breakpoints, it is possible that 
TP53 intron 1 rearrangements have been missed in many 
studies. In addition, the suggested specificity of TP53 intron 
1 rearrangements for OS is based on screens of a limited 
number of samples [7–9]. Further, it seems possible that TP53 
intron 1 rearrangements do not only contribute to sporadic OS 
but also to LFS, which is driven by germline TP53 mutations. 
In the present study, we analyze the nature of TP53 intron 1 
rearrangements, screen the to date largest collection of OS 
and other tumor types for such rearrangements, describe 
the identification of a TP53 intron 1 disrupting germline 
inversion in a four generation LFS family and characterize 
this locus and TP53 activity in tumors of this family.
RESULTS
Characterization of recurrent rearrangement 
points in intron 1 of TP53
We analyzed the genome structures of four pre-
therapeutic OS using DNA paired-end tag sequencing 
(DNA-PET), a genome-wide mate-pair sequencing 
approach [13–15] and predicted 434, 289, 348 and 
420 SVs, respectively, to be somatically acquired 
(Supplementary Tables S1–S6, Figures S1A and S1B, S2 
and S3A, S3B and S3C). We identified seven breakpoints 
within a small region of intron 1 of TP53 in three OS 
tumors (Figure 1, Figure S4 and Supplementary Table S7) 
and the fourth (AJF) had a 94 kb deletion that included 
the entire TP53 gene as well as neighboring genes 
(Figure 1A and 1B). Tumor YZH showed a balanced 
translocation between TP53 intron 1 and chromosome 1. 
The sequence of the breakpoints showed the presence of 
the same 555 bp and 293 bp of the TP53 and chromosome 
1 loci, respectively, on both sides of the translocations 
(Supplementary Figure S5A and S5B). Tumor PZP had a 
12.5 kb inverted insertion originating from chromosome 
6 containing ENPP1 exons 19 to 25 including the 
stop codon (Supplementary Figure S6A and S6B). In 
addition, the TP53 intronic sequences on both sides 
of the insertion overlapped by 59 bp suggesting that a 
similar mechanism was responsible for the translocations 
in both YZH and PZP. Tumor KRD had complex inter-
chromosomal translocations with the three different 
partner chromosomes 1, 5 and 6 (Figure 1B) implying that 
these are three independent events. At least one event had 
to be non-clonal meaning that two or three independent 
clones with structural rearrangements in TP53 intron 
1 underlie this tumor. The translocation breakpoints in 
intron 1 of TP53 with chromosomes 1 and 6 were only 
45 bp apart with an overlap of 46 bp of the intron 1 
sequence. The overlap and orientations were compatible 
with one event of similar mechanism as for tumors YZH 
and PZP. In contrast, the DNA-PET mapping regions 
of the chromosome 5 translocation suggest that this 
rearrangement occurred on the other allele of TP53 or in 
an independent clone (Figure 1B).
Centromeric of the breakpoint cluster region (2.5 
kb of its center towards exon 1 of TP53) data of the 
Encyclopedia of DNA Elements (ENCODE) [16] show 
strong signals of open chromatin and active enhancers. 
It seems possible that the open chromatin state and/
or the active transcription of TP53 contribute to the 
rearrangement mechanism. Six of the seven breakpoints 
were located within long interspersed elements (LINE), 
and the seventh breakpoint was within a short interspersed 
element (SINE). While the breakpoint partner sites do 
not show enrichment for LINE or SINE sequences, it is 
striking that five of the seven partner breakpoints also have 
strong signals of open chromatin within a region of 10 kb 
(Supplementary Figures S7A and S7B, and S8 to S12).
In two of the three tumors with TP53 intron 1 
rearrangements, the breakpoint locations predicted gene 
fusions forming TP53-ENPP1-TP53 and SUCO-TP53 
(Supplementary Table S7). Interestingly, both fusion 
gene partners are involved in bone biology. ENPP1 has 
been shown to be a key regulator of ossification [17]. 
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SUCO (SUN domain containing ossification factor) is 
an essential regulator of postnatal osteoblast maturation 
[18]. Furthermore, we found both genes expressed 
in a collection of in-house established OS cell lines 
(unpublished data). The expression of the rearranged 
genes in bone supports the idea that active expression 
might mechanistically contribute to the translocations.
Somatic TP53 rearrangements are a frequent 
phenomenon specific for OS
We designed a break-apart FISH test using probes 
flanking the TP53 gene (Figure 2A) and investigated a 
series of 215 pre-therapeutic OS samples arranged on a 
tissue microarray (TMA). We found 11% (23 out of 215) 
of the cases to have rearrangements at the TP53 locus 
(FISH break-apart positive; Figure 2B). Of note, in all 23 
FISH positive cases, both alleles showed the break-apart 
signal. However, FISH positive patients did not differ from 
negative patients in terms of overall-survival (p = 0.6), 
event-free survival (p = 0.7), occurrence of metastases, 
or response to neoadjuvant chemotherapy (Table 1 and 
Supplementary Tables S8 and S9). Rearrangements at this 
locus nevertheless appear to be a recurrent finding in OS. 
To test whether the TP53 rearrangement also occurred in 
other bone-forming tumors that sometimes can be difficult 
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Figure 1: Translocation hotspot in intron 1 of TP53 in OS samples. (A) Genes derived from the UCSC known genes database 
[43] (top) and copy number information derived from DNA-PET sequencing data of four OS samples (blue tracks, bottom) are shown in the
Genome Browser. Genes transcribed from the plus strand are represented in gold, genes transcribed from the minus strand are represented
in green. Boxes indicate exons, barbed lines indicate introns. The TP53 locus for patients PZP, KRD, and YZH has a copy number of two
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Figure 2: Translocation hotspot in intron 1 of TP53 in OS samples. (A) Location of BAC clones which have been selected 
for FISH relative to TP53 and immediate neighbouring genes. Other genes of the track have been deleted for clarity. Color code matches 
fluorophore of FISH analysis shown in B. (B) Examples of a negative and positive break-apart signal of two color FISH which has been 
used to screen 267 formalin fixed and paraffin embedded (FFPE) OS samples and 141 other bone-forming tumors. (C) Copy number 
overview of 73 OS tumors at the TP53 locus based on CytoScan array analysis. Top panel shows the cumulative copy number across all 
samples with red indicating loss and blue gain in copy number. Lower panel shows the copy number gains and losses for each of the 73 OS 
tumors individually. Note the changes in copy number within intron 1 of TP53 detectable in 23 cases (yellow box).
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Table 1: Characteristics of OS patients
OS TMA OS fresh frozen
All FISH positive (out 
of 215 evaluable)
All Intron 1 CN change
Gender 254/267 (95.1%) 23/23 (100%) 73/73 (100%) 24/24 (100%)
 male 129 9 39 13
female 125 14 34 11
Age at diagnosis 258/267 (96.6%) 23/23 (100%) 73/73 (100%) 24/24 (100%)
 average 24.3 years 17 years 17.3 years 18.6 years
 median 17 years 15 years 15 years 15.5 years
 range 4–88 years 6–48 years 3–56 years 5–56 years
Observation period 259/267 (97%) 23/23 (100%) 72/73 (98.6%) 24/24 (100%)
 average 61.6 months 46.6 months 73.9 months 64.6 months
 median 35 months 24 months 66.5 months 64 months
 range 0–287 months 0–179 months 0–205 months 2–196 months
Response to neoadjuvant 
treatment 180/267 (67.4%) 19/23 (83%) 66/73 (90.4%) 21/24 (87.5%)
good (< 10% viable tumor) 102 14 35 10
poor (≥ 10% viable tumor) 78 5 31 11
Metastases 267/267 (100%) 23/23 (100%) 65/73 (89%) 19/24 (79.2%)
 yes 101 9 39 10
 no 166 14 26 9
Survival 259/267 (97%) 23/23 (100%) 72/73 (98.6%) 24/24 (100%)
 alive 174 18 55 16
 deceased 85 5 17 8
TP53 immunhisto-chemistry 212/267 (79.4%) 19/23 (83%)
 negative 170 15
 positive 42 4
Location 23/23 (100%) 24/24 (100%)
femur 14 12
 tibia 5 8
 jaws 2 -
 humerus 1 1
fibula 1 1
 other - 2
OS TMA series / OS Fresh Frozen series: number of evaluable cases / total number of cases (percentage) CN, copy number
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to distinguish histologically from OS in small biopsies, we 
analyzed another series of 124 bone-forming tumors and 
tumor-like lesions using our FISH assay. None of these 
cases showed evidence of TP53 rearrangement. To further 
exclude TP53 intron 1 rearrangements in other tumor 
types we used our FISH assay to analyze an additional 
966 tumors on a TMA (Supplementary Tables S10 and 
S11). None of the 966 tumors showed a break-apart signal 
suggesting the somatic TP53 intron 1 rearrangements 
represent a specific finding in OS.
To further validate our findings by another platform, 
we analyzed an independent set of 73 pre-therapeutic 
fresh-frozen OS samples for copy number alterations 
(CNAs) using CytoScan® high density arrays. We found 
that 74% (54 out of 73) of the OS samples had alterations 
affecting the TP53 gene. Amongst these alterations, 23 
showed transition points into copy number losses (n = 17) 
or gains (n = 3) or abrupt transitions from losses into gains 
(n = 3) in intron 1 of the gene (32% of total samples, 23 
out of 73, Figure 2C). Again, the rearrangements did not 
correlate with any clinico-pathological parameters.
TP53 intron 1 rearrangement in a family with LFS
Since mutations of TP53 are associated with LFS 
it seemed possible that TP53 intron 1 rearrangements 
could constitute a previously underappreciated category 
of alterations that can cause LFS. We revisited an LFS 
family with 12 affected members with cancer across four 
generations in which we previously had been unable to 
identify a coding TP53 mutation or a co-segregating, 
potentially damaging and disease-causing alteration based 
on exome sequencing of patients P1, P2 and P13 (Figure 
3A and data not shown). Copy number analysis of DNA 
from blood of patients P1 and P13 by single nucleotide 
polymorphism (SNP) array revealed evidence for an 
approximately 2.5 kb deletion in intron 1 of TP53 including 
exon 1 (Supplementary Figure S13 and Table S12). 
However, we were not able to amplify the fusion point of a 
deletion by PCR. We then used a custom sequence capture 
assay for targeted paired-end sequencing of the TP53 locus 
to search for a rearrangement point. We identified a 445 kb 
inversion spanning from the breakpoint cluster region in 
intron 1 of TP53 towards the centromere (upstream of TP53) 
with a loss of 2,275 bp of intron 1/exon 1 of TP53 (Figure 
4A and 4B). The lost sequence was in agreement with 
the deletion identified by SNP arrays. In the adult family 
members tested, we found this specific rearrangement co-
segregating with the disease, implicating the rearrangement 
as the causative alteration (Figure 3B and 3C).
Twelve different protein isoforms of TP53 (p53, 
p53β, −γ, Δ40p53α, −β, −γ, Δ133p53α, −β, −γ, Δ160p53α, 
−β, −γ) can be generated by alternative splicing, 
alternative promoter usage, and alternative initiation sites 
of translation which have different functional properties 
(reviewed in [19, 20]). A weak promoter is located just 
upstream of exon 1, a strong promoter 1 kb downstream of 
exon 1 and a third promoter at exon 5 [19, 21]. Transcripts 
for p53 (full length) and the Δ40p53 isoforms contain 
the non-coding exon 1. The intron 1 rearrangements 
disconnect the exon 1 of TP53 and the two first promoters 
from the remaining gene body. To investigate the impact 
of TP53 rearrangements on TP53 expression, we obtained 
RNA from blood of LFS patients H2 and P13, OS lung 
metastasis of H2 and a cell line derived from the lung 
adenocarcinoma of P13.
We performed quantitative reverse transcription 
polymerase chain reactions (qRT-PCRs) targeting 
transcripts encoding for the twelve described p53 
isoforms and for isoforms Δ133α, −β, −γ and Δ160α, 
−β, −γ (TP53 delta), respectively, and found a reduction 
of transcripts by 23–53% for the blood of H2 and P13 
where the rearrangement was in a heterozygous state, and 
a reduction by 89–100% for the OS lung metastasis of H2 
and a cell line derived from the lung adenocarcinoma of 
P13 (Figure 5). This implies that the rearrangements result 
in a loss of TP53 transcription and function rather than a 
switch to reported transcripts lacking exon 1.
To test for deletions of the second allele in tumors, 
copy number analysis using OncoScan FFPE Express 
(Affymetrix, Inc.) were performed on tumor samples of 
H2 (two OS lung metastases that developed six months 
apart), P1 (undifferentiated pleomorphic sarcoma) and 
P13 (lung adenocarcinoma and meningioma). Loss of 
heterozygosity (LOH) at the TP53 locus occurred in all 
five investigated tumors (Figure 6A and Supplementary 
Figures S14 and S15). Semi quantitative genomic PCR for 
LFS-BP2 showed a stronger signal for the LFS breakpoint 
than for the non-rearranged allele suggesting a duplication 
of the rearranged allele and loss of the non-rearranged 
allele with the weak PCR signal derived from stroma 
contamination (Figure 6B). Our findings suggest LOH as 
a frequent mechanism for TP53 inactivation after an initial 
intron 1 rearrangement.
DISCUSSION
Rearrangement hotspot in TP53 intron 1
More than 20 years ago, rearrangements in 
TP53 in OS were identified by Southern blot [7–9]. 
Although based on a small number of samples, these 
rearrangements were thought to be specific for OS. 
Recently, TP53 rearrangements have been rediscovered 
in OS in more than 50% of 32 OS by whole-genome 
sequencing at a higher resolution [10]. In our study, we 
also found TP53 intron 1 rearrangements to be the most 
recurrent focal rearrangement point in four OS samples. 
We found evidence for TP53 rearrangements in 11% (23 
out of 215) of OS samples by FISH and copy number 
changes in intron 1 of TP53 in 32% (23 out of 73) of 
OS samples by CytoScan arrays. Importantly, there were 
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no rearrangements found in other bone-forming tumors 
(0 out of 124) by FISH analysis. Due to the low resolution 
of the bacterial artificial chromosome (BAC) probes of the 
FISH experiments which were 169 kb and 159 kb in size, 
respectively, the 23 detected rearrangements might include 
translocations outside intron 1 of TP53. However, we did 
not observe other rearrangements which could result in the 
‘break-apart’ FISH signal in the whole-genome DNA-PET 
data of the four sequenced OS samples. Similarly, Chen 
et al. also found the majority of breaks in intron 1 [10], 
suggesting that most of the rearrangements detected by 
FISH were due to intron 1 rearrangements. In addition, 
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Figure 3: TP53 intron 1 rearrangement in a family with LFS. (A) Pedigree of a family with LFS. Squares and circles represent 
males and females, respectively. Filled symbols indicate individuals with early onset cancer. Symbols with a diagonal line indicate that the 
individual was deceased at the time of recruitment. Diamonds represent several additional family members whose gender should not be 
disclosed. Individuals of whom DNA samples have been obtained are numbered with individuals tested positive for TP53 exon 1 deletion 
by MLPA in red. TP53 rearrangement carrier without cancer at the age of 10 years is indicated by a white symbol with a black dot. (B) PCR 
analysis of positive control and TP53 intron 1 rearrangement points (LFS-BP1 and LFS-BP2) of family members of whom high quality DNA 
was available. DNA quality of P12 did not allow PCR amplification, including positive control (not shown). a, LFS breakpoint 1 (BP1); b, 
LFS breakpoint 2 (BP2); c, positive control amplicon at the RNA polymerase II locus (POLR2A); sample IDs correspond to A with affected 
individuals in red. L, ladder. (C) Sanger sequencing of rearrangement points LFS-BP1 and LFS-BP2 at the TP53 locus of P2. Micro homologies 
between the two participating break point regions are illustrated by green vertical lines. Genomic coordinates are based on NCBI build 37.
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the FISH analysis did not have the resolution to identify 
small insertions as discovered in tumor PZP or deletions 
of similar sizes, thus the actual frequency of TP53 intron 1 
rearrangements might be underestimated. Further, we found 
TP53 intron 1 rearrangements in OS by CytoScan analysis 
which has the resolution to locate the breakpoints to the 
first intron of TP53. The different frequencies of identified 
TP53 rearrangements by FISH and CytoScan arrays might 
be explained by the lack of sensitivity of the FISH assay for 
the identification of small rearrangements. The differences 
of TP53 intron 1 rearrangement frequencies between our 
study and the report of Chen and colleagues may be due to 
different analysis protocols or sampling biases.
TP53 intron 1 rearrangement mechanism
Three main types of mechanisms for genome 
rearrangements have been established: homologous 
recombination, replication-based mechanisms, and 
non-replicative non-homologous repair [22, 23]. The 
TP53 intron 1 locus does not show significant sequence 
similarity with the seven translocation partner sites, 
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Figure 4: Inversion of 445 kb affecting intron 1 of TP53 in a family with LFS. (A) University of California, Santa Cruz (UCSC) 
genome browser view [43] of the TP53 locus with representative TP53 and WRAP53 transcripts, and H3K27Ac binding information of 
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arguing against a homology driven rearrangement 
mechanism. A replication coupled mechanism seems 
to be unlikely as well since a) it would require two 
replication fork invasions occurring in parallel at the 
same locus, b) it would involve two non-homologous 
chromosomes and replication-based mechanisms such 
as fork stalling and template switching (FoSTeS), 
which to the best of our knowledge have been described 
only for intra-chromosomal rearrangements, and c) we 
did not find evidence for rearrangement points which 
‘switch back’ to the original TP53 chromosome 17. The 
rearrangement points of non-replicative non-homologous 
repair, with the subgroups non-homologous end joining 
(NHEJ) and alternative end joining, are characterized 
by the absence of large homology but the presence of 
micro-homology of a few base pairs, blunt end joining 
or the insertion of small stretches of ‘junk’ DNA of 
unknown origin.
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Figure 6: Tumors of LFS family show LOH at the TP53 locus. (A) OncoScan array derived copy number and allele frequency 
plots of the TP53 locus of OS lung metastasis of H2 show copy number neutral LOH. Chromosome 17 at 7.544 Mb to 7.618 Mb is shown 
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reference (normal); y-axis of allele frequency shows homozygous allele calls for all single nucleotide polymorphisms in the window 
with values close to 0 and 1, respectively. (B) Semi quantitative PCR of LFS-BP2 (a), the wild type allele at the BP2 locus (b) and RNA 
polymerase II (positive control, c) of H2 germline DNA (30 PCR cycles) and H2 OS lung metastasis (28 PCR cycles) is shown. L, ladder.
Chapter 2. Results
32
Oncotargetwww.impactjournals.com/oncotarget
The TP53 intron 1 region does not seem to be 
compatible with these common mechanisms of genome 
rearrangements or might be classified as a subcategory 
of NHEJ with sequence duplication. What we found 
in the three OS tumors with sequenced TP53 intron 1 
rearrangement points is different since both sides of the 
balanced intron 1 rearrangements contain a stretch of 
identical sequence of 46 bp to 555 bp. We therefore suggest 
a mechanism where a double strand break with long single 
stranded DNA overhangs occurs (Supplementary Figure 
S16A to S16G). The single stranded DNA overhangs might 
get filled in by the DNA repair machinery allowing blunt 
end fusions with other double strand breaks. Remarkably, 
all three OS tumors in which we initially found the TP53 
rearrangements share this unique feature of breakpoint 
sequences suggesting that they were caused by the same 
mechanism. The break point regions of the TP53 locus and 
the translocation partner sites show a pattern of general 
active chromatin marks and gene expression in OS and/
or bone tissue. The open state of the chromatin and/or 
the active expression of the respective genes may lead or 
contribute to the formation of the TP53 intron 1 specific 
rearrangements.
Somatic SVs in TP53 intron 1 are specific to OS
We assayed a comprehensive tumor collection of 
more than ten tissue types with a total of 1,090 non-
OS tumors and 215 OS and show that the mechanistic 
event of the somatic rearrangements in TP53 is highly 
specific to OS. In contrast, our findings in the LFS 
family indicate that TP53 intron 1 can also occur in the 
germline and once such a SV is present as a germline 
alteration it can give rise to not only OS but multiple 
types of cancer, including adenocarcinoma, meningioma, 
astrocytoma, colon cancer, basal cell and squamous cell 
carcinoma of the skin. Interestingly, none of these tumor 
types were positive in our FISH TMA assay (n = 54, 
n = 14, n = 11, n = 62, n = 23 and n = 10, respectively) 
indicating that the mechanistic occurrence of TP53 
intron 1 rearrangements in the soma is specific for the 
osteoblast lineage, the believed cell of origin for OS [24]; 
however, the pro-cancer effect of such rearrangements 
supports tumor growth in many other tissues. Similarly, 
TP53−/− and TP53+/− knockout mice develop not only OS 
but also lymphoma, carcinoma and testicular cancer [25]. 
Again, our FISH analysis of tumors of these types did not 
show evidence for somatic TP53 intron 1 rearrangements 
(n = 33, n = 566, n = 33, respectively). It therefore seems 
plausible that the OS specificity of the TP53 intron 1 
SVs is based on the mechanism of the rearrangement 
that leads it to occur only in osteoblast lineage with 
observable frequency, rather than OS being the specific 
consequence of the alteration. Cell lineage specific DNA 
replication properties or transcriptional processes might 
be responsible for the remarkable specificity of the 
described rearrangements.
Other genes at the rearrangement hotspot
It remains possible that the intron 1 rearrangements 
affect other genes at this locus which could result in 
pro-malignant effects. RP11–199F11.2 (Hp53int1 or 
D17S2179E) is a non-spliced, probably non-coding 
transcript in intron 1 of TP53 which is transcribed in 
the same orientation as TP53 (Figure 1B). It has been 
identified by a targeted cDNA library screen but its 
function is unknown [26]. Further, exon 1 of TP53 
overlaps with WRAP53, a gene which is oriented 
in antisense relative to TP53, on the plus strand of 
chromosome 17, that has been found to upregulate TP53 
transcripts. Downregulation of WRAP53 is reported 
to lead to significant suppression of p53 induction in 
response to DNA damage [27]. WRAP53 protein has been 
characterized as an essential protein for the localization 
and processing of nuclear ribonucleoproteins [28, 29].
Germline SVs in TP53 intron 1 can cause LFS
We found germline rearrangements in the TP53 intron 
1 hotspot likely to be causative for LFS in a large family. 
Our findings are in agreement with the second hit model 
for tumor suppressor genes where all 23 FISH positive OS 
showed two break-apart signals and the LFS family had 
the rearrangement in a heterozygous state in the germline 
followed by LOH in all tumors. Our qRT-PCR experiments 
suggest that the overall transcription of TP53 is lost upon 
intron 1 rearrangement but it remains possible that in certain 
tissue/tumor contexts or depending on regulatory elements in 
the rearrangement partner sites, such rearrangements could 
cause a shift towards the expression of the shorter isoforms 
Δ133p53 and Δ160p53. In contrast to p53, Δ133p53 is 
defective in promoting apoptosis [21]. The comparison 
of TP53 transcripts in breast tumor versus normal tissues 
revealed obvious differences with Δ133p53 being expressed 
in 24 out of 30 breast tumors but not in 8 normal breast tissue 
samples [21]. This is supported by a clinical study which 
found Δ133p53 isoforms to be abnormally expressed in renal 
cancer, suggesting that they play a role in carcinogenesis 
[30]. Further, Δ133p53α inhibits p53-mediated replicative 
senescence, promotes cellular proliferation of normal human 
fibroblasts by inhibiting p21 expression, and represses the 
expression of miR-34a to regulate p53-mediated senescence 
[31]. Cotransfection experiments indicated that Δ133p53 has 
a dominant negative effect on the proapoptotic properties 
of p53 [21]. p53 forms tetramers to execute its function as 
a transcription factor. Coimmunoprecipitation experiments 
showed that Δ133p53 forms a complex with p53 and it is 
likely that this interaction mediates a negative effect on p53 
function of the intact allele by interfering with the tetramer 
structure [19].
TP53 coding mutations are identified in 70% 
of classic LFS families [3]. Germline TP53 intron 1 
rearrangements might be present in some of the remaining 
30% of families, suggesting that LFS and Li-Fraumeni-like 
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(LFL) families should be tested for such rearrangements. 
This could be tested using FISH and TP53 capture-based 
sequencing approaches for break point identification 
as in our study. Only a few cases have been reported 
where genomic structural alterations, usually deletions, 
cause cancer syndromes [32–39] and one study where a 
Robertsonian translocation results in a highly increased 
risk for childhood acute lymphoblastic leukemia with 
focal chromosome 21 amplification [40]. We present here 
a very rare phenomenon of a rearrangement hotspot which 
can give rise to both somatic rearrangements as well as 
a germline cancer syndrome. It seems possible that the 
open chromatin state together with components of the 
transcription machinery and characteristic LINE sequences 
underlie the fragility of this locus. The disruption of 
the gene structure results in loss of p53 function and 
thereby promotes cancer. In conclusion, intron 1 of TP53 
represents a rare case of a tumor type dependent somatic 
rearrangement hotspot that can also acquire germline SVs 
causing a Mendelian inherited cancer syndrome.
METHODS
OS patient samples for DNA-PET sequencing
DNA of four treatment naive OS tumors and paired 
normal blood were obtained from the Biopathology 
Center (BPC) of the Children’s Oncology Group (COG), 
a cooperative group that includes medical centers in the 
United States, Canada, Mexico, Australia, New Zealand 
and selected countries in Europe. Informed consent of the 
participating patients or legal representatives has been 
obtained and approval of the respective institutional ethics 
review boards has been granted.
DNA-PET libraries construction, sequencing, 
mapping and data analysis
DNA-PET library construction from 1 to 4 kb 
fragments of genomic DNA, sequencing, mapping 
and data analysis were performed as described in [13] 
with refined bioinformatics filtering as described in 
[41]. High throughput sequencing by 2 x 35 bp or 2 x 
50 bp was performed on SOLiD sequencers (v3plus 
and v4, respectively) according to the manufacturer’s 
recommendation (Life Technologies). The short reads 
were aligned to the NCBI human reference genome build 
37 (hg19) using Bioscope (Life Technologies).
Custom sequence capture and breakpoint 
identification in a LFS family by paired-end 
sequencing
The TP53-containing region chr17:7,520,000–
7,680,000 (NCBI build 37) was defined for a custom 
sequence capture (SeqCap EZ Choice, Roche NimbleGen 
Inc.). Repetitive regions are usually excluded for sequence 
capture assays. Since most of the observed breakpoints 
in OS were in LINE sequences, we forced to include 
repetitive sequences of the intron 1 region of TP53 
(chr17:7,579,941–7,590,694). Illumina sequencing library 
was constructed and capturing was performed according 
to the manufacturer’s recommendations and the library 
was sequenced on an Illumina HiSeq 2000 by 2x50 bases. 
Reads were mapped to the human reference genome (NCBI 
build 37) by BWA and read-pairs were filtered of which one 
read mapped to the TP53 target region and the paired read 
mapped outside of that region. Reads of similar mapping 
pattern were clustered together as described earlier [13] and 
prioritized for validation by PCR and Sanger sequencing 
based on cluster size (number of paired-reads with similar 
map ping patterns). Identified TP53 breakpoints were 
screened by PCR in all LFS family members of whom 
DNA was available. Validation PCRs were conducted using 
Jumpstart REDAccuTaq LA DNA Polymerase (Sigma-
Aldrich) following manufacturer’s instructions with 120 ng 
DNA template. Where sample was insufficient, the genomic 
DNA was amplified using REPLI-g Mini Kit (Qiagen) 
and 3 ul of 1:20 diluted amplification product were used 
as templ ate for validation PCRs. PCRs were performed 
using the following primer pairs: CTCAAAAGGCC 
ATCAAAAGG and GTATGGTGGCCTGTTCCTGT 
(LFS-BP1), GGCTGCTGGGAGTTGTAGTC and AGCT 
ATCTTGACCCCACACG (LFS-BP2), CCCGAATA 
GCTGGGATTACA and GCAAGTGCAC 
AGGAAGATGA (LFS-BP1-wt), GGAGGAATCC 
TGCATTGTGT and CAGGCTTCAGACCTGTCTCC 
(LFS-BP2-wt), GCTGCTGGACGTGAGTATGA and 
AGTTCCAACAATGGCTACCG (positive control primers 
for POLR2A), and the following cycling conditions: 3 min 
at 94°C, (20 s at 94°C, 30 s at 58°C, 2 min at 68°C)x15, (20 
s at 94°C, 30 s at 55°C, 2 min at 68°C)x20, 5 min at 68°C.
Tissue samples and patient’s characteristics for 
fluorescence in situ hybridization (FISH) and 
CytoScan screen
All tissue samples were obtained from the archives 
of the Bone Tumor Reference Center at the University 
Hospital Basel and the Clinical Cooperation Group 
Osteosarcoma at the Helmholtz Zentrum Muenchen. Only 
specimens from patients without prior treatment were 
included in the study. FISH analyses were performed 
on nine TMAs comprising OS samples of 267 patients, 
samples from other bone-forming tumors or tumor-like 
lesions of 144 patients, and a collection of 1,163 tumors of 
various types and normal tissue samples. For the CytoScan 
HD Arrays (Affymetrix, CA, USA) genomic DNA from 
fresh frozen samples of 73 independent OS patients was 
used. Full patient’s characteristics are presented in Table 1 
and Supplementary Tables S8, S10 and S11.
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Dual-color break-apart FISH
BAC clones RP11–1081A10 and RP11–107F4 
(BACPAC, Children’s Hospital Oakland Research 
Institute, USA) were nick-translated (Abbott 
Laboratories, USA) and labeled with fluorescent dUTPs 
(Enzo Life Sciences, USA) resulting in red labeling of 
RP11–1081A10 and green labeling of RP11–107F4. 
The in situ hybridisation was performed according to 
routine protocols. Tumors were considered to have a 
rearrangement in the 5’ region of TP53 when at least 
10% of cells showed clearly separated green and red 
hybridisation signals (= FISH positive/break-apart).
CytoScan HD arrays
Genome-wide CytoScan HD Arrays (Affy-
metrix, CA, USA) were performed according to the 
manufacturer’s instructions using 250 ng of genomic 
DNA from each tumor sample. To evaluate copy number 
variations (CNV), data was processed using the Nexus 
Copy Number software (Version 7.0, BioDiscovery, CA, 
USA) with integrated algorithms for segmentation and 
normalization.
Clinical characteristics of a four-generation LFS 
family
All members of the LFS family who contributed 
samples to this study or legal representatives gave informed 
consent and are indicated with numbers in Figure 3A. The 
study was approved by the respective ethical review boards. 
P1 was diagnosed with colon cancer at age of 22 years, an 
oligodendroglioma at 34 years, and an undifferentiated 
pleomorphic sarcoma at 40 years, and basal cell carcinoma 
and squamous cell carcinoma of the skin, P2 a phyllodes 
tumor of the breast at 12 years, P6 a rhabdomyosarcoma at 
33 months, P12 an OS at 19 years, H2 an OS at 13 years, 
P13 bilateral ductal carcinoma in situ at 32 and 33 years, 
meningioma at 38 years, and adenocarcinoma of the lung at 
40 years. Family members P1, P7, P13, P12, H1, H2, H4, 
H5 and H6 were analyzed by multiplex ligation-dependent 
probe amplification (MLPA) (MRC-Holland) according to 
the manufacturer’s recommendation to test for deletions in 
TP53 with 2 probe sets in exon 1, and one probe set each 
in exons 2 – 9, 11, and 12. Both probe sets for exon 1 with 
probe pair TGTAGCTGCTGGGCTCCGGGGACACT 
and TTGCGTTCGGGCTGGGAGCGTGCTTTCCACGA 
(exon 1) and CCATTTCCTTTGCTTCCTCCGGCA and 
GGCGGATTACTTGCCCTTACTTGTCATGGCGACTGT 
CCAG (5’ of exon 1) indicated a heterozygous deletion of 
exon 1 for P1, P13, P12, H2 and H4 but not for P7, H1, H5 
and H6. The presence of the deletion co-segregated with 
affection status except for H4 who was tested positive but 
had no cancer at the age of 10 years (of note, H4 is being 
followed with repeat imaging due to suspicious lesion in the 
brain that could represent the development of an early tumor).
qRT-PCR of TP53 in samples of LFS family
RNA was isolated from PAXgene Blood RNA 
Tubes using the PAXgene Blood miRNA kit (Qiagen). 
RNA from fresh frozen tumor, H2, and RNA from a tumor 
derived cell line, P13, were isolated using RNAeasy 
Mini kit (Qiagen). The one step qRT-PCR was carried 
out using QuantiTect Probe RT-PCR kit (Qiagen), with 
a total of 50 ng RNA per PCR. The TaqMan primer/
probe set (LifeTechnologies) was used for TP53 full 
length (HS01034249) and the PrimeTime primer/probe 
set (Integrated DNA Technologies Inc.) for transcripts 
encoding for Δ133p53 and Δ160p53 were designed using 
sequences from Marcel and colleagues [42]. qRT-PCRs 
were performed on a Bio-Rad CFX device. Cq values were 
normalized against GAPDH as ΔCq and displayed relative 
to normal blood control as ΔΔCq as fold-change (2−ΔΔCq).
OncoScan FFPE Express (Molecular Inversion 
Probe) array
Samples were processed using the Affymetrix 
OncoScan FFPE Express kit according to the 
manufacturer’s instructions using 80 ng of genomic 
DNA from each tumor sample. To evaluate copy number 
variations (CNV) data was processed using the Nexus 
Copy Number software (Version 7.5, BioDiscovery).
Sequencing data
Sequences have been submitted to the Short Read 
Archive (http://trace.ncbi.nlm.nih.gov/Traces/sra/) at the 
National Center for Biotechnology Information (NCBI) 
with the study reference number PRJNA244486. LFS 
array data can be accessed at Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo/) with the study ID 
GSE64293.
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SUPPLEMENTARY FIGURES AND TABLES
Supplementary Figure S1: Genome rearrangements of four primary OS analyzed by DNA-PET sequencing.  
(A) Genomic SVs enriched for somatic events identified by genome-wide mate-pair sequencing of long DNA fragments of four OS tumors 
are displayed by Circos [1]. The human genome is arranged in a circle with the chromosome number and the cytogenetic bands displayed 
in the outer ring, the somatic copy number alterations in the next inner concentric ring (red, amplifications; blue, deletions), followed by 
deletions, tandem duplications, inversions/unpaired inversions, and in the center of the circle inter-chromosomal rearrangements. Isolated 
and complex inter-chromosomal rearrangements are represented by orange and black lines, respectively. (B) Distribution of SV categories 
which are enriched for somatic events in the four OS tumors shown in A, X-axis indicates absolute numbers of color coded SV types as 
described in the legend.
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Supplementary Figure S2: Copy number profile of four primary OS derived from DNA-PET sequencing. Chromosomes 
are aligned on the x-axis and copy number values are on the y-axis. All four OS display a large number of copy number alterations.
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Supplementary Figure S3: Evidence for chromothripsis in OS tumor KRD. (A) Copy number profiles of chromosomes 13, 
5 and 6 derived from concordant mapping paired-end tag sequencing data relative to simulation control. Chromosomes are aligned on the 
x-axes and copy number values are on the y-axes. Black dots indicate copy number based on 10 kb windows. Red lines are smoothened 
copy number across neighboring windows. (B) Enlarged copy number profile of chromosome 13 positions 47.7 Mb to 115.1 Mb. Data 
points are based on 10 kb windows. (C) Capture of genomic Circos plot [1] including chromosomes 13, 5 and 6. Information displayed in 
the concentric rings is as follows from outside to inside: chromosome number; cytogenetic banding, copy number with gains in red and 
losses in blue; deletions; tandem duplications; inversions/unpaired inversions; inter-chromosomal rearrangements. Color coding for inter-
chromosomal SVs is indicated in orange and inter-chromosomal SVs in complex regions in black.
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Supplementary Figure S4: Validation of TP53 rearrangements by PCR and Sanger sequencing. Patient IDs are indicated 
in bold capital letters. Bases matching between the rearrangement and the reference sequences of the participating regions are indicated by 
vertical lines. Micro homologies between the two participating break point regions are illustrated by green vertical lines. Break point IDs 
are shown in red.
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Supplementary Figure S5: Balanced translocation between intron 1 of TP53 and a locus on chromosome 1 in OS 
patient YZH. (A) Chromosome 17 and 1 loci of the human reference genome (hg19) which show the PET mapping regions indicating 
the balanced translocation between the two loci. Genes showing the major splice variants derived from the UCSC known genes database 
[2] are shown on top and smoothened copy number information derived from DNA-PET sequencing data is shown at the bottom (purple 
tracks) in the Genome Browser. Genes transcribed from the plus strand are represented in green, genes transcribed from the minus strand 
are represented in blue. Boxes indicate exons, barbed lines indicate introns. Mapping regions of 5’ and 3’ PET clusters and read orientations 
are indicated by dark red and pink arrow heads, respectively, with turquois lines indicating the side of breakpoint. Gray and yellow shading 
indicate sequences of 555 bp and 293 bp which are shared by both sides of the balanced translocation product for chromosome 17 and 1, 
respectively. Red lines indicate connectivity between the two chromosomes. Note that DNA-PET coordinates differ from the exact break 
point coordinates which have been determined by PCR and Sanger sequencing and which are shown in Table S7. (B) Translocation outcome 
as indicated by DNA-PET truncating TP53 and duplicating gray and yellow shaded sequences.
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Supplementary Figure S6: Inverted insertion of 12.5 kb of chromosome 6 into intron 1 of TP53 in OS patient 
PZP. Identification of an inverted insertion originating from chromosome 6 containing ENPP1 exon 19 to the 5’ part of exon 25 into intron 
1 of TP53 by DNA-PET. For more detailed track information, see legend of Supplementary Figure S5, for exact break point coordinates, 
see Table S7. (A) Chromosome 17 and 6 loci of the human reference genome (hg19) which show the PET mapping regions indicating the 
inverted insertion. (B) Insertion outcome as indicated by DNA-PET creating a potential fusion transcript between exon 1 of TP53 (right 
blue box) and exon 19 to the first part of exon 25 of ENPP1. Since exon 1 of TP53 is non-coding, and the inserted part of ENPP1 exon 25 
contains a stop codon, the formation of a fusion protein is unlikely.
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Supplementary Figure S7: TP53 break point cluster region is located near sites of active chromatin and DNA breaks 
occur in LINE sequences. UCSC genome browser view (http://genome.ucsc.edu/; [2]) of the TP53 intron 1 locus. (A) ENCODE 
epigenetic information is derived from the analysis of commonly used cell lines [3]. Tracks from top to bottom are: gene annotation after 
exclusion of ‘problematic’ transcripts; user track indicating the break point cluster region; histone 3 lysine 27 acetylation (H3K27ac) 
chromatin immunoprecipitation-sequencing (ChIP-seq) of seven cell lines as a superimposed layered track suggests active regulatory sites; 
DNaseI hypersensitive sites derived from ChIP-seq and a uniform peak analysis represent open chromatin; integrated active chromatin 
information prediction of DNaseI hypersensitivity, formaldehyde-assisted isolation of regulatory elements (FAIRE), and ChIP-seq of three 
cell lines; chromatin state segmentation analysis: dark red = active promoter, light red = weak promoter, orange = strong enhancer, yellow 
= weak/poised enhancer, dark green = transcriptional transition/elongation, light green = weak transcription. (B) TP53 intron 1 break points 
are indicated by red vertical lines and IDs. Below are UCSC track information on repetitive DNA sequences.
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Supplementary Figure S8: Regulatory information of translocation partner site on chromosome 1 of TP53 translocation 
in OS patient KRD. UCSC genome browser view of repetitive sequences and ENCODE regulatory information. Break point location is 
indicated by red arrow. For track description, see legend of Supplementary Figure S7.
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Supplementary Figure S9: Regulatory information of translocation partner site on chromosome 6 of TP53 translocation 
in OS patient KRD. UCSC genome browser view of repetitive sequences and ENCODE regulatory information. Break point location is 
indicated by red arrow. For track description, see legend of Supplementary Figure S7.
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Supplementary Figure S10: Regulatory information of translocation partner site on chromosome 5 of TP53 
translocation in OS patient KRD. UCSC genome browser view of repetitive sequences and ENCODE regulatory information. Break 
point location is indicated by red arrow. For track description, see legend of Supplementary Figure S7.
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Supplementary Figure S11: Regulatory information of partner site on chromosome 1 of TP53 balanced translocation 
in OS patient YZH. UCSC genome browser view of repetitive sequences and ENCODE regulatory information. Break point locations 
are indicated by red arrows. For track description, see legend of Supplementary Figure S7.
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Supplementary Figure S12: Regulatory information of genomic region on chromosome 6 which got inserted into TP53 
in OS patient PZP. UCSC genome browser view of repetitive sequences and ENCODE regulatory information. Break points of the 
12.5 kb segment which got inserted into intron 1 of TP53 are indicated by red arrows. For track description, see legend of Supplementary 
Figure S7.
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Supplementary Figure S13: Copy number analysis of the TP53 locus of LFS family members 1 and 13 by CytoScan 
array. CytoScan array derived copy number analysis of LFS patients 1 and 13 and as copy number loss control gastric cancer cell line 
SNU16. Gene content of chr17:7,544,275..7,619,275 (NCBI genome build 37) is shown on top, log2 ratios of genomic marker intensities 
(y-axis) are displayed across the locus (x-axis). SNU16 has a heterozygous deletion of the entire locus (log2 ratio ca. 0.5) and intensities of 
seven markers of patients 1 and 13 show lower intensities (log2 ratio ca. 0.5, red box) which was not called by Chromosome Analysis Suite 
version CytoB-N1.2.2.271 (r4615; Affymetrix).
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Supplementary Figure S14: Copy number analysis of the TP53 locus of two tumors of LFS family member P13 by 
OncoScan array. OncoScan array derived copy number analysis of lung carcinoma and meningioma of LFS patient P13. Gene content 
of chr17:7,544,000..7,618,000 (NCBI genome build 37) is shown on top, log2 ratios of genomic marker intensities (y-axis) are displayed 
across the locus (x-axis). Copy number ratio relative to control indicates the presence of two chromosome copies and B allele frequency 
shows only homozygous variant calls with frequencies close to 1 or 0, respectively, indicating LOH.
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Supplementary Figure S15: Copy number analysis of the TP53 locus of metastasis of LFS family member H2 by 
OncoScan array. OncoScan array display is as described for Supplementary Figure S14.
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Supplementary Figure S16: Hypothetical TP53 intron 1 rearrangement mechanism in OS. Schematic representation of a 
hypothetical rearrangement mechanism that can explain the duplication of 46 bp to 555 bp flanking the TP53 intron 1 rearrangement points. 
We suggest that at a site of intense transcription, a large ‘bubble’ of two single DNA strands or an accumulation of more than one, maybe 
stalled, transcription bubbles occur. DNA breaks on both strands at different positions in the bubble(s) followed by end repair and NHEJ 
with other chromosomal partner sites. (A) to (G) chronological order of events. Single DNA strands are represented by light/dark green and 
red lines, respectively. DNA double strand pairing is represented by short gray lines. After opening of the DNA double strand, two single 
strand breaks occur that are not complementary to each other, i.e. that are at different sites of the bubble, resulting in a double strand break 
with about 50 to 550 bases of single strand 5’ overhangs. Complementary strands are filled in 5’ > 3’ by the DNA repair machinery (dashed 
lines) resulting in a duplication of the single stranded segments. This process can take place at two different loci in the same cell (and same 
transcriptional hub) and can result in the fusion of different genomic regions by NHEJ (F). (G) As a result, both reciprocal fusion products 
contain the same flanking sequences. ss-break, single strand DNA break. Of note, we observed only in patient YZH that also the non-TP53 
locus (chr. 1) shows duplication of break point-flanking sequences suggesting that the non-TP53 translocation partner site can have no or 
short single strand overhangs.
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Supplementary Table S1: Sequencing statistics of four OS primary tumors by DNA-PET using the 
SOLiD platform
Library Sample Total beads Both tags 
mapped
Span [bp] Within span Within span 
(NR)1
Redun-
dancy
Coverage2 dPETs3 dPET 
clusters 
(size 2+)4
DHO004HG19 AJF 172,897,363 92,577,911 1510-2570 89,073,088 66,594,042 1.34 46.85 1,383,636 2,278
DHO005HG19 PZP 275,786,428 102,187,549 1910-3060 86,873,155 62,826,184 1.38 53.78 13,893,715 3,811
DHO006DHO008HG19 KRD 286,596,700 168,109,213 660-3980 146,976,367 42,328,532 3.47 23.13 9,695,122 2,733
DHO007DHO009HG19 YZH 378,703,399 167,518,527 1140-4030 147,613,747 60,005,658 2.46 44.98 10,336,682 3,707
1)non-redundant paired reads; exclusion of identical PCR amplicons
2)physical genome-wide coverage
3)discordant mapping paired-end tags
4)clusters of dPETs of which their tag one reads and tag 2 reads map to the same regions (regions A and B, respectively), 
connecting the same two regions
Supplementary Table S2: Statistics of filtering of dPET cluster artifacts before identification 
of SVs
dPET clusters of size ≥3 before artifact filtering 4737
Filter clusters with superclustersize >40 and 
UniqueClusterSize <6
218
Blast1 score >2000 265
Blast1 alignment type EC 140
MaxSelfChainLeftCov >80 240
MaxSelfChainRightCov >80 6
Match with simulated library 226
Exclude Overlap 1
dPET clusters of size ≥3 after artifact filtering 3641
For explanation of individual steps see Materials and Methods and (Hillmer, Yao et al. 2011; Ng, Hillmer et al. 2012).
Supplementary Table S3: Statistics of germline and somatic SVs identified in four OS tumors
DHO004HG19 DHO005HG19 DHO006DHO008HG19 DHO007DHO009HG19
AJF PZP KRD YZH
Deletion 773 603 358 532
Tandem duplication 20 3 11 15
Unpaired inversion 87 72 92 110
Isolated translocation 49 53 129 80
Inversion 33 30 31 39
Insertion 18 30 17 27
Complex 
rearrangement
68 57 111 193
Total 1,048 848 749 996
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Supplementary Table S4: Statistics of somatic SVs identified in four OS tumors
DHO004HG19 DHO005HG19 DHO006DHO008HG19 DHO007DHO009HG19
AJF PZP KRD YZH
Deletion 289 177 63 112
Tandem duplication 15 1 7 10
Unpaired inversion 56 46 64 89
Isolated translocation 34 36 119 72
Inversion 3 0 2 4
Insertion 9 6 2 4
Complex 
rearrangement
28 23 91 129
Total 434 289 348 420
Supplementary Table S5: Statistics of genes affected by somatic SVs of four OS primary tumors
Type of gene alteration Number of genes
Genes in deletions (<1Mb) 39
Genes in tandem duplications (<1Mb) 2
Genes spanning SVs within one intron 181
Genes spanning SVs affecting coding sequences 31
Fusion genes 67
5’ truncated genes 265
3’ truncated genes 329
Supplementary Table S6: Somatic SVs of four OS primary tumors (Supplementary Data Set)
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Supplementary Table S7: Break point coordinates of TP53 affecting rearrangements in four OS 
tumors
Sample SV ID Strand 
left
Validated break left Strand 
right
Validated break 
right
Structural 
variation
Truncated 
gene left 
(strand)
Truncated 
gene right 
(strand)
Predicted 
fusion gene 
or mode of 
truncation
AJF D38 + chr17:7,557,506 + chr17:7,651,285 deletion ATP1B2(+) DNAH2(+) ATP1B2-DNAH2
KRD CT54 + chr5:137,520,904 + chr17:7,586,797 complex 
inter-chr.
KIF20A(+) TP53(–) 2 x 3’ 
truncation
KRD CT7 – chr6:36,559,119 + chr17:7,588,049 complex 
inter-chr.
– TP53(–) 3’ truncation
KRD CT15 + chr1:172,555,688 – chr17:7,588,094 complex 
inter-chr.
SUCO(+) TP53(–) SUCO-TP53
PZP T5 – chr6:132,198,8011) + chr17:7,586,8841) insertion 
inter-chr.
ENPP1(+) TP53(–) TP53-ENPP12)
PZP T12 + chr6:132,211,834 – chr17:7,586,948 insertion 
inter-chr.
ENPP1(+) TP53(–) ENPP1-TP532)
YZH T6 – chr1:226,260,906 + chr17:7,587,974 isolated 
translocation
– TP53(–) 3’ truncation
YZH T13 + chr1:226,261,198 – chr17:7,588,529 isolated 
translocation
– TP53(–) 5’ truncation
1)DNA-PET mapping coordinates; rearrangement point could not be amplified by PCR
2)One fusion transcript based on an insertion of a part of ENPP1 into TP53 (see Figure S5)
Supplementary Table S8: Bone-forming tumors or tumor-like lesions other than OS
Diagnosis n Diagnosis n
Fibrous dysplasia 42/50
Fibrocartilaginous 
mesenchymoma
4/4
Aneurysmal bone cyst 14/17 Nora lesion 2/2
Osteoid osteoma 14/15 Osteofibrous dysplasia 2/2
Ossifying fibroma 13/15 Osseous dysplasia 2/2
Reactive bone formation 12/13 Desmoplastic fibroma 2/2
Osteoblastoma 8/8 Adamantinoma 1/1
Myositis ossificans 7/9 Non-ossifying fibroma 1/1
n = number of evaluable cases/total number of cases
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Supplementary Table S9: Overall survival of TMA OS patients stratified for TP53 FISH signal and 
protein expression
Overall survival 5 years 10 years
TP53 FISH
 FISH negative (n = 192) 61.20% 58.70%
 FISH positive (n = 23) 64.90% 64.90%
TP53 immunhistochemistry
 IHC negative (n = 170) 59.80% 57.10%
 IHC positive (n = 42) 59.20% 54.30%
Supplementary Table S10: TMA content and result of TP53 FISH analysis
Tissue type n
Adrenal gland, adenoma 4/4
Brain, astrocytoma 11/12
Brain, glioblastoma 15/17
Brain, Meningeoma 14/15
Brain, normal 1/1
Brain, oligodendroglioma 5/5
Breast, ductal carcinoma 18/20
Breast, lobular carcinoma 16/18
Breast, medullary carcinoma 21/24
Breast, mucinous carcinoma 7/8
Breast, normal 1/1
Breast, tubular carcinoma 8/9
Cervix, in situ carcinoma 10/11
Colon, adenoma 41/46
Colon, carcinoma 21/24
Colon, normal 0/0
Endometrium, endometrioid carcinoma 12/13
Endometrium, normal 1/1
Endometrium, serous carcinoma 11/11
Esophagus, adenocarcinoma 3/3
Esophagus, normal 2/2
Esophagus, small cell carcinoma 1/1
Esophagus, squamous cell carcinoma 7/8
Fat tissue, normal 0/0
Gall bladder, carcinoma 12/13
Gall bladder, normal 5/6
Heart, normal 4/4
(Continued)
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Tissue type n
Kidney, chromophobe carcinoma 2/3
Kidney, clear cell carcinoma 24/27
Kidney, normal 3/3
Kidney, oncocytoma 8/8
Kidney, papillary carcinoma 11/12
Larynx, carcinoma 13/14
Liver, hepatocellular carcinoma 28(32
Liver, normal 5/5
Lung, adenocarcinoma 54/61
Lung, large cell carcinoma 15/17
Lung, normal 4/5
Lung, small cell carcinoma 15/15
Lung, squamous cell carcinoma 30/32
Lymph node, Hodgkin Lymphoma 15/18
Lymph node, non Hodgkin Lymphoma 18/19
Lymph node, normal 2/2
Mesothelioma 13/14
Myometrium, normal 2/2
Myometrium, myoma 18/22
Nerve, neurofibroma 12/14
Nerve, schwannoma 8/9
Oral cavity, carcinoma 18/21
Oral cavity, normal 5/5
Ovary, endometrioid carcinoma 18/20
Ovary, mucinous carcinoma 3/3
Ovary, normal 0/0
Ovary, serous carcinoma 17/18
Pancreas, adenocarcinoma 14/15
Pancreas, normal tissue 4/6
Paraganglioma 5/6
Parathyroid, adenoma 17/21
Parathyroid, normal 0/0
Pheochromozytoma 10/11
Prostate, adenocarcinoma 33/37
Prostate, normal 9/9
Salivary gland, cylindroma 11/11
Salivary gland, normal 6/6
(Continued)
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Tissue type n
Salivary gland, pleomorphic adenoma 16/18
Salivary gland, Warthin tumor 7/8
Skeletal muscle, normal 2/3
Skin, basal cell carcinoma 23/27
Skin, histiocytoma 9/10
Skin, Kaposi sarcoma 8/9
Skin, melanoma 32/36
Skin, naevus 22/24
Skin, normal 4/4
Skin, squamous cell carcinoma 10/10
Small intestine carcinoma 8/9
Small intestine, normal 0/0
Soft tissue, giant cell tumor of tendon sheath 10/11
Soft tissue, hemangioma, capillary type 6/6
Soft tissue, leiomyosarcoma 13/15
Soft tissue, lipoma 5/5
Soft tissue, liposarcoma 6/6
Soft tissue, pleomorphic sarcoma 9/10
Stomach, carcinoma, diffuse type 7/8
Stomach, carcinoma, intestinal type 14/17
Stomach, normal 4/5
Testis, non-seminomatous carcinoma 16/20
Testis, normal 3/3
Testis, seminoma 14/14
Thymus, normal 1/1
Thymus, thymoma 8/8
Thyroid, adenoma 11/12
Thyroid, follicular carcinoma 12/13
Thyroid, normal 1/1
Thyroid, papillary carcinoma 5/5
Urinary bladder, invasive carcinoma 10/11
Urinary bladder, non-invasive carcinoma 10/10
Urinary bladder, normal 15/16
Vulva, squamous cell carcinoma 8/8
Total tumor 966/1072
Total normal 84/91
Total tumor + normal 1,050/1,163
n = number of evaluable cases/total number of cases
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Supplementary Table S11: Summary of TMA TP53 FISH analysis
Kind of tissue n
Normal tissue 84/91
Brain tumors 45/49
Breast tumors 70/79
Gynecologic tumors 97/106
Genitourinary tumors 128/142
Others 118/131
Gastrointestinal tumors 208/234
Lung tumors 114/125
Lymphoid tumors 33/37
Skin tumors 104/116
Soft tissue tumors 49/53
Total 1,050/1,163
n = number of evaluable cases/total number of cases
Supplementary Table S12: Copy number variations of two affected LFS family members based 
on CytoScan array analysis
Patient CN1 
State
Type Chr Min2 Max2 Size (kb) Marker 
Count
Confidence Genes Comment for CNV 
shared between patient 
1 and 2
1 0 Loss 2 41,239,606 41,250,106 10.5 5 0.9954
1 1 Loss 2 168,172,736 168,180,626 7.89 11 0.9297
13 1 Loss 2 168,172,736 168,180,626 7.89 11 0.9623
1 1 Loss 3 160,772,598 160,778,822 6.224 9 0.9388 PPM1L
13 3 Gain 4 132,780,784 132,894,269 113.485 45 0.8855
1 3 Gain 5 32,108,414 32,162,756 54.342 53 0.9247 PDZD2, GOLPH3 CNV site in DGV
13 3 Gain 5 32,108,414 32,166,970 58.556 55 0.9186 PDZD2, GOLPH3 CNV site in DGV
13 1 Loss 7 3,833,336 3,852,657 19.321 14 0.9512 SDK1
13 0 Loss 8 39,234,303 39,357,501 123.198 8 1.0000
ADAM5P, 
ADAM3A
13 1 Loss 8 84,367,320 84,380,551 13.231 11 0.9519
1 1 Loss 8 96,076,737 96,098,249 21.512 14 0.9106 MIR3150 CNV site in DGV
13 1 Loss 8 96,076,737 96,098,249 21.512 14 0.9538 MIR3150 CNV site in DGV
13 3 Gain 12 32,005,944 32,062,001 56.057 40 0.9289
1 1 Loss 12 69,023,587 69,032,212 8.625 9 0.9250 RAP1B
13 3 Gain 14 106,022,513 107,051,759 1029.25 23 0.9158
KIAA0125, 
ADAM6, 
NCRNA00226, 
NCRNA00221
(Continued)
Chapter 2. Results
60
www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2015
Patient CN1 
State
Type Chr Min2 Max2 Size (kb) Marker 
Count
Confidence Genes Comment for CNV 
shared between patient 
1 and 2
13 1 Loss 15 20,175,623 22,504,198 2328.58 48 0.8801
HERC2P3, 
GOLGA6L6, 
GOLGA8C, 
BCL8, POTEB, 
NF1P1, 
LOC646214, 
CXADRP2, 
LOC727924, 
OR4M2, OR4N4, 
OR4N3P
CNV site in DGV
1 1 Loss 15 22,300,190 22,504,198 204.008 38 0.8682
LOC727924, 
OR4M2, OR4N4, 
OR4N3P
CNV site in DGV
13 3 Gain 16 34,455,753 34,762,298 306.545 84 0.9135
LOC283914, 
LOC146481, 
LOC100130700
13 1 Loss 17 28,303,998 28,317,131 13.133 18 0.9198 EFCAB5
1 1 Loss 18 1,722,426 1,838,901 116.475 110 0.9158
13 3 Gain 18 51,345,688 51,423,648 77.96 57 0.9415
13 3 Gain 19 20,833,215 20,987,762 154.547 123 0.9063 ZNF626
13 1 Loss 19 28,294,543 28,318,358 23.815 15 0.9048
13 3 Gain 19 58,364,597 58,383,708 19.111 20 0.9187 ZNF587, ZNF814
1 1 Loss 20 32,806,979 32,822,219 15.24 9 0.9050
13 3 Gain 22 22,861,993 23,358,013 496.02 65 0.9360
ZNF280B, 
ZNF280A, 
PRAME, 
LOC648691, 
POM121L1P, 
GGTLC2, 
MIR650, IGLL5
1 2 Gain X 2,706,943 2,713,139 6.196 2 0.2191 XG
1 2 Gain X 58,094,436 62,058,620 3964.18 19 0.2466
1 4 Gain X 150,192,436 150,195,253 2.817 8 0.9315
1Copy number
2Position based on NCBI human reference Build 37
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O
steosarcomas (OS) are primary malignant tumours of
bone with complex karyotypes showing abundant
structural and numerical aberrations. Rapid tumour
progression and early metastatic spread are the rational for
multimodal treatment approaches that can achieve long-term
survival in about 60% of patients. Effective treatment options are
still lacking for the remaining 40% of patients suffering from
refractory or recurrent disease, however1. A partial explanation
for treatment failure might lie in different aetiologies responsible
for the structural aberrations marking the onset of the disease and
resulting in a variety of mutations in genes and pathways of
which only few are targetable. OS arise owing to mutations in the
TP53 tumour suppressor gene2–4 and a plethora of other cancer
drivers, as for example RB1 (refs 2–4), ATRX2,3, DLG23 (ref. 2),
RUNX2 (ref. 5), WRN6,7, RECQL4 (refs 5,7,8), CDKN2A/B9,
BLM7, PTEN3 and other PI3K/Akt/mTOR pathway members‘
each of which contribute only to a small proportion of patients.
As a consequence, widely applicable therapeutic targets have not
been identiﬁed so far.
The introduction of high-throughput sequencing of cancer
genomes has expanded a list of potential OS driver genes, but
disappointingly failed to provide important leads that could
improve patients’s care. In fact, data published so far only
conﬁrmed that the intricate nature of these tumours develops
through cancer heterogeneity promoting the accumulation of
chromosomal aberrations, kataegis and chromothripsis2–4.
Marked inter- and intratumoural heterogeneity seems to be
linked to the observed differences in treatment efﬁcacy and
clinical outcome of the respective patients10, but the particular
sets of mutations underlying these patterns, the clonal frequencies
of driver mutations and how different (sub-)populations of
tumour cells relate functionally to each other, remains largely
unknown. In this study, we search for driver gene mutations in
123 OS and attempt to reduce the complexity of their genomes by
applying abstraction analyses supplemented by clonal mapping
and ordering. Finding common traits of different cell lineages
within and between tumours seems to constitute a ﬁrst step
towards developing more individualized and effective treatment
strategies in the future.
Results
Mutation processes moulding the exomes of 31 OS. Our
discovery set for whole-exome sequencing comprised 31 OS,
which were sequenced at a median depth of B150 (range
131–370) alongside with paired constitutional DNA from
peripheral blood (Table 1). All tumour samples were derived
from pre-therapeutic biopsies. Making use of Stampy and
Platypus programs for mapping and variant calling, the number
of somatic base substitutions (single-nucleotide variants (SNVs))
and indels called with high conﬁdence ranged from 7 to 3,153
(median¼ 66.5) and 17 to 529 (median¼ 33.5) per exome,
respectively. Of these, a median of 21 SNV changes (range 4–174)
and seven small indels (range 2–210) were potentially functional
within protein-coding regions. The SNV spectrum for each OS
exome is shown in Fig. 1a and Supplementary Figs 1 and 2. With
two exceptions, the C:G4T:A changes were the most common
changes followed by C:G4A:T and T:A4C:G changes. The
mutation burden of OS was similar to the ageing signature of
most tumour types from the pan-cancer analysis11, however,
a decomposition of mutation spectra with a non-negative
matrix factorization algorithm revealed a pattern similar to the
signatures 3 and 5 (Fig. 1b and Supplementary Fig. 3). A subset of
tumours of this class is known to acquire a characteristic pattern
of substitution mutations including kataegis and the presence of
signature 3 was strongly associated with BRCA1 and BRCA2
mutations within breast and pancreatic cancer types11,12.
Driver mutations impair cell control of genome integrity. For
the discovery of somatic driver mutations we restricted our
analysis to protein-coding regions. A minimum variant allele
frequency of 0.05 was set. We then prioritized genes for further
investigation by ﬁltering mutations to exclude all SNVs with
moderate or benign predicted functional effects (Sorting
Intolerant From Tolerant (SIFT) score¼o0.05 and Mutation
Taster and PolyPhen2 40.8). All protein-truncating and splice-
site mutations were retained. We then identiﬁed genes that were
mutated in two or more tumours and inspected all variant reads
in the Integrated Genome Viewer to exclude any mutations
at sites of evidently poor quality. Eventually, 26 genes
(Supplementary Data 1) including some that had already been
reported in the context of OS (for example, ARTX, SFPQ,
FGFRL1 and RB1) remained2–4,13.
Since patients with Werner, Li–Fraumeni, Rothmund–
Thomson and Bloom syndromes have a comparably higher risk
of OS8,14,15, we examined our sequencing data for germline
mutations in the WRN, TP53, RECQL4 and BLM genes. We
identiﬁed two germline TP53 mutations (OS-241 and OS-228),
one germline WRN mutation in addition to loss of heterozygosity
(LOH) around the locus (OS-230) and two rare germline
RECQL4 variants with unknown signiﬁcance (OS-227 and OS-
238). We then applied the same prioritization scheme to the
remainder of genes with germline variants. Prioritized cancer
drivers not previously reported in OS included RET, MUTYH,
NUMA1, FANCA, BRCA2 and ATM. We chose these genes for
further investigation, based on the presence of at least two clearly
pathogenic mutations and/or co-segregation of mutations with
cancer in the respective families. Furthermore, these genes were
excellent functional candidates.
We validated mutations detected in 388 genes (Supplementary
Data 2) by Ion Torrent sequencing in the discovery set of
tumours and then undertook replication testing of 30 genes
(Supplementary Data 3) in a set of additional 92 unpaired
OS. The analysis of merged variant calls from 123 tumours
yielded a total of 22, 10 and 11 TP53, RB1 and ATRX
mutations, respectively (Supplementary Table 1). Three tumours
acquired somatic RET mutations. One patient, OS-250, carried a
germline RET mutation, which at the time of diagnosis
had not yet manifested by multiple endocrine neoplasia type 2
but the mutation co-segregated with breast cancer and
rhabdomyosarcoma in two ﬁrst-degree relatives. Two de novo
germline RET mutations previously associated with late-onset
multiple endocrine neoplasia type 2 were identiﬁed in
patients OS-224 and OS-242. We also identiﬁed seven MUTYH
mutations (germline or somatic) and four, four, three and
one mutations in the FANCA, MDC1, NUMA1 and PTEN
genes, respectively. Somatic missense mutations in MDC1 and
NUMA1 genes affected conserved residues of protein domains
encoding nuclear localization signal and/or interacting with
other proteins of BRCA complex, for example CHEK2.
MUTYH mutations were equally distributed between an endo-
nuclease domain and a NUDIX-type hydrolase domain. There
were also two somatic WRN mutations affecting a
DNA-binding domain and three germline mutations in the
ATM gene, two of which have been linked to breast cancer
susceptibility before16,17.
The Intogen18 pathway analysis reassuringly identiﬁed ATRX
and RB1 as the main drivers (Supplementary Data 4). The
Intogen list of drivers did not include TP53 since there was only
one mutation in the discovery set of tumours, but TP53 and three
other genes (RB1, ATRX and ATM) were notably reported by
Intogen as drivers in the pan-cancer analysis19. Exploring gene
ontology of the remaining genes we found that many, if not all
genes, have been functionally related to DNA damage repair,
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chromosomal segregation and cell cycle control of genome
integrity8,20–24.
Structural and copy-number alterations. We next turned our
attention to somatic copy-number alterations (SCNA; Fig. 2a,b),
which affected 0.2 (OS-251) to 87% (OS-038) of OS genomes.
The median size of a SCNA called with high-sensitivity
settings was 4.7Mb and a typical genome contained 69 of such
events. Analysis of single-nucleotide polymorphism arrays using
dedicated data-processing methods identiﬁed large-scale genomic
instability25 and LOH26,27 signatures similar to that of breast and
ovarian cancers with BRCA1/2 inactivation in 91% (112/123;
Fig. 2c) and 78% (96/123; Fig. 2d) of OS, respectively.
The most frequent SCNA events involved gains of the long arm
of chromosome 8 (75%). It has been plausibly suggested that
gains of 8q target MYC in OS, but chromosome 8 gains in our set
of tumours involved very long segments without evidence of
targeting any gene speciﬁcally. Similarly, other frequent gains of
1p (55%), 1q (53%), 5p (46%), 6p (56%), 17p (66%) and 18p
(33%) involved large regions. Large deletions were almost as
Table 1 | Clinicopathological and summary mutation data for each OS.
ID Age Histology Site SNV Indels Dn:Ds Ts:Tv %SCNA Clonality
OS-046 10 Mixed Femur 91 24 2.8 1.76 67.45 3
OS-059 13 Osteoblastic Fibula 50 29 1.18 1.38 67.1 4
OS-061 12 Chondroblastic Femur 106 36 1.8 1.65 67.5 7
OS-063 17 Teleangiectatic Humerus 127 48 1.13 1.75 64.3 6
OS-065 15 Osteoblastic Tibia 78 34 1.75 1.43 44.2 3
OS-079 45 Osteoblastic Femur 48 20 2.35 1.17 56.2 2
OS-224 11 Osteoblastic Tibia 310 397 1.62 1.64 57.1 14
OS-225 14 Osteoblastic Tibia 38 25 1 1.53 50.8 2
OS-226 11 Osteoblastic Tibia 52 36 1.77 1.36 57.8 6
OS-227 19 Osteoblastic Femur 29 32 3 1.41 0.2 3
OS-228 13 Chondroblastic Femur 48 24 2 1.28 59.3 4
OS-230 18 Chondroblastic Tibia 192 185 1.5 1.23 62.5 11
OS-231 13 Chondroblastic Tibia 195 246 1.39 1.18 81.8 8
OS-232 21 Extraosseous Femur 606 529 2.59 1.18 61.1 16
OS-234 17 Osteoblastic Humerus 46 20 3.8 1.29 60.5 4
OS-235 14 Osteoblastic Tibia 52 23 1.7 0.79 76.2 5
OS-236 19 Chondroblastic Femur 46 37 2.6 1.29 59.4 5
OS-237 14 Chondroblastic Femur 29 28 1.33 1.89 44.9 5
OS-238 17 Osteoblastic Tibia 63 33 2 2.49 38.3 6
OS-240 15 Osteoblastic Femur 32 19 3.75 1.66 15.6 6
OS-241 5 Osteoblastic Fibula 7 19 – 0.4 NA 2
OS-242 14 Osteoblastic Tibia 35 17 7.33 0.94 26.4 4
OS-250 14 Osteoblastic Femur 70 35 1.25 0.79 20.5 4
OS-251 9 Osteoblastic Femur 106 38 1.64 0.89 0.2 9
OS-252 16 Chondroblastic Femur 253 33 0.82 2.37 34.7 4
OS-253 6 Chondroblastic Tibia 71 47 3.33 0.82 56.7 3
OS-253M 6 Chondroblastic Lung 167 56 2.15 0.77 70.1 12
OS-254 27 Mixed Fibula 33 20 1.25 2.14 30.1 1
OS-255 12 Chondroblastic Tibia 3,153 459 2.56 2.01 33.9 7
OS-256 17 Osteoblastic Tibia 50 44 2 1.78 55.6 4
OS-257 12 Mixed Tibia 1,993 345 1.35 1.92 17.6 4
OS-258 20 Unknown Humerus 104 29 2.22 1.66 29.4 7
NA, not applicable
SNV denotes high-quality somatic single-nucleotide variants; Dn:Ds denotes the ratio of non-synonymous to synonymous exonic mutations; Ts:Tv denotes a ratio of somatic exonic transitions to
transversions; % genome changed by SCNA, per cent of genome affected by copy-number changes; clonality denotes a number of clones estimated by PyClone algorithm.
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Figure 1 | Somatic SNV spectra and mutation signatures. (a,b) Data are derived from exomes of each tumour. Note that OS with very few somatic
SNVs are included for sake of completeness.
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common as gains, the most frequent involving chromosomes
3 (50%), 6q (45%), 5q (40%), 8p (43%), 10 (56%), 13 (50%),
16 (64%), 17 (47%), 18q (34%) and 19 (54%). Deletions of
these chromosomes almost invariably included main OS drivers
including TP53, BRCA2, RET, WRN, FANCA and RB1 (Fisher
exact test, Po0.01; Supplementary Fig. 4). We also found good
evidence supporting SCNA mutations in the BRCA1 gene itself
(26%) and in members of the homologous recombination repair
pathway—BAP1 (38%), PTEN (50%) and PALB2 (43%)—in
which exome sequencing did not identify any mutation.
We speciﬁcally searched for small (o1Mb) and focal
SNCAs that might represent oncogene ampliﬁcations or tumour
suppressor deletions. After ﬁltering out common variants,
20,758 regions were identiﬁed although only 80 were
found to be recurrent (deﬁned as having frequencies 415%;
Supplementary Fig. 5 and Supplementary Data 5). Two focal
SCNA involved gene loci with a strong a priori importance
in OS2,9, including a deletion of CDKN2A/2B located at
chromosome 9p21 (15%) and a deletion of DLG2 at
chromosome 11q14 (24%). Other SCNA were detected in
known fragile sites (WWOX, for example), deeply intragenic
regions as well as microRNAs and genes with no prior association
to cancer.
We then assessed the signiﬁcance of called SCNA regions by
using a random sampling model similar to the GISTIC analysis
(Supplementary Figs 6 and 7). After ﬁltering for SCNAs with
adjusted P values o0.01, 92, 412 and 322 ampliﬁcations (copy
number 44), gains (copy number¼ 3) and deletions (copy
number o2) remained (Supplementary Data 6), respectively.
TP53, RB1, PTEN, RUNX2, BAP1 and CDKN2A/B genes were
reassuringly among the over-represented SCNA regions, as well
as several new loci including a homozygous loss of interferon
genes on chromosome 9 (chr9: 21,248,029–21,408,261) and an
ampliﬁcation of a 10-gene locus on chromosome 1 (chr1:
59,762,489–62,907,413). We then re-examined each candidate
SCNA events for association with overall and/or disease-free
survival using the Cox regression model. Five loci (including
CDKN2A/B and TP53) were associated with an adverse outcome
of patients (Supplementary Fig. 8). Three SCNA loci were
associated with earlier onset of disease (Supplementary Fig. 9).
BRCAness as an emergent property of OS. Our hypothesis of
‘BRCAness’ does not replace the existing view of OS as a
monoclonal expansion of one initial TP53 mutant cell, but rather
offers an explanation of how the vulnerability to chromosomal
breakage may be sustained parallel to or in the absence of TP53
mutations. Using PyClone28 estimates of cellular frequencies we
found that TP53 and RB1 driver mutations were clonal events in
58 tumours (47%; Fig. 3). The remaining tumours (n¼ 65, 53%)
showed good evidence of the acquisition of genomic
instability through alternative pathways—for example, by
MUTYH mutations20—well before TP53, RB1 mutations and/or
BRCA-like traits emerged. We envision that OS at this stage also
acquired a propensity to shatter into subpopulations of cancer
cells. Given enough time, different cancer cell lineages are likely
to acquire private SCNAs in the BRCA1/2 genes (and in their
67 binding partners) simply by chance, and by the time the
disease emerges, different clonal populations will have already
gained partial or full deﬁciency in homologous recombination
repair. We ﬁnd this view consistent with evidence that, on
average, a typical OS carries 17 SCNA mutations in BRCA genes
and their core binding partners (Fig. 4a and Supplementary
Data 7), mutations in different ‘BRCA’ genes can be functionally
equivalent (for example, PALB2, CHEK2, PTEN and ATM
mutations result in chromosomal instability analogous to
BRCA1/2 mutations29–33) and OS are polyclonal (Table 1).
We therefore estimated the relative importance of each of the
69 ‘BRCA’ genes from the clonality of their SCNA mutations. For
Fig. 4b we used a clustering method based on Euclidian distances;
the individual position of each gene in the plot is the product of
clonal and subclonal frequencies of its SCNA events. It is not
surprising that the most frequently mutated and thus outlying
genes were TP53, RB1, BRCA2 and PTEN, and that TP53 and RB1
became even more outlying when SNV changes were included.
In fact, TP53 and RB1 were the only two genes mutated with
somatic SNV/indel mutations at a frequency 43%. Putative
cancer drivers with a propensity to carry clonal SCNAs were an
android receptor gene, the RNA gene XIST, the BRCA1 binding
partners RBBP7 and NCOA2, a BRCC3 metaloprotease unit of the
BRISC complex and CSTF2 that prevents inappropriate RNA
processing at sites of DNA repair.
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Figure 2 | Copy-number variation analysis. (a) Copy-number proﬁle of 123 OS genomes. (b) Signiﬁcantly over-represented copy-number alterations.
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Efﬁcacy of talazoparib inhibition in OS cell lines. Currently
there is no available OS cell line, which is fully deﬁcient in BRCA1
or BRCA2. Although this may constitute a bottleneck for current
experimental approaches, some OS cell lines can carry mutations
in other genes of the homologous recombination pathway leading
to defects functionally analogous to BRCA1 and BRCA2 muta-
tions (Fig. 4c). We tested three cell lines, one being a double
mutant in PTEN and ATM (MNNG/HOS) and two with
heterozygous SCNA mutations in the checkpoint kinase 2 CHEK2
(SAOS2) and FANCD2 gene (SJSA-1), respectively. SJSA-1 and
SAOS2 cells were included in the study mainly for comparative
purposes since the heterozygous mutations did not seem
sufﬁcient to result in homologous recombination repair
deﬁciency. Indeed, in vitro tests showed only a limited response of
SAOS2 and SJSA cells to a standalone 72-h treatment with
the phase-3 poly ADP ribose polymerase (PARP) inhibitor
talazoparib (Fig. 5). By contrast, MNNG/HOS cells showed good
evidence of IC50 after standalone treatment, and even a better
response when talazoparib was combined with the alkylating
agent temozolomide and the topoisomerase I inhibitor SN-38.
The reason for pursuing combined treatment strategies was that
the cytotoxicity of talazoparib results from the availability of
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single-stranded DNA breaks, which temozolomide and SN-38 are
particularly effective in creating34. Talazoparib concentrations of
up to 5 mM used in our experiments have been considered
therapeutically achievable concentrations in vivo according to a
recent study of Hopkins et al.35.
Discussion
Cataloguing mutations from 123 tumours has yielded several new
insights into the underlying mutational mechanisms in OS.
We identiﬁed clearly monoclonal mutation events in TP53 or RB1
in 47% of cases, whereas additional 40% of tumours could be
explained by invoking mutations in alternative driver genes.
Eight of these genes—BRCA2, BAP1, RET, MUTYH, ATM,
PTEN, WRN and RECQL4—are well-known Mendelian cancer
drivers, whilst the four remaining genes (ATRX, FANCA,
NUMA1 and MDC1) have been reported in the context of cancer
susceptibility2,22–24. In total, 87% of OS could be explained by any
of the 14 driver genes. Our ﬁndings thus supplement the
‘traditional’ TP53-centred model of OS evolution such that
molecular pathways functionally similar to TP53 can drive its
initial phases by conferring to genome instability. Tumours
without clonal TP53 mutations may still acquire subclonal TP53
mutations later which adds B25% to the total mutation
prevalence. This is important to realize when interpreting
ﬁndings of other studies as, for example, Chen et al.2 reported
structural and SNV mutations in TP53 in 30 of 34 genome-
sequenced tumours. In a second study, whole-exome sequencing
of 53 paediatric OS yielded a 75% prevalence of TP53 mutations3.
The difference between these and our estimate might in part
result from our inability to identify rearrangements within the
ﬁrst intron of TP53 (which we estimated at 15% frequency36), but
other aspects being equal, we conclude that not all previously
reported TP53 mutations are clonal and thus represent the
triggering event. Instead we envision a situation, in which
multiple oncogenic pathways drive chromosomal aneuploidy and
instability in early stages of OS evolution.
Mutational landscapes of two tumours without TP53 muta-
tions (Fig. 6) shall illustrate our hypothesis. The ﬁrst tumour
(OS-046) does likely acquired a homozygous mutation in
NUMA1, resulting in mitotic segregation errors that at some
point led to the chromoplexy of chromosomes 2, 8 and 17 driven
by inter-chromosomal exchanges. The evidence supporting
NUMA1 mutation as a triggering event in OS-046 stems
from the fact that all somatic SNV mutations were monoclonal,
which would be hardly possible if they were sequential to the
chromosomal instability. Similarly, an early evolutionary history
of the second tumour (OS-059) could have been driven either by
a germline MUTYH mutation or by a somatic RB1 mutation.
Mutations in both genes were found hemizygous in a tumour,
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Figure 5 | Cell viability assays. MNNG, SAOS2 and SJSA-1 OS cells were treated for 72 h with indicated talazoparib, temozolomide and SN-38
concentrations. Cell viability was assessed by a MTT assay and is expressed as percentage of untreated cells. Data are shown as mean±s.d. of three
independent experiments, each performed in triplicates. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
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both mutations were clonal events and the functions of both
genes are related to chromosomal instability2,20. However, a
parsimonious explanation would still favour a single somatic hit
in the MUTYH gene over two somatic hits in RB1.
In a recent study Nik-Zainal et al.12 described a distinct proﬁle
(which they termed proﬁle D) of substitutions and deletions in
breast cancer with BRCA1/2 mutations, which later was reported
by Alexandrov et al.11 as signature 3 in a pan-cancer analysis.
With two outliers (OS-241 and OS-079) we found this signature
(as a combination of signatures B and C; Fig. 1b) in 29/31 (94%)
tumours from which exome-sequencing data were available. This
seems particularly interesting because early evolution of OS has
historically been attributed to TP53 and RB1 driver mutations,
but the root molecular cause of its genomic complexity (in later
phases) remains unclear. Seeking to validate this ﬁnding we
turned to whole-genome copy-number proﬁles of 123 OS and
speciﬁcally looked for characteristic large-scale copy-number
changes that also constitute the hallmark of BRCA1/2-mutated
breast cancer12. Surprisingly, 84% of the analysed tumours
fulﬁlled these criteria, suggesting that exome ﬁndings are likely to
be correct and that various degrees of BRCAness are acquired
throughout OS evolution. A recent study in ovarian cancer
developed a LOH-based homologous recombination deﬁciency
score, which reﬂects the number of subchromosomal LOH
segments with a size exceeding 15Mbp. Intriguingly, a high
homologous recombination deﬁciency-LOH score, as seen in 78%
of OS assayed in our study, was shown to correlate with
deﬁciency in homologous repair and a positive response to a
combination treatment including a PARP inhibitor in breast
cancer27.
Putative deﬁciency in homologous repair and other similarities
between OS and tumours with BRCA-like phenotype indicate
a speciﬁc weakness that could be therapeutically exploited.
Speciﬁcally, the inhibition of PARPs contributing to DNA
damage repair was shown to induce cell cycle arrest and
apoptosis in BRCA1-, BRCA2- and PALB2-deﬁcient breast
cancers29,37. Furthermore, cancer cells with mutations in the
ATM pathway members and PTEN gene were also shown to be
sensitive to PARP inhibitors, thus raising the possibility that a
‘synthetic lethality’ approach could also be effective in OS30,33.
We sought to test this possibility on selected OS cell lines
(MNNG/HOS, SAOS2, SJSA-1, ZK58, HOS, MG-63 and U2-OS)
but none of them carried bi-allelic BRCA1/2 mutations. We
found, however, a good response of MNNG/HOS cells carrying a
disruptive gain in the PTEN gene and a deletion of the ATM gene
to a standalone treatment with the phase-3 PARP inhibitor
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talazoparib. Combined with the alkylating agent temozolomide or
the topoisomerase I inhibitor SN-38, 0.1 and 5mM concentrations
of talazoparib led to an even greater decrease of MNNG/HOS cell
viability, respectively. Furthermore, a good response of HOS and
MG-63 cells to the phase-2 PARP inhibitor olaparip was recently
reported by Smith et al.29.
Using OS cell line experiments impose a few limitations to our
study, however. Perhaps the most striking one stems from the
paucity of OS cell lines truly deﬁcient in BRCA1/2. This may
be surprising, but it should be noted that OS cell lines arise
through monoclonal expansions of one cancer cell surviving
immortalization, which may not necessarily be the most common
cell type in the tumour it is derived from. The molecular portrait
of OS presented here prerequisites the existence of intratumour
heterogeneity, which is in fact lost in vitro. The polyclonal nature
of OS also implies that BRCA-like traits of OS genomes might
result not only from BRCA1/2 mutations alone but also from
mutations in other genes of the homologous recombination
pathway, each of which confers to additional biological
properties. These limitations do not invalidate our ﬁndings or
conclusions, but suggest that, for example, responsiveness of
individual tumours to PARP inhibitors will not only depend on
the proportion of cancer cells with BRCA-like features but also on
the speciﬁc mutations and genes that bring about homologous
recombination deﬁciency.
In conclusion, the presented data support a BRCA-like
phenotype as a unifying trait of OS independently of which
oncogenic pathway drives tumorigenesis. We have shown that at
least 14 different genes underlie the disease, including Mendelian
cancer drivers for which OS has not been reported to belong
within their phenotypic repertoire. More importantly, the effect
of mutations within different genes and pathways seem to
complement each other and result in a speciﬁc signature
characteristic for BRCA1/2-deﬁcient tumours. Our ﬁndings
warrant further testing of PARP inhibitors in experimental
settings and eventually sequencing of individual tumours for
therapeutically targetable driver gene mutations.
Methods
Sample description. The discovery set comprised 31 previously untreated OS
samples, paired with peripheral blood or normal tissue. A paired primary tumour
and a metastasis was sequenced in one patient. Informed consent was obtained from
all patients and ethical approval was obtained from the local ethical
committee of Heidelberg (project no. S-327/2011) for the analysis of anonymized
samples and for the purpose of driver gene discovery. All tumour samples were
re-evaluated by an experienced bone pathologist and conﬁrmed the diagnosis and a
tumour content470% per sample. Genomic DNA was extracted from each tumour
and paired blood sample using standard methods. The replication set comprised 92
unpaired frozen pre-therapeutic tumour biopsies, which were subjected to the DNA
extraction the same way as the 31 tumours of the discovery set.
Exome sequencing. Exome capture was performed using the Agilent SureSelect
kits (version 4). Samples were quantiﬁed using the Qubit system (Invitrogen) and
sequencing libraries constructed from 1 mg DNA. Samples were sequenced using
the Illumina HiSeq 2000 platform as paired 100-bp reads with Chemistry version
3.0, with the aim of target coverage of 100 for the blood DNA and 200 for the
tumours. After removal of PCR duplicates using Picard, reads were mapped with
Stampy version 1.0.12 onto the Human Reference Genome (GRCh37d5/hg19).
SNVs and small indels were called with Platypus version 0.5 using the tumour-
normal pairs of bam ﬁles together to ensure comparable calls at every locus.
Variants were only called if they were assigned sufﬁciently high posterior
probability (phred score 420). We removed the allele bias ﬁlter to increase
sensitivity. Finally, for selected variants, we made sure that the automatic call
matched the data by expert visual inspection of the mapped reads onto the
reference genome using read direction colouring on top of the standard integrated
genomic viewer scheme.
Annotation was performed using ANNOVAR using hg19 reference genome
and 2014 versions of standard databases and functional prediction programs.
We excluded duplicated genomic regions (490% homology) from the analysis and
variants within regions with low mapability scores. Variants were annotated with
ANNOVAR Refseq gene model using dbSNP(135); 1,000 genomes project allele
frequencies (October 2014), 6,500 exome-sequencing project allele frequencies,
University of Santa Cruiz (UCSC) segmental duplication scores and UCSC 46
species conservation scores and predictions of functional importance from SIFT,
PolyPhen2 and Mutation Taster.
For ﬁltering of variant calls for analysis, calls were ﬁrst compared between
matched constitutional and tumour samples to identify somatic mutations. For the
analysis of mutation burden and mutation spectra, we applied the following
exclusion ﬁlters to somatic variants: (i) presence in a segmental duplication region
or a region with mapability scoreo0.5; (ii) variant present in any read from paired
normal sample; (iii) fewer than 10 reads in total at the variant site in the normal
sample; (iv) fewer than 8 reads in total in the tumour; (v) fewer 3 three variants in
the tumour; variant allele frequency o5% in the tumour; and (vi) presence of
variant in public databases (Exome Variant Server, 1,000 genomes project and
Complete Genomics 69 reference genomes) at a frequency 42%. Variants
identiﬁed in constitutional DNA from any of the other local, non-cancer
sequencing project (for example, 29 million variants across 284 samples from the
Oxford-Illumina WGS500 consortium) were discarded as being more likely due to
systematic error in our pipeline than genuine somatic mutations.
Ion Torrent technical replication. Technical replication of mutations identiﬁed by
exome sequencing of 31 OS was carried out by Ion Torrent sequencing using a
custom Ion AmpliSeq 388 gene panel (gene list and genomic coordinates available
as Supplementary Data 2). Approximately 100 ng DNA was used for sequencing.
We sequenced to an average depth of 300 and used the Ion Reporter software for
variant calling. Variant calls were annotated using the ANNOVAR software and
the same databases as for exome-sequencing data. Variants present in the exomes
were assessed alongside the equivalent Ion Torrent data. In addition, visual
inspection with the integrated genomic viewer genome browser was required for
variant calls with posterior quality scores of 20–30. For speciﬁc RET mutations we
tested additional family members by Sanger sequencing. In addition, we used the
Ion AmpliSeq 388 gene panel to validate mutations from 15 randomly picked
samples that underwent Illumina MiSeq sequencing.
Targeted Illumina re-sequencing. Biological replication was carried out using
1 mg of DNA from 92 additional tumours and Illumina MiSeq re-sequencing to an
average depth of 480 . The custom Nimblegen target enrichment kit was used to
capture all exons of 30 genes (that is, 13 main OS drivers and their 17 interaction
partners; Supplementary Data 2) and a B20-kb region encompassing the TP53
gene. An average coverage of the target region was 92%. Read mapping, ﬁltering
and variant calling was done with the Stampy-Platypus pipeline using the same
setting as for the discovery set of 31 exomes.
Mutation spectra and signatures. For each tumour, somatic SNV frequencies
were calculated and the deviation of their spectra from the background
(determined across all samples) was assessed using w2-test (df¼ 5). The
trinucleotide spectrum was normalized according to 3-mer frequencies in the
reference exome (Agilent SureSelect (version 4)). Somatic mutation signatures were
inferred using the R package38, in which a mutation spectrum was decomposed
with a non-negative matrix factorization algorithm. The decomposition was
performed for prior sets of 2, 3 and 4. The optimal number of signatures (r¼ 3)
was manually chosen based on the maximum differentiation between the
signatures. The signature analysis was repeated 10 times with the same results
obtained after each run.
Affymetrix CytoscanHD array data analysis. Affymetrix CytoscanHD arrays
were processed with ChaS 2.1 and Nexus 7.5 software such that SCNA events larger
than 50 kb with a minimum support of 21 probes were considered for subsequent
analysis. Gene annotations were extracted using Ensembl REST API GRCh37
assembly. We assessed statistical signiﬁcance of called SCNA regions by an
algorithm similar to the GISTIC39 analysis, which identiﬁes SCNA with frequency
higher than expected by chance. Concretely, for each chromosome SCNA events
were resampled to generate uniform distribution and then signiﬁcance was assessed
across all positions in 1-kb windows by deriving Benjamini–Hochberg adjusted
P values (q values). Each candidate SCNA was subjected to survival analysis with
subsequent multiple testing correction using Benjamini–Hochberg q valueso0.05.
For event-free survival and overall survival we used Cox proportional hazards
regression model.
In vitro cell line experiments. OS cell lines were grown in RPMI 1640 medium
(SJSA-1), minimum essential medium supplemented with 10% fetal calf serum
(MNNG/HOS) or in McCoy’s 5A medium supplemented with 15% fetal calf
serum. Talazoparib was obtained from Selleckchem (Munich, Germany). Control
tests for mycoplasm contamination were carried out routinely (two times a month)
using a PCR-based and commercially available detection kit according to the
manufacturer’s protocol (VenorGem, Minerva Biolabs, Berlin, Germany).
Furthermore, authentication of cell lines has been carried out by genotyping using
microsatellite markers (Supplementary Data 8) to exclude cross-contaminations.
Cell viability was assessed by a 3-(4,5-dimethylthiazol-2-yl)-2,5-
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diphenyltetrazolium bromide assay according to the manufacturer’s instructions
(Roche Diagnostics, Mannheim, Germany). Statistical signiﬁcance was assessed
by Student’s t-test (two-tailed distribution, two sample, unequal variance).
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Figure S1 – Mutation signatures of 31 exome-sequenced osteosarcomas. (a) Contribu-
tion of each signature to filtered SNV mutation burden of each tumor. (b) mutations within
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Osteosarcoma is the most common primary tumor of the bone for which the identification of the 
underlying genetic alterations has remained difficult. Applying an integrative genomics 
approach in 337 patients we identified previously unknown germline bona fide pathogenic 
mutations in the RET proto-oncogene in 2% of cases, which is a proportion similar to TP53-
related osteosarcomas. These RET mutations appear to couple functional kinase activity to 
dysfunctional ligand binding in the same molecule and act in cooperation with (epi)genetic 
alterations compromising cell cycle regulation and homologous recombination repair. Our 
findings indicate that patients carrying pathogenic RET germline mutations are at an increased 
risk of developing osteosarcoma (odds ratio 9.12) and highlight RET as a potential target for 
multi-targeted tyrosine kinase inhibitors.  
The RET proto-oncogene (REarranged during Transfection) encodes a single-pass transmembrane 
receptor tyrosine kinase for the glial cell line-derived neurotrophic factor family of ligands. Its pivotal 
role in medullary thyroid cancer (MTC) development is well-established: while RET activating 
mutations are present in approximately 43% of sporadic MTCs1, germline alterations can be identified 
in 95 to 98% of patients with the autosomal dominant endocrine tumor syndrome MEN2 (multiple 
endocrine neoplasia type 2)2. Although more than 100 RET variants have been reported to date, most 
recurrent variants are limited to a number of key residues in the extracellular and kinase domains. 
Genotype-phenotype correlations allowed an estimate of the risk of developing MTC and other RET-
associated disorders, including pheochromocytoma and parathyroid adenoma3. 
Studies using phosphoproteomic screening proposed that the activation of receptor tyrosine kinases 
including RET contributes to the development of metastatic osteosarcoma4. Since confirmation of 
these results awaits the identification of the underlying pathogenic somatic or germline alterations, we 
reasoned that RET mutations could have contributed to the development of an osteosarcoma in a 34-
years-old patient (family ID: OS 263). The patient was diagnosed with MTC (age 30, Fig. 1) and 
carried a germline bona fide pathogenic RET mutation, p.Ser891Ala, which confers a moderate risk 
of MTC3, and which was also present in the patient’s mother who was diagnosed with MTC at age 66. 
Using an integrative analysis of the patient’s osteosarcoma we identified loss of the RET wild-type 
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allele resulting from a structural rearrangement of chromosome 10, together with somatic (epi-) 
mutations in cell cycle regulators RB1, ATRX and TP53 (Fig. 1).  
We therefore hypothesized that RET mutations might define a molecular subtype of osteosarcoma and 
examined protein-coding sequence variants (SV) in the germline of additional 336 affected 
individuals of European, Asian and American ancestry (our patients n=248, public data n=89, 
Supplementary Fig. 1). Using a two-pronged strategy – searching for functionally important variants 
and filtering using consensus mutation classification criteria5 – six additional patients were identified 
to carry SVs encoding known bona fide pathogenic RET mutations (p.Val292Met, p.Gly321Arg, 
p.Asn361Lys, p.Lys603Glu, p.Cys620Arg, and p.Cys620Ser). Four more patients carried RET 
missense SVs of uncertain clinical significance (p.Pro218Arg, p.Phe381Leu, p.Leu389Phe, and 
p.Tyr1038Ala). Pathogenic RET germline mutations in osteosarcoma patients have all been 
considered moderate in terms of risk level for MTC3. Six of seven mutations and three of four SVs 
with uncertain clinical significance mapped to the extracellular domain of the protein, especially to 
the cadherin-like (CLD) and cysteine-rich (CR) domains. Complete clinical and genetic information 
of the eleven patients are depicted in the Supplementary Table 1. None of these patients had a 
personal history of MTC and family history was uneventful. 
RET mutations mapped predominantly to the extracellular domains of the protein, often at or next to 
the sites where both gain-of-function and loss-of-function mutations occur. Specifically, in two of our 
patients we identified dual-type Janus mutations at the cysteine 620 residues which have been 
associated with both MEN2 and Hirschsprung’s disease. Like the two mutually incompatible faces of 
the Roman god Janus, these mutations lead to proteins incapable of responding to the glial cell line-
derived neurotrophic factor family of ligands, but can also stimulate cell proliferation as typical 
MEN2 mutations do6. Similarly, the studies of CLD domain mutations confirmed that a likely 
pathogenic mechanism is coupling functional kinase activity to dysfunctional ligand binding in the 
same molecule7. 
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To compare the prevalence of germline RET mutations in osteosarcoma patients to the population, we 
analyzed exome sequencing data compiled from 53105 individuals included in the Exome 
Aggregation Consortium (ExAC). We excluded data from individuals with cancer who have been 
included in Cancer Genome Atlas studies. The cumulative odds of any American Thyroid 
Association-classified MEN2 type A or familial MTC-predisposing RET mutation in osteosarcoma 
patients were significantly higher than the odds in the ExAc population (odds ratio 9.12, 95% CI, 4.26 
to 19.54, P<0.0001, ExAC sequence variant database version 3.1).  
We then examined chemotherapy-naïve tumor biopsies from eight carriers of germline SVs in RET 
for somatic alterations. A second hit by loss of heterozygosity involving the germline wild-type RET 
allele was found in three (37.5%) out of eight osteosarcomas (Supplementary Fig. 2). No additional 
somatic RET mutations were detected. In some respect genomes of the RET-mutant tumors were 
similar to those of previously described osteosarcomas; tumors were microsatellite-stable, but had a 
comparably higher mutation burden, chromosomal instability with preponderance to deletions, 
chromothrypsis, kataegis and frequent rearrangements/fusion genes at loci harboring the MYC, 
ERBB2, FGFR1-4, TP53 and RB1 genes (Fig. 2, Supplementary Fig. 3 and 4, Supplementary Table 
2). Signature analysis confirmed the acquisition of BRCA-like traits also in RET-mutant 
osteosarcoma. Unlike previously-published clonal structures of osteosarcoma genomes, most somatic 
driver mutations, indels, fusion genes and chromosomal copy-number changes in RET-mutant 
osteosarcomas were either heterozygous or subclonal events.  
Based on our findings, osteosarcoma must be considered a part of the tumor spectrum of RET-
associated disorders. Consideration of RET mutation testing in osteosarcoma patients, and conversely, 
awareness of an increased risk to develop osteosarcoma in patients with RET-associated disorders 
could enable early identification of tumor predisposition-related disease and at-risk family members. 
When added to the list of genetic aberrations in tyrosine kinase genes in osteosarcoma4,8, mutations in 
RET emphasize the critical role of cell cycle dysregulation in osteosarcoma development and 
highlight the potential benefits of the use of multi-targeted tyrosine kinase inhibitors with anti-RET 
activity. 
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 Online Methods 
Patients, Samples and Data Types 
Osteosarcoma patients comprise four cohorts of which the first three – Swiss, German and Australian 
patients – include 248 individuals, whilst exomes of 89 patients have been retrieved from the 
TARGET dataset. Annotations of patients, data types and the cohorts are depicted on Fig. 1, 
Supplementary Fig. 1 and Supplementary Table 1. Informed consent was obtained from all patients 
and ethical approval was obtained from the local ethical committee of Heidelberg (ref. S-327/2011) 
and Ethikkommission beider Basel (ref. EK: 274/12) for analysis of anonymized samples and for the 
purpose of driver gene discovery. The Australian patients were enrolled under the umbrella of the 
International Kindred Sarcoma Consortium9.  
DNA and RNA extraction 
DNA and RNA was extracted from fresh-frozen tumor samples using a TissueLyser (Qiagen) and the 
AllPrep DNA/RNA Micro or Mini Kit (Qiagen) according to the manufacturer’s instructions. RNA 
was incubated with RNAse-Free DNase (Qiagen) according to the manufacturer’s instructions. 
Constitutive DNA was extracted from whole blood using QIAamp DNA blood mini kit (Qiagen). 
Quality of both RNA and DNA was assessed by Nanodrop or 2100 Bioanalyzer (Agilent), 
respectively.  
Exome sequencing 
Exome capture was performed using the Agilent SureSelect kit version 4. Samples were quantified 
using the Qubit system (Invitrogen) and sequencing libraries constructed from 0.5-1 µg DNA. 
Samples were sequenced using the Illumina HiSeq 2000 or 4000 platform as paired 100-bp reads with 
the aim of a minimum target coverage of 150x. After removal of PCR duplicates using Picard, reads 
were mapped with BWA version 0.7 and Stampy version 1.0.23 onto the Human Reference Genome 
(GRCh37d5/hg19).  
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Whole-genome sequencing 
DNA samples were quantified using the Qubit system (Invitrogen) and sequencing libraries 
constructed from 0.5µg of DNA. Samples were sequenced using the Illumina HiSeq 2000 or 4000 
platform as paired 100-bp reads with Chemistry version 3.0, with the aim of a minimum target 
coverage of 15x. Quality control, removal of PCR duplicates and Stampy/BWA mapping was done 
using the bioinformatics pipeline used for exome sequencing.  
Gene-Panel sequencing 
Target sequencing was carried out using 1µg of DNA and Illumina MiSeq resequencing to an average 
depth of 480x. The custom Nimblegen enrichment array was constructed to capture coding exons of 
30 genes and ~20kb region encompassing the TP53 gene. Am average coverage of the target region 
was 92%. Read mapping, filtering and variant calling was done with the Stampy-Platypus pipeline 
using the same settings as for exome sequencing.  
RNA sequencing 
Ribo-depleted fraction of the RNA samples was isolated from the total RNA before conversion to 
cDNA. The cDNA was end-repaired, A-tailed and adapter-ligated. The prepared libraries were size-
selected, quality-controlled before pair-end sequencing over a lane of a flow cell.  
Variant calling 
SVs and small indels were called with Platypus version 0.8.1 using the tumour-normal pairs of bam 
files together to ensure comparable calls at every locus. Where available, reads from whole genomes 
and exomes were pooled. Variants were only called if they were assigned sufficiently high posterior 
probability (phred score >20). We removed the allele bias filter to increase sensitivity. For selected 
variants, we made sure that the automatic call matched the data by expert visual inspection of the 
mapped reads onto the reference genome using read direction colouring on top of the standard 
integrated genomic viewer scheme.  
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Annotation was performed using ANNOVAR (release date version 2016-02-01) with the hg19 
reference genome and 2015 versions of standard databases and functional prediction programs. We 
excluded duplicated genomic regions (>90% homology) from the analysis and variants within regions 
with low mapping scores. Variants were annotated with ANNOVAR Refseq gene model using 
dbSNP(135); 1,000 genomes project allele frequencies (August 2015), 6,500 exome-sequencing 
project allele frequencies, The ExAC database of variant frequencies, University of Santa Cruiz 
(UCSC) segmental duplication scores and UCSC 46 species conservation scores and predictions of 
functional importance from SIFT, PolyPhen2 and Mutation Taster.  
Germline and somatic mutations were identified by comparison of matched constitutional and tumor 
samples. For the analysis of mutation burden and mutation spectra, we applied the following 
exclusion filters to somatic variants: (i) presence in a segmental duplication region or a region with 
mapability score <0.5; (ii) variant present in any read from paired normal sample; (iii) fewer than 10 
reads in total at the variant site in the normal exome; (iv) fewer than 8 reads in total in the tumor 
exome; (v) fewer three variants in the tumour exome; variant allele frequency <5% in the tumour; and 
(vi) presence of variant in public databases (Exome Variant Server, 1,000 genomes project and 
Complete Genomics 69 reference genomes) at a frequency >1%. Variants identified in constitutional 
DNA from any of the other local, non-cancer sequencing project (for example, 29 million variants 
across 284 samples from the Oxford-Illumina WGS500 consortium) were discarded as being more 
likely due to systematic error in our pipeline than genuine somatic mutations. 
Structural rearrangements 
Structural variants were predicted from whole-genome sequencing data using breakdancer version 
1.4.5 and the Human Reference Genome GRCh37d. Candidate rearrangements which were present in 
a normal control genome, or mapping to any decoy chromosome or having less than 6 supporting 
reads were filtered out.  
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Mutation spectra and signatures 
For each tumor, somatic sequence variant frequencies were calculated and the deviation of their 
spectra from the background (determined across all samples) was assessed using Chi square-test 
(df=5). The trinucleotide spectrum was normalized according to 3-mer frequencies in the reference 
exome (Agilent SureSelect (version 4)). Somatic mutation signatures were inferred using the R 
package38, in which a mutation spectrum was decomposed with a non-negative matrix factorization 
algorithm. The decomposition was performed for prior sets of 2 to 6. The optimal number of 
signatures (r=6) was manually chosen based on the maximum differentiation between the signatures. 
The signature analysis was repeated 10 times with the same results obtained after each run. 
Methylation 
250 ng of DNA were used on an Infinium MethylationEPIC BeadChip (Illumina, USA). Differential 
methylation analysis between tumors was performed in R using the Chip Analysis Methylation 
Pipeline for Illumina HumanMethylation450 and EPIC chips (version 1.11.1). The data was 
normalized by beta-mixture quantile normalization and methylation variable positions were 
segmented into biologically relevant differentially methylated regions using the Probe Lasso 
algorithm. 
Fusion gene prediction  
For each sample, 45 million sequencing reads were aligned to the Human Reference Genome (hg19) 
using TopHat version 2.0.10. Fusion gene predictions were performed with fusioncatcher software, 
version 0.99a and ericscript version 0.5.5, using ensembl_v84.  
Pyclone Analysis 
For each tumor, pyClone12 probabilistic model was used to convert allelic count data of successfully 
validated somatic mutations into cellular frequencies, representing the fraction of cells in the tumour 
population containing a specific set of mutations. 
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Data Availability 
Exome/genome-sequencing data have been deposited in the European Nucleotide Archive under the 
study accession number: PRJEB11430 and the secondary study accession number: ERP012816. 
Affymetrix CytoscanHD data are available in the ArrayExpress database 
(www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-3998. Sequencing data from the 
International Sarcoma Kindred Consortium are not publically available. Sequencing data of the 
TARGET initiative is available for controlled access in the database for Genotypes and Phenotypes 
(https://dbgap.ncbi.nlm.nih.gov).  
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Figure 1 – The germline RET mutation c.2671T>G and the genetic profile of the pa-
tient’s osteosarcoma. (a) Multiple thyroid cancer (MTC) in the history of the family 263.
The index patient with osteosarcoma (OS) is indicated by an arrow. (b) Sanger sequencing chro-
matograms from normal and tumor tissue depict the mutation and (c) the loss of the wild-type allele
on the chromosome 10. Inter- and intra-chromosomal rearrangements affecting chromosome 10
are shown on the right. (d) Somatic driver mutations in RB1 and ATRX affected by non-neutral
copy-number loss of heterozygosity. (e) Mutation burden of the tumor. The outermost layer displays
chromosomal orientation and the locations of osteosarcoma driver genes. The next inner layers depict
chromosomal losses, gains and SV densities, respectively. Putative sites of kataegis are highlighted in
orange, chromosomal gains are in blue and losses in red. The two innermost tracks depict inter- and
intra-chromosomal rearrangements. (f) Methylome profile of the patient’s osteosarcoma comprises
1701 genes and is compared to 28 RET-wild type osteosarcomas and constitutional DNA of respective
patients. The analysis was carried out in triplicates and only genes with P values <0.00001 are shown.
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Figure 2 – Germline RET sequence variants identified in 337 osteosarcoma patients.
(a) Variants are shown as lollipop structures with type indicated by color. Mutations affecting
cadherin-like domains (CLD) 2 and 3 were mapped onto the protein domain structure 4UX8 (DOI:
10.2210/pdb4ux8/pdb) which was constructed by Goodman et al.15 (b) Mutation burden of RET-
mutant and RET-wild type osteosarcomas. (c) Signatures and signature contributions of mutation
processes in four osteosarcoma genomes with RET mutations. Signature numbers are referring to the
COSMIC Mutational Signatures Catalogue [110]. (d) Posterior clonal frequencies of the osteosarcoma
driver mutations with RET mutations being highlighted.
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Figure S1 – Patients and Cohorts. Data from 248 own osteosarcoma patients and 89 patients
from the TARGET initiative was analyzed. Data types, which include Cytoscan HD copy number arrays,
RiboZero transcriptomes, Illumina Epic methylation arrays, whole-genome/exome sequencing data
and targeted sequencing, and the respective DNA and RNA sources are indicated for each patient
subset. RET mutations which are classified as pathogenic (red) and RET variants with unknown
clinical significance (blue) are listed.
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Figure S2 – Overview of RET-mutated Osteosarcomas. Information about the presence of
LOH at the RET locus, the presence of the enhancer RET mutation p.Gly691Ser and driver mutations
in the TP53 and RB1 genes. Mutational events include disruptive gains, chromosomal losses and point
mutations with known pathogenic effect (*).
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Figure S3 – Comprehensive Genomic Analysis of Osteosarcomas. Mutation burden of
the tumors 128 (a.), 224 (b.) and 242 (c.) depicted as Circos plots. The outermost layer displays
chromosomal orientation and the locations of osteosarcoma driver genes. The next inner layers depict
chromosomal losses, gains and SV densities, respectively. Putative sites of kataegis are highlighted in
orange, chromosomal gains are in blue and losses in red. The two innermost tracks depict inter- and
intra-chromosomal rearrangements (grey) and fusion genes (blue and green).
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Figure S4 – Copy-Number Profile of RET-mutated Osteosarcomas. Copy number
profiles as calculated from whole-genome sequencing data by Nexus Copynumber are shown for the
whole genome (a.); the TP53 tumor suppressor gene (b.); RB1 Retinoblastoma 1 (c.); and the RET
proto-oncogene. Gains: blue, losses: red, loss-of-heterozygosity: yellow, allelic imbalance: purple
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Figure S5 – Copy-Number Profile of RET-mutated Osteosarcomas. Copy number
profiles as calculated from whole-genome sequencing data by Nexus Copynumber are shown for
CDKN2A Cyclin Dependent Kinase Inhibitor 2A (a.); FGFR2 Fibroblast Growth Factor Receptor 2;
FGFR4 Fibroblast Growth Factor Receptor 4 (c.). Gains: blue, losses: red, loss-of-heterozygosity:
yellow, allelic imbalance: purple
93
Chapter 2. Results
OR
1 5 10 15 20 25 300.2
increased in controls
0.04
increased in cases
MEN2A + FMTC variants
MEN2A variants
FMTC variants
Osteosarcoma patients 
vs controls
OR (95% CI) p value
8.030 (3.756-17.161)
9.919 (3.608-27.264)
6.298 (1.985-19.984)
<0.0001
<0.0001
<0.0001
Figure S6 – Cumulative odds ratio of RET mutations in the osteosarcoma cohort versus
normal population. The prevalence of RET germline mutations in the osteosarcoma cohort was
compared to the ExAC population comprising of 53105 individuals (excluding individuals from TCGA
studies). Cumulative odds ratios were calculated for mutations grouped according to the American
Thyroid Association. MEN: multiple endocrine neoplasia type 2A, FMTC: familial medullary thyroid
carcinoma. Error bars represent upper and lower 95% confidence intervals. P values were calculated
using Fisher’s exact test.
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3 Discussion and Outlook
3.1 TP53 Intron 1 Hotspot Rearrangements are Specific to Spo-
radic Osteosarcoma and Can Cause Li-Fraumeni Syndrome
A hallmark of OS is the high amount of chromosomal instability resulting in marked inter-
tumoral heterogeneity and a high abundance of structural variations. In an attempt to
characterize this genomic chaos, we sequenced four pretherapeutic tumors with whole-
genome DNA-PET, a method which is sensitive for copy number neutral- and copy number
changing-rearrangements (see section 1.3.6 on page 13). We identified between 289 and 434
somatic SV per tumor, confirming the expected complexity. We found TP53 to be the most
recurrently affected gene: One tumor had a deletion of the whole gene, one tumor showed
a balanced translocation between TP53 and chromosome 1, one tumor had an inverted
insertion from chromosome 6, and the last tumor had multiple complex inter-chromosomal
translocations with chromosomes 1, 5, and 6 serving as partner sites. Complex rearrangements
of this sort entail multiple breakpoints in the affected gene. Using a specialized bioinformatics
pipeline and Sanger sequencing for validation, we reconstructed the total of seven TP53
breakpoints in the tumors at base pair level and observed a clustering in intron 1. However,
it is important to note that, while the TP53 breakpoints were recurrently located within this
hotspot region, the rearrangement partners differed from tumor to tumor which complicates
the detection of such events. We further found TP53 intron 1 rearrangements in the shape of
a 445 kb inversion and a 2.5 kb deletion co-segregating with cancer in a four-generation LFS
family.
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3.1.1 What Is the Frequency of TP53 Intron 1 SVs in Osteosarcoma?
From the four pretherapeutic primary OS we sequenced with DNA-PET (discovery cohort), all
cases showed rearrangements involving the TP53 gene and all TP53-internal breakpoints were
located in intron 1. We validated our findings in two independent cohorts of primary prether-
apeutic OS with FISH and SNP-based copy number arrays. First, FISH on a tissue microarray
(TMA) of formalin fixed paraffin embedded (FFPE) samples revealed rearrangements in 11%
of cases (23 of 215). In the second cohort we found rearrangement breakpoints in intron 1 as
indicated by copy number transitions in 32% cases (23 of 73). Notably, the TP53 locus was
affected by copy number changes in 54 of 73 (74%) cases of this cohort. Therefore, intron 1
rearrangements, while not the only type of event, do contribute substantially to TP53-altering
events. During the time of publishing these results, Chen and colleagues also reported on
recurrent intron 1 rearrangements in 45% of their OS cohort as identified by whole-genome
sequencing [96]. The differences in the observed frequencies can be explained by varying
sensitivities and limitations of the techniques used. FISH has a relatively low resolution due
to the size of the BAC clones (159 and 169 kb in our assay) and because of optical limitations
of fluorescence microscopy. Copy number arrays have a higher resolution but fail to detect
copy number neutral events, such as inversions or balanced translocations. This limitation
is of importance, since three out of four DNA-PET sequenced tumors carried copy number
neutral intron 1 SV, and the inversion in the Li-Fraumeni family only resulted in a small
deletion which is close to the detection limit of copy number arrays and undetectable by
FISH. It is therefore possible that the actual frequency of intron 1 rearrangements is higher
than predicted by our analyses. Even though sequencing does provide base pair-resolution,
difficulties can arise in genomically complex loci or in regions with sequence repeats. As
discussed in section 3.1.2, intron 1 is rich in repetitive elements and all breakpoints we
observed were located in such regions. Therefore, we used DNA-PET sequencing for our
initial discovery cohort, which is is particularly designed to span such problematic regions,
hence avoiding mapping artifacts and increasing the sensitivity for SV detection in repeat
regions. Chen and colleagues sequenced their discovery cohort with a conventional paired-
end approach, which might explain the higher intron 1 SV frequency in our discovery cohort.
Intrinsic cohort properties or a selection bias could also explain inter-study differences: we
only included pretherapeutic biopsy samples, while the sample set of Chen and colleagues
also included metastases. Taken together, our data suggest that TP53 intron 1 rearrangements
are the most recurrent rearrangements in OS and occur with a frequency of at least 11-32%.
This highlights the frequently overlooked role of copy number neutral structural variants in
tumorigenesis, alongside the more studied SNV and copy number alterations.
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3.1.2 The Breakpoint Sequence Context of TP53 Intron 1 SVs May Not Be Com-
patible With Common Rearrangement Mechanisms
DNA-PET followed by Sanger sequencing allows the identification of rearrangement break-
points and its sequence context at base pair resolution. All seven TP53 breakpoints we
observed were located in similar repetitive elements; six breakpoints in long interspersed nu-
clear elements (LINE) repeats and one in short interspersed nuclear elements (SINE) repeats.
It has been reported that repetitive DNA sequences contribute to rearrangement susceptibility
[111]. Such repetitive sequences make up ∼50% of the human genome [74] and consist of
transposable DNA elements, including the aforementioned LINE and SINE, simple sequence,
tandem repeats, and low-copy repeats, such as segmental duplications. Repeat-dependent
rearrangements seem to mainly result from a mechanism termed nonallelic homologous
recombination (NAHR) [111]. In this process, paralogous sequences are paired and cross-
over, resulting in deletions, inversions and duplications. While most NAHR mediated events
are intrachromosomal, interchromosomal NAHR does exist [112, 113]. Contrarily to our
observations, NAHR is mainly implicated in recurrent rearrangements where size, genomic
content, and rearrangement partner sites are identical between unrelated individuals [114]
and the current understanding of NAHR does not explain the breakpoint-flanking sequence
duplications we observed.
Other characteristics of the TP53 intron 1 rearrangements we described also do not seem to
be fully compatible with known mechanisms of structural variations. They include a) low se-
quence homology between intron 1 and the partner sites, b) occurrence of interchromosomal
and complex rearrangements, c) recurrence of TP53 intron 1 but varying partner locations,
and d) duplication of the breakpoint-flanking sequence of up to 555 bp. For instance, homol-
ogous recombination based mechanisms require several hundred basepairs of uninterrupted
sequence identity between rearrangement partners [115]. In microhomology-mediated break-
induced replication (MMBIR) or fork stalling and template switching (FoSTeS) mechanisms,
a nick on the template strand during replication causes stalling or collapse of the replication
fork, which is later resolved by DNA template switching based on microhomology. MMBIR
has been proposed to be underlying most non-recurrent disease-causing structural variants
[116]. Interchromosomal rearrangements between distinct replication forks due to these
template switching mechanisms do occur and multiple template switches can further result
in complex rearrangements [117]. While some of our observed breakpoints include a few
basepairs of homology, these regions are smaller than the 5-25 bp typically required for
MMBIR [118] and breakpoint sequence duplication is not common in MMBIR.
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Another known rearrangement mechanism is the non-replicative non-homologous end joining
(NHEJ), which plays an important role in the immune system's V(D)J recombination, where it
generates antibody diversity. In NHEJ, the ends of double-stranded DNA break (DSB) are first
modified by addition or deletion of bases to make them compatible, and subsequently ligated
[119]. These modifications leave a “scar” in the DNA sequence at the site of rejoining. A
particularly well studied disease where NHEJ is pathogenetically involved is dystrophinopathy,
caused by rearrangements in the DMD dystrophin gene. The DMD protein is crucial for
normal muscle function and structure and therefore its loss causes muscle weakness and
the loss of walking ability. Introns 45-50 of DMD contain rearrangement hotspots, similar to
intron 1 in TP53. In contrast to the complex rearrangement events we observed in OS, in
the DMD gene, NHEJ predominantly causes deletions [120], with breakpoint-surrounding
sequence duplications of up to 25 bp [120]. Another similarity between DMD and TP53
intron 1 rearrangements is the enrichment of repetitive elements such as LINE and SINE.
Nevertheless, the larger length of breakpoint sequence duplications and the complex nature
of the rearrangements we observed do not fit the classical understanding of NHEJ.
3.1.3 The TP53 Intron 1 Rearrangement Mechanism May Be Transcription De-
pendent
Data from the Encyclopedia of DNA Elements (ENCODE) based on DNAse hypersensitivity
sequencing and chromatin immunoprecipitation-sequencing (ChIP-seq) histone acetylation
experiments [121] show strong signals of open chromatin and active enhancers, respectively,
2.5 kb upstream of the breakpoint cluster region, as well as within 10 kb of six out of
seven partner breakpoints in the sequenced tumors and in the LFS family. It is therefore
tempting to speculate that the rearrangement mechanism we observed is based on active
transcription of TP53 and the rearrangement partners. Supporting this hypothesis is the fact
that our preliminary RNA sequencing data (unpublished) finds the two genes overlapping the
breakpoints in sporadic OS, SUCO and ENPP1, to be expressed in primary OS cell lines. The
gene adjacent to the partner breakpoint in the LFS is HES7. Strikingly, all three genes are
involved in bone development. HES7 is a member of the Notch pathway and mutations can
lead to spondylocostal dysostosis, an axial skeleton growth disorder [122]. ENPP1 encodes
the plasma-cell membrane glycoprotein 1, and its expression regulates bone mineralization
[123]. Plasma-cell membrane glycoprotein 1 (PC-1) expression in turn is regulated by the
growth factors transforming growth factor beta (TGF-beta) and fibroblast growth factor
(FGF) [124, 125], which are abundantly expressed in osteoblasts [126]. In mouse, Suco, also
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known as Osteopotentia (Opt), has been found to be crucial for osteoblast function and bone
formation [127]. Since OS prevalence is correlated to the pubertal growth spurt, it seems
likely that these genes are actively transcribed at the time of tumorigenesis and therefore
may contribute mechanistically to TP53 intron 1 rearrangements.
Active transcription as a contributor to genomic rearrangements has been observed in a
genome-wide analysis of SV breakpoint distributions in some cancer types [128]. A hy-
pothetical, transcription dependent rearrangement mechanism is depicted and discussed
in detail in supplementary figure S16 of the original publication [129]. In short, during
active transcription of a genomic locus, the respective template DNA sequence is unwound
by the RNA polymerase elongation complex, forming a transcription bubble [130]. If two
single-stranded DNA break (SSB) occur on different strands and positions in the bubble, a
DSB would result, with a stretch of unpaired overhangs. The DNA repair machinery may fill
in the complementary nucleotides, producing blunt ends which can be fused together with
other DSBs. During the interphase, sites of active transcription are located in specialized
compartments [131]. The close proximity between transcribed strands might promote false
re-assembly of blunt ends, leading to rearrangements. While explaining our observations, to
confirm this hypothesis more mechanistic insights, for example about the size of transcription
bubbles at the affected loci and the relationship to the duplicated regions, would be necessary.
Also, the ligation mechanism which fuses the two blunt ends remains to be elucidated.
3.1.4 What Are the Functional Consequences of the Intron 1 Rearrangements
in the Four Sequenced Tumors?
Genomic rearrangements can result in fusion proteins. The BCR-ABL fusion caused by a
translocation in chronic myeloid leukemia is the most prominent example of this phenomenon
[132]. It is thus tempting to speculate that the recurrent TP53 rearrangements produce gene
fusions, in which an oncogene is put under the control of the TP53 promoters. However, our
data from the limited number of five cases does not support this hypothesis. In two of the
four initial tumors sequenced by DNA-PET, the TP53-affecting arrangements resulted in gene
fusions. One case putatively produces a TP53-ENPP1-TP53 fusion transcript, which is lacking
a start codon and which is truncated by the stop codon in ENPP1 exon 25 and therefore is
unlikely to translate into a protein. The second case results in a SUCO-TP53 fusion, in which
the exons 1-15 of SUCO are fused upstream of the TP53 exons 2-12. The chimeric structure
of the fusion protein and the membrane localization of SUCO may prevent the physiological
function of the p53 protein. Due to the lack of RNA from these patient samples, we were not
able to investigate the expression levels of the predicted fusion transcripts.
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DNA sequencing data for the remaining cases do not suggest gene fusions at the TP53
locus. Rather, the rearrangements result in partial or complete loss of TP53 expression, as
is illustrated by our data of a four generation LFS family. There, the inversion ranging 445
kb upstream from intron 1 towards the centromere disconnects two of the three known
promoters from the TP53 gene body. The remaining third promoter located in intron 4, is
left intact. This internal promoter is driving the expression of the shortened TP53 isoforms
∆133p53 and ∆160p53. These isoforms are conserved across different species and in TP53
homologues, which further underlines their biological relevance. Interestingly, these isoforms
are reported to lack TP53's typical proapoptotic activity [133]. Expression of the ∆133p53α
isoform is deregulated in several cancers, including colorectal carcinoma, breast cancer, acute
myeloid leukemia (AML), and melanoma; ∆133p53β has been shown to increase the risk of
cancer recurrence and death in breast cancer patients [134, 135, 136]. Similarly, ∆160p53
isoforms promote enhanced cell survival, proliferation, invasion and adhesion in vitro [137].
Taking this into consideration, it would seem plausible that the intron 1 rearrangements
contribute to OS tumorigenesis by shifting expression towards the ∆133p53 and ∆160p53
isoforms due to the removal of the promoters which generate the full-length protein. However,
our real-time quantitative reverse transcription PCR (RT-qPCR) experiments in the affected
LFS family revealed a 23-53% reduction of overall TP53 expression in the blood, where
the rearrangements were present in a heterozygous state, and 89-100% reduction in the
paired tumors with LOH at that locus. This suggests that the rearrangements' functional
consequence is not an isoform shift but loss of TP53 expression which, considering the gene's
function, will likely give rise to further genomic instability, in accordance with the classical
model of osteosarcomagenesis (see figure 6 on page 18). Given the relatively small number
of tumors in which we have characterized the functional consequences of TP53 intron 1
rearrangements, we cannot rule out that an isoform shift contributes to tumorigenesis in
other OS cases.
Other functional consequences need to be considered. Intron 1 of TP53 overlaps with the
transcripts of WRAP53 and HP53INT (also known as RP11-199F11.2). WRAP53 encodes three
different transcripts by alternative transcriptional start site usage. WRAP53α is an antisense
transcript to TP53 and is required to maintain elevated endogenous p53 messenger RNA
(mRNA) levels in OS cell lines, likely by stabilizing the mRNA through a WRAP53α/p53 RNA
interaction. The transcript is also necessary to increase p53 protein levels in response to DNA
damage [138]. WRAP53β encodes the WRAP53β protein, which acts as a scaffold during
the assembly of double-stranded DNA break repair complex components, including 53BP1,
BRCA1, and RAD51 [138, 139]. Loss of WRAP53β might therefore impair the accurate repair
of DNA lesions by homologous recombination repair (HRR). The function of WRAP53γ is
still elusive. In our described LFS family, the small 2'275 bp deletion in intron 1 contains the
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Figure 7 – Rearrangement breakpoints and overlapping transcripts in TP53 intron 1.
Clustering breakpoints identified by DNA-PET and targeted sequencing in four sporadic OS cases and a
LFS family are displayed (dashed lines) in context of the TP53 gene structure, whereby the non-coding
exon 1 and parts of exon 11 are colored in lighter gray. Promoter 3 (P3) which drives expression of
the full length p53 protein and ∆40p53 isoform and promoter 1 (P1) driving ∆133p53 and ∆160p53
isoforms are shown. Promoter 2 (P2) is driving expression of Hp53Int1, a transcript of unknown
function. The loss of genetic material occurring in parallel to the 450kb inversion in the LFS family is
depicted as gray shaded region. Observed rearrangements with intron 1 breakpoints disconnect the
main promoter P1 from the gene body and either delete parts of the WRAP53 transcript or potentially
disrupt its regulatory elements acting in cis. Functions of the antisense transcript WRAP53α and the
scaffold protein WRAP53β are indicated. Figure adapted from Henriksson et al. [140] and Marcel et
al [141].
transcription start sites of both WRAP53β and WRAP53γ. The intron 1 breakpoints of the
OS tumors from the discovery cohort are also located in close proximity to the promoters
of WRAP53 and HP53INT1 and these rearrangements might therefore also displace the
transcripts from their regulative elements (see figure 7 on page 103). It is thus possible that
reduced WRAP53β levels contribute to tumorigenesis in sporadic OS and the LFS family, by
further reducing TP53 levels and its ability to induce DNA repair.
3.1.5 LOH as a Common Second Hit After TP53 Intron 1 Rearrangements
A striking observation is the occurrence of copy number neutral LOH at the TP53-locus with
concomitant loss of the non-rearranged allele in all five tumors we analyzed in the LFS
family. Copy number neutral LOH are a common form of LOH, as was demonstrated in
neurofibromatosis, glioblastoma, and hematolymphoproliferative malignancies [142, 143].
They are not detectable with classical cytogenetic methods and thus their importance in
pathogenesis might have been widely overlooked until recently, when SNP-arrays and high-
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throughput sequencing became more widespread. Copy number neutral LOH in tumor cells
can change gene expression by duplication or deletion of epigenetic marks. If acquired after a
mutational event, copy number neutral LOH can transform the mutation from a heterozygous
to a homozygous state.
In our LFS family, the acquired LOH acted as a second hit, in accordance with Knudson's
two-hit hypothesis of cancer evolution [144], by doubling the rearranged allele, while the
wild-type allele is lost. This is in concert with our TP53 expression data, which show a loss of
expression in the tumors. Also, in the validation cohort of sporadic OS which we assayed with
FISH, all of the 23 rearrangement-positive cases overwhelmingly showed two break-apart
signals and no wildtype-like fusion signal. The absence of any pathogenic SNV in TP53 as
a second hits in all five LFS tumors, as well as in the four tumors sequenced by DNA-PET
seems surprising, given the fact that most mutations inactivating the gene in LFS are missense
mutations. This disparity may be explained by the generally high amount of chromosomal
instability which is typical for OS. Further, intron 1 rearrangements can affect WRAP53
transcripts. Loss of WRAP53α and β isoforms have been demonstrated to reduce p53 protein
expression and DNA repair capabilities [138], and thus may further increase the likelihood
of LOH as a second hit. In our copy number arrays, 75% of cases which show copy number
transitions in TP53 intron 1 also show copy number neutral or copy number changing LOH at
the locus. Both observations support the idea that LOH after TP53 rearrangements represent
a common second hit in OS. Furthermore, several studies in mice have demonstrated that
TP53+/−strains show a different tumor spectrum (mainly osteosarcomas) than TP53−/−mice,
which mostly develop lymphomas, indicating that inactivation of the second TP53 allele in
OS is not restricted to humans. Remarkably, OS in TP53+/−mice also show LOH at that locus
[145].
Several mechanisms have been proposed to underlie somatically acquired copy-number
neutral LOH events in cancer. Non-disjunction during mitosis can result in copy number
neutral LOH affecting whole chromosomes. Subchromosomal events are thought to arise due
to mitotic recombination between identical low copy repeats [146] or by a repair attempt
of DSB induced deletions, whereby the lost region is restored using the remaining allele
as a template. Subchromosomal copy number neutral LOH events have been found in OS
by other studies and a significant increase in these events correlates with poor response to
neoadjuvant chemotherapy [147]. Rearrangements and LOH in the TP53 gene have been
found in 40% of a recent sequencing study, supporting our observation of LOH as a frequent
second hit [96].
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3.1.6 Specificity of TP53 Rearrangements in Osteosarcoma and Li-Fraumeni
Syndrome
Using a customized TP53 break-apart FISH with probes flanking the whole gene and ∼35
kb of the upstream region, we demonstrated a rearrangement frequency of 11% in OS, but
found no events in other bone-forming tumors, such as fibrous dysplasia, aneurysmal bone
cyst and ossifying fibroma (n = 124). We also found no positive cases in any other tumor
types unrelated to bone, including gastrointestinal-, genitourinary-, lung- or skin tumors (n
= 966). While cases with TP53 intron 1 rearrangements have been described before, our
work represents the largest screen of OS and other tumor types for such rearrangements,
and their striking specificity to a subset of OS was previously unknown. The reason for this
specificity is currently not understood and requires further functional in vitro and in vivo
studies. Nonetheless, our analysis of the sequence context of intron 1 rearrangements allows
the hypothesis that the rearrangement mechanism is dependent on active transcription (see
section 3.1.3). Interestingly, the genes located at or adjacent to the rearrangement partner
sites are involved in bone biology and are expressed in OS cell lines. It is therefore possible
that tissue-specific expression patterns trigger the intron 1 rearrangement mechanism with
a higher frequency in bone than in other tissues, and replication stress caused by intensive
bone-restructuring in the pubertal growth phase might further increase the possibility of its
occurrence. It is well established that transcriptional activity can be fundamentally different
between cell types. Cell lineage specific DNA replication properties, transcriptional processes
and chromatin conformations might therefore ultimately be responsible for the remarkable
specificity of the described rearrangements.
The LFS-family carrying a germline TP53 intron 1 rearrangement did not only develop OS
but multiple types of cancer, including adenocarcinoma, meningioma, astrocytoma, colon
cancer, basal cell and squamous cell carcinoma of the skin. This does not directly contradict
our observed specificity in sporadic tumors; it remains possible that, while rare outside of
bone, this type of rearrangement occurs in the germline. The oncogenic effect, which in
this family we demonstrated to be generic loss of TP53 expression, evidently contributes to
tumorigenesis in many other tissues.
3.1.7 The Role of Intron 1
Another remarkable feature of the TP53 breakpoints we identified in sporadic OS and LFS
is their clustering into a ∼4'500 bp region in intron 1. While this first intron is the largest
intron of the gene, the accumulation of breakpoints at this particular locus and the lack of
breakpoints in other regions still is striking. We analyzed breakpoint sequence contexts and
found direct, inverted, complementary, and mirror repeats within 50 bp of each breakpoint
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in intron 1. These repeats can lead to the formation of non-canonical DNA conformations
such as cruciforms and left-handed Z-DNA. These structures have been shown to impede
DNA replication and in consequence can result in breaks [148]. However, repeats of this
kind are also present in other regions of the gene where we do not observe any breaks. Their
contribution to the accumulation of breakpoints in intron 1 therefore remains unclear. In
section 3.1.3 we hypothesized that the rearrangement mechanism is transcription depen-
dent. Compared to the other parts of the gene, intron 1 of TP53 is located closest to the
transcriptional regulators and two promoters. Depending on the transcription dynamics
in the cell, the likelihood of a DNA break occurring at a given site might be a function of
its distance to transcription initiation sites, leading to accumulation of breaks in the first
intron. Intron 4 also contains a promoter. However, this third promoter is thought to be weak
and the short variants whose expression it drives are not expressed at high levels in normal
cells, which could explain the lack of rearrangements we see at this position. Besides the
internal promoter, TP53 intron 1 overlaps with the transcripts of WRAP53 and HP53INT1.
An alternative start site coding for the WRAP53γ splice variant is located just upstream of
the breakpoint cluster and in addition, the promoter of Hp53Int1 is located in intron 1. The
expression of these two transcripts and the resulting open chromatin could contribute to the
instability of the locus.
3.1.8 Clinical Utility
The eventual clinical consequences of our findings remain to be elucidated. Our data does
not support any role of TP53 intron 1 rearrangements as a prognostic or predictive marker;
no statistically significant correlation was observed to clinicopathological markers, including
survival, occurrence of metastases, or response to neoadjuvant chemotherapy. This can be
explained by the fact that the main functional consequence of the rearrangements are a loss of
TP53 expression, which is frequently seen in OS as a result of large deletions encompassing the
whole gene, and would thus result in comparable disease phenotypes (see section 3.1.4). In
small biopsies, OS can be difficult to distinguish from histologic mimics, such as osteoblastoma,
aneurysmal bone cysts or undifferentiated pleomorphic sarcoma, particularly in core needle
biopsies [26]. Robust molecular OS specific biomarkers are still lacking. The remarkable
specificity of intron 1 rearrangements we describe for a subset of OS could therefore be of
diagnostic use in difficult cases. The diagnosis of Ewing sarcoma, for instance, is based on
rearrangements of EWSR1 besides pure morphology, but in contrast to OS, the frequency
of these events is substantially higher (roughly 85%) [149]. Although EWSR1 does not
exclusively fuse with FLI1 in Ewing sarcoma, the most common rearrangement partners
can be detected by breakpoint-polymerase chain reaction (PCR), which is a lot less complex
than DNA-PET sequencing. Alternatively, FISH is a technique which is well established in
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most diagnostic institutions. However, the lacking sensitivity for some copy number neutral
events might make its use in detecting TP53 intron 1 rearrangements difficult in a routine
diagnostic setting. In many pathology departments, tumors are increasingly analyzed by
gene panel- or exome sequencing, which are, however, not sensitive towards all types of
genomic rearrangements. In the future, more sensitive sequencing approaches are likely to
be routinely used in diagnostic settings, which might render intron 1 rearrangements a useful
marker nevertheless.
Besides sporadic OS, intron 1 rearrangements might have diagnostic implications in LFS. The
classical LFS diagnosis is based on cancer occurrence patterns in the family, since only in 70%
of cases the causal mutations in TP53 can be identified. Current clinical routine testing in
LFS patients includes Sanger sequencing of the TP53 exons for discovery of point mutations
and small InDels, as well as multiplex ligation-dependent probe amplification (MLPA) for
copy number analysis. These methods are not suitable to detect copy number neutral
rearrangements or rearrangements with only very small regional copy number changes, as
we found in OS and the LFS family. Awareness of genomic rearrangements as a contributing
factor to TP53 aberrations in the 30% of LFS patients with unidentified mutations might
lead to a more thorough and complete molecular diagnosis. This might prove invaluable for
identifying at-risk individuals and for providing the appropriate genetic counselling. Another
important clinical consequence of identifying LFS cases is based on the observation that 30%
of germline TP53 mutation carriers develop secondary tumors in the radiation field of a
primary tumor [107]. If more LFS patients can be identified as such, appropriate radiation
therapy decisions could be made to reduce the risk of secondary tumors. Due to the nature
of the observed rearrangements, which only possess one recurrent rearrangement partner
in intron 1, a comprehensive and straight-forward screen with PCR or MLPA is not possible.
DNA-PET or custom capture sequencing to identify rearrangements like we used in our studies
is labor and cost intensive and is not validated for clinical settings. That being said, novel long-
read sequencing methods such as PacBio's SMRT and Oxford Nanopore are being developed,
which generate continuous sequence information of fragments of up to 20 kb [150]. Such
long reads have the potential to greatly facilitate SV breakpoint identification and validation,
since they are able to span repeats and complex breakpoint regions. Alternative methods
combining tiling-PCR with long read sequencing have already been proposed to leverage
these technological advances for identifying breakpoints of SV with unknown rearrangement
partners [151].
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3.2 Exome Sequencing of Osteosarcoma Reveals Mutation Signa-
tures Reminiscent of BRCA Deficiency
We characterized (SNV) and copy number states of a large OS cohort of 123 pretherapeutic
samples, using next-generation sequencing and SNP-based copy number arrays. We initially
sequenced the exomes of a discovery set of 31 OS biopsies with matched normal samples.
After stringent filtering based on quality metrics and functional annotation, we found a
median of 21 and seven somatically acquired and potentially pathogenic SNV and InDels
per tumor, respectively. Based on these data, we further sequenced a replication cohort
of 92 additional tumors using targeted panel-sequencing of 13 initial candidate genes and
their 17 interaction partners (see table 3 on page 141). Combining the data, we found
SNV in the previously reported OS driver genes TP53, RB1, and ATRX in 18%, 8%, and 9%.
Further recurrently mutated genes included MUTYH and RET. We then analyzed copy number
alterations in the 123 tumors and found highly altered genomes. Similar to SNV, recurring
clonally disrupted driver candidates (either by losses or by disruptive gains) included TP53,
RB1, and ATRX. Taken together, exome sequencing and copy-number array data showed
that no monoclonal and thus potentially triggering event in a single gene seemed to be
responsible for causing the majority of OS cases. However, 47% of tumors could be explained
by TP53 and RB1 mutations, and clonal mutations in twelve other well-known cancer-driver
or -susceptibility genes could explain additional 40% of tumors.
Interestingly, most tumors showed CNA in BRCA1/BRCA2, PTEN, PALB2, ATM, CHEK2, and
in other genes involved in homologous recombination repair (HRR), a pattern of mutations
similar to those seen in BRCA-deficient breast and ovarian cancers (so-called “BRCAness”). Of
note, the majority of these CNA were subclonal. Prompted by these findings we hypothesized
that BRCAness could represent a common functional trait in OS with potential therapeutic
implications, since HRR deficiency is known to be specifically targetable by poly ADP ribose
polymerase (PARP) inhibitors. We therefore compared the mutational signatures from our
exome sequencing cohort with those reported in a pan-cancer analysis and found that 94% of
cases (29/31) carried a signature which has been associated with BRCA1/BRCA2 mutations
in breast cancer. Furthermore, we found characteristic copy-number patterns as described in
BRCA1/BRCA2 mutated breast cancer in ∼91% of OS, and 78% of OS fulfilled the criteria of a
homologous recombination deficiency score based on sub-chromosomal LOH segments, which
have been shown to correlate with homologous repair deficiency and a positive response to
PARP inhibitors. First in-vitro experiments using the commercially available OS-cell line MG-
63 showed a marked reduction in cell viability in response to the PARP inhibitor talazoparib.
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Figure 8 – Prevalence of somatic mutations across human cancer types. Tumor samples
are represented as dots, red horizontal lines are the median numbers of mutations in the respective
cancer type. The vertical axis (log scaled) shows the number of non-silent mutations per megabase.
OS samples are highlighted with orange background. Figure and all data points for non-OS samples
adapted from Lawrence et al [152].
3.2.1 What Can We Learn from Exome-Sequencing of 31 Osteosarcomas?
Osteosarcoma Is Characterized by a Modest SNV Burden
Exome sequencing of 31 OS with paired normal DNA revealed a median of 66.5 somatically
acquired SNV (equal to 1.7 SNV/Mb), of which 28.5 were non-silent (0.72 SNV/ Mb). When
these numbers are put into context of a pan-cancer study which involved 3'083 tumors of 27
subtypes, OS presents itself as a subtype with a modest SNV burden [152] (see figure 8 on
page 109). While our bioinformatics pipeline differs from the pan-cancer study and therefore
some numeric bias might have been introduced, the mutation numbers can still serve as a
rough indicator for mutational load. Cancers induced by carcinogens such as tobacco and UV
light show a ∼10x higher SNV burden than tumors from our OS cohort, yet the observed SNV
burden is still ∼3x higher than that of other pediatric tumors (Ewing sarcoma: 0.28 SNV/Mb;
AML: 0.33 SNV/Mb) and is comparable to that of prostate cancer (0.73 SNV/Mb).
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Besides carcinogens, genomic instability e.g. due to microsatellite instability can lead to
a high SNV burden. In microsatellite instability, genetic hypermutability results as a con-
sequence of defective DNA mismatch repair and is commonly observed in colorectal and
gastric cancers. Recently, microsatellite instability has gained importance as a biomarker
for cancer immunotherapy: high mutational burden might translate into a bigger repertoire
of neoantigens presented by the tumor cells, which can increase the discriminatory power
of the immune system between healthy cells and neoplasms and thus improve response to
immunotherapy [153]. Inhibition of the PD-1/PD-L1 immune checkpoint blockade, which in
homeostasis is required to avoid autoimmune responses, is a promising targeted treatment
strategy and antibody-based drugs for metastatic melanoma, non-small-cell lung cancer, and
bladder cancer have already been approved. While our sequencing data shows some outliers
with high SNV burden, in general OS seems to be microsatellite-stable and from this point of
view shows no molecular rationale for immunotherapy approaches.
Osteosarcomas Show Somatic Mutation Signatures Associated with BRCA-Deficiency
Besides for screening of individual SNV, whole-genome and exome-sequencing data can be
used to search for patterns in the mutational catalog of a tumor, which can reveal information
about the underlying mutational processes. Prominent examples of such processes are
reflected in specific DNA changes such as G>T/C>A transversions induced by tobacco
carcinogens and C>T/CC>TT transitions formed after exposure to UV light [154, 155]. In
signature analysis, these nucleotide changes are extended to mutation motifs, which include
the surrounding trinucleotide sequence context. Each mutational motif and its frequency
as found across all samples are shaped into a matrix. Mathematical non-negative matrix
decomposition then attempts to break down the ensemble of mutations from each sample
into a fixed number of specific mutational signatures: The two resulting matrices describe
individual signatures and their contribution to the mutation burden present in each sample,
respectively [156]. These signatures can metaphorically be thought of as stamps, consisting of
mutation motifs that occur together and are likely the result of a distinct mutational process.
Large sequencing efforts have led to the compilation and curation of mutational signatures
and their proposed aetiologies [110, 157]. Selected signatures and their occurrence in cancer
subtypes are illustrated in figure 9 on page 118. Using this approach, we found signature 3
to be present in 94% of OS exomes (29 of 31), which has previously been described in breast,
ovarian, and pancreatic cancers. In the pan-cancer analysis this signature was furthermore
associated with failure of DNA double-strand break repair by homologous recombination and
was correlated with germline and somatic BRCA1 and BRCA2 mutations [110].
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3.2.2 What Can We Learn from Copy Number SNP Arrays in 123 Osteosarco-
mas?
The Typical Osteosarcoma Genome is Highly Affected by CNAs
0.2 - 87% of the genomes of 123 OS samples were affected by CNA (median 51%). This is
considerably more than in other cancer types and is in line with the historical association
of OS with complex genomes. A study in which 3'131 tumors from 26 histologic subtypes
were analyzed for somatic CNA revealed that on average 31% of the genome was amplified
or deleted in a typical cancer sample and less than 0.5% in normal samples [158].
Osteosarcomas Are Not Driven by Focal Deletions or Amplifications of Tumor Suppres-
sors or Oncogenes
Genomically unstable tumors often show focal CNA which affect genes of importance for
tumorigenesis. Such small CNA are usually the result of selection for deletions of tumor
suppressor genes or amplification of oncogenes during tumor evolution. Common examples
are amplifications of MYC or MDM2, and deletion of ATM and NOTCH1. We observed copy
number gains at the MYC 8p locus in 78% of cases, but these changes were mostly large
segmental events. Nonetheless, in our dataset we found 80 focally altered regions which are
recurrent (here defined as occurring in >15% of cases). Of these, only 2 encompassed genes
with known association to OS: DLG2 at locus 11q14 was altered with focal deletions in 24%
of cases and recently reported to be mutated by genomic rearrangements in OS in 53% [96].
DLG2 is a known tumor suppressor in Drosophila [159], but its role in human cancer is still
unknown. We further found the paralogous cyclin-dependent kinase inhibitors CDKN2A/2B
at locus 9p21 to be focally deleted. CDKN2A encodes the two proteins p16 and ARF. P16 is
an inhibitor of CDK4-dependent inactivation of RB1 and loss of p16 can therefore phenocopy
RB1 loss [160]. Taken together, even though our data supports the common characteristic of
a highly unstable genome, we do not find good evidence for recurrent focal CNA affecting
cancer driver genes in the majority of the tumors.
Recurrently Disrupted Genes Are Involved in Homologous Recombination Repair
When looking into genes which are recurrently disrupted by large non-focal CNA (copy
number losses or disruptive gains) we found the classical OS drivers TP53 and RB1 to be
frequently affected. This is in line with previous results from our group and others [129, 96],
which are based on smaller cohort sizes. Interestingly, most other recurrently disrupted genes
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are functionally tied to the HRR pathway: BRCA2, (47%) FANCA (51%) , BRCA1 (26%),
BAP1 (31%), PTEN (50%), and PALB2 (43%). Of note, the last three genes were exclusively
mutated by CNA, and not by SNV. Functional and potential clinical consequences are further
discussed in sections 3.2.4 and 3.2.5.
3.2.3 Integration of Sequencing and copy Number Data: Clonal Mutations in
14 Driver Genes Can Explain the Majority of Osteosarcomas
To gain a more complete picture of putative driving events in the OS genomes, we combined
sequencing and copy number data after excluding subclonal aberrations, since they are more
likely to be passenger mutations present only in a subset of cancer cells, or have emerged
after the tumor developed polyploidy and therefore after the initiation of genomic instability.
We then assembled pathogenic mutations and disruptive copy number changes in genes with
strong a priori implication in cancer. Using this approach we found that 47% of cases can be
explained by TP53 and/or RB1 aberrations. Notably, the vast majority of RB1 aberrations
are based on genomic rearrangements manifested as CNA, whereas TP53 showed both CNA
and SNV. This is in line with the traditional view which historically attributed early OS
tumorigenesis to TP53 and RB1 driver mutations [91].
Another 40% of cases could be explained by aberrations in the additional 12 genes BRCA2,
BAP1, RET, MUTYH, ATM, PTEN, WRN, MDC1, FANCA, ATRX, NUMA1, and RECQL4 (see
Figure 3 of the published results in section 2.3 for a full overview) [161]. RECQL4 encodes
a RecQ DNA helicase and its loss of function has previously been found to predispose to
OS as part of the tumor spectrum of Rothmund-Thomson syndrome [162]. ATRX regulates
chromatin remodelling as a member of a protein complex and was recently found to be a
prognostic marker in neuroblastoma [163]. NUMA1 is a nuclear matrix protein involved in
microtubule linking during mitosis and SNV in the gene are associated with increased risk
for breast cancer [164], yet its role in OS is unknown. When exploring the gene ontology of
the remaining driver genes we found that they are all functionally associated with genome
integrity and HRR. The potential implications of this observation for therapy is discussed in
section 3.2.5. In total, 87% of the 123 tumors from our cohort carried aberrations in the
above 14 genes, whereby the majority are copy-number driven, except for RECQL4 and WRN,
which exclusively had missense mutations. Taken together, our findings suggest that, besides
the known OS drivers TP53 and RB1, multiple oncogenic pathways can initiate chromosomal
instability in early stages of tumor development and thus complement the traditional model
of OS tumorigenesis (see figure 6 on page 18).
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3.2.4 BRCAness as a Unifying Trait of Osteosarcoma
The observation of an accumulation of mutations in key genes of the HRR pathway has been
made also in other cancers. BRCA1/BRCA2 mutations are important tumor susceptibility
markers in familial breast cancer and lead to extreme levels of genomic instability in these
tumors, characterized by chromosomal rearrangements and CNA. BRCA2 binds to the DNA
recombinase RAD51 and guides it to damaged DNA, so HRR can be initiated; BRCA1 is
controlling the signal transduction processes modulating HRR [165]. HRR uses DNA recom-
bination to repair DNA double-strand breaks with high-fidelity. If HRR is impaired, cells need
to rely on more destructive DNA repair pathways to repair DSB, such as NHEJ, which can
result in genomic rearrangements. It was later discovered that mutations in BRCA1/BRCA2
as well as other modulators of HRR do not only cause familial breast cancer, but are also
widespread in sporadic tumors, where they promote similar complex genomes [166]. This
led to the definition of BRCAness as a phenocopy of BRCA1 or BRCA2 mutations; it describes
the situation in which an HRR defect exists in a tumor, in the absence of a germline BRCA1 or
BRCA2 mutation [167]. Soon after its discovery, BRCAness gained special interest, since it is
linked to increased sensitivity to platinum salts and targeted agents such as PARP inhibitors
(this is discussed further in section 3.2.5 on page 115). We found several indicators for
BRCAness in the 123 OS cases, which shall be discussed in the following.
Aberrations in HRR Genes
As discussed above, BRCAness by definition requires defects in genes of the HRR pathway. In
our cohort of 123 OS, the accumulation of aberrations (mainly by CNA) in HRR associated
genes is striking: a typical OS in our cohort carried 17 aberrations in these genes. Of note is
that most of these events were subclonal; it is likely that this is a consequence of intratumor
heterogeneity and that independent tumor subclones acquired different aberrations which
affect the HRR pathway.
Somatic Mutation Signatures
Somatic mutation signatures can infer mutational processes (see section 3.2.1 on page section
110). A large pan-cancer study of 7'052 tumors identified a signature which was strongly
associated with BRCA1 and BRCA2 mutations [168]. This signature, commonly referred to as
signature 3, is characterized by a relatively even contribution of all 96 sequence motifs (see
figure 9 on page 118). A whole-genome sequencing study of ovarian cancer later also found
signature 3 in tumors with mutations in other HRR pathway components [169]. Our exome
sequencing data showed this signature in 94% (29/31) of cases, which included tumors
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where we could not identify any BRCA1/BRCA2 mutations, but where other HRR genes were
mutated. The process which leads to signature 3 specific base substitutions as a consequence
of HRR deficiency is not well understood. It is thought that it might be a result of an attempt
to compensate HRR deficiency by increased recruitment of error-prone polymerases to bypass
DNA lesions [170].
A Specific LOH-Pattern
Abkevich and colleagues demonstrated that in ovarian cancer and 57 cancer cell lines,
mutations in the BRCA1/BRCA2 genes lead to an accumulation of LOH regions, which are
sub-chromosomal, but greater than 15 Mb in length. Based on this, the group created a
so-called HRD score (homologous recombination deficiency score), which is defined as the
number of such LOH regions per genome. Similar to mutation signatures, they could show
that an increased HRD-score is not only observable in BRCA1/BRCA2 mutated tumors, but
also when other HRR-related genes are affected [171]. Consequently, the HRD-score was
proposed to serve as a marker for BRCAness. Several studies have shown that an HRD-score
of >10 can predict treatment response to PARP inhibitors, a class of drugs which specifically
target cells with HRR deficiency. This threshold is also reflective of HRR deficiency in tumors
of the esophagus, lung, and prostate [172, 89]. It is therefore a valid assumption that the
HRD-score is applicable to multiple cancer types. When we applied the analysis to our
cohort, we found that 78% qualify as HRR deficient. However, some questions about the
transferability of the HRD-threshold remain. When correlating the score to PARP inhibitor
response in triple-negative breast cancer, Telli and colleagues derived the above threshold of
>10 from the 10th percentile of the HRD score distribution in a set of 260 ovarian and breast
cancer tumors, with aberrations in the BRCA1/BRCA2 genes, or promoter methylation of the
BRCA1 or RAD51C gene. They then validated their prediction of BRCAness by measuring
the response of the respective patients to PARP inhibitor treatments. At the current point
we are not able validate the threshold for OS, since no appreciable number of patients has
been treated with PARP inhibitors, but the HRD-score might still hold predictive value in OS
nonetheless.
Large-scale Copy Number Transitions
Another predictor of BRCAness is based on tumor genome complexity and was established by
Popova et al., who analyzed large-scale copy number transitions (LST) in BRCA1-mutated
basal-like breast carcinomas [173]. The group demonstrated that tumors with BRCA1 defi-
ciency are enriched in LST of >10 Mb in size. They were able to predict BRCA1 inactivation
by defining a threshold of 15 and 20 of such LST per near-diploid and near-tetraploid tumor
114
3.2. Exome Sequencing of Osteosarcoma Reveals BRCAness Signatures
genomes, respectively, with high sensitivity. Ploidy is usually measured by flow cytometry
and analysis of DNA content per cell. Since our study setup does not provide these data, we
applied both threshold values to our cohort. This results in a prediction of 91% (threshold =
15) and 73% (threshold = 20) of BRCAness positive cases. As with the LOH based HRD-score,
we cannot exclude tumor type specific threshold variations between breast tumors and OS,
since no PARP inhibitor treatment data of OS patients are available at this point.
3.2.5 BRCAness as a Possible Targeted Treatment Strategy for Osteosarcoma
The Rise of PARP Inhibitors
In the past few years, inhibitors of PARP have drawn a lot of interest as a targeted treatment for
tumors with HRR pathway deficiency. Amongst the six known primary DNA repair pathways,
HRR is responsible to resolve DSB with high fidelity. Conversely, PARP-1 plays an important
and rate-limiting role in SSB repair, where it identifies the site of DNA lesions and recruits
the repair complexes of the BER pathway, including the APE1 endonuclease [174]. SSBs
are common in any cell and can be caused by free oxygen radicals originating from normal
metabolism, UV light, and replication errors. Several drugs have been developed which
inhibit PARP-mediated SSB repair, either by impairing PARP-1's DSB sensing role in BER,
or by trapping the PARP-1 protein bound to the site of DNA damage. When the replication
machinery encounters an unrepaired SSB or a trapped PARP-DNA complex, DSB will arise.
In normal cells, these are repaired by HRR. However, in cancer cells which do not have a
working HRR pathway, the accumulating DSB will be repaired by low-fidelity NHEJ, which will
eventually result in extreme chromosomal instability and cell death [175]. This constellation,
where simultaneous inhibition of two pathways leads to cell death and inhibition of only one
of these does not, is called synthetic lethality (see figure 10 on page 119).
The clinical utility of PARP inhibitors has been demonstrated in several studies [177], and
the PARP inhibitor olaparib has received Food and Drug Administration (FDA) approval for
the treatment of refractory BRCA-mutated ovarian cancer. Other drugs, such as veliparib and
niraparib are currently in Phase III evaluation for treatment of breast cancer and recurrent
solid tumors [178]. Importantly, a landmark study in prostate cancer has shown that sensitivity
to PARP inhibitors is not restricted to BRCA1/BRCA2 deficient tumors, but also extends to
tumors with aberrations in HRR-related genes [179]. To this date, no OS-specific trial with
PARP inhibitor has been conducted. However, we think that our findings of BRCAness as an
abundant feature of OS provide the needed rationale for evaluating PARP inhibitors for the
treatment of OS.
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3.2.6 PARP Inhibitors and Osteosarcoma
Prompted by the results presented in this work, the sensitivity of several OS cell lines
towards the PARP inhibitor talazoparib was tested [180]. The study demonstrated that OS
cell lines were indeed sensitive to talazoparib and that the response correlated with their
mutation signatures and the resulting degree of BRCAness. Also, the response correlated
with aberrations in HRR-related genes, such as PTEN, ATM, BAP1, BARD1 or FANCA, and a
high HRD-score. Furthermore, another group recently reported good response of the OS cell
lines HOS and MG-63 cells to olaparib [181].
Despite these first preliminary results in cell lines, open questions about the potential efficacy
of PARP inhibitor in OS remain. First, our data suggests that OS is a tumor with consider-
able intratumor heterogeneity. This polyclonal nature is lost or altered in cell lines, where
immortalization and prolonged culturing can lead to a selection of subclones, which were
not necessarily the most prevalent in the tumor they are derived from. Furthermore, in
prostate cancer patients which were treated with olaparib, most responders carried biallelic
aberrations in BRCAness related genes [179]. In our data of 123 OS, mutations in HRR-genes
were mainly heterozygous or subclonal CNA. It is conceivable that heterozygous mutations in
multiple HRR-genes can synergistically add up to HRR deficiency. Another possibility is that
CNA are present in homozygous states, but only in a subset of tumor cells due to intratumor
heterogeneity. The methods used in our study are not able to discriminate between the two
scenarios. To gain a more detailed picture, methods like multiregion sequencing or even
single cell sequencing would need to be employed. Nonetheless, the majority of primary OS
are sensitive to cisplatin treatment, indicating that the DNA repair mechanisms are impaired.
If this property persists in recurrent and metastatic tumors, PARP inhibitors might represent
an additional approach to exploit this weakness.
Indications for “compound-BRCAness“ were also found in a prostate cancer study, where sev-
eral responsive patients only harbored heterozygous mutations in their sequenced BRCAness
genes [179]. Ultimately, response to PARP inhibitor in OS will likely be governed by the
nature of mutations, the players of HRR which are mutated, and the subclonal structure which
underlies the intratumoral heterogeneity. Multiple PARP inhibitor companion diagnostic
assays have been developed based on the genomic markers discussed above. However, so far
only sequencing of BRCA1/BRCA2 has received FDA approval. It remains to be elucidated
how well these assays predict PARP inhibitor response to “compound-BRCAness“. Since
PARP inhibitors are thought to target HRR-deficient cells independent of which BRCAness
genes are mutated, a functional biomarker for HRR-activity would ultimately hold the most
predictive value. An immunohistochemical marker surveying the ability of cells to accumulate
RAD51 in the nucleus as response to DNA damage has been proposed [167]. A challenge
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for the application of such assays in research and clinics is that in the basal state almost no
RAD51 accumulates in the nucleus; DNA-damage needs to be induced by drugs or radiation
first in order to assay the HRR response. An avenue to explore is would be to perform
immunohistochemistry (IHC) of RAD51 after ex vivo DNA damage induction, e.g. in primary
tumor cell cultures [182].
Challenges of PARP Inhibitor Treatment
Several mechanisms for resistance to PARP inhibitor have been identified [183]. Secondary
mutations which reverse the pathogenic effect of SNV in the HRR-gene by restoring the open
reading frame are found in ovarian cancers, but the overall frequency of this phenomenon is
not clear. Since most HRR-affecting aberrations in our cohort are CNA, secondary SNV are
not likely to be a major contributor to resistance, but compensation of heterozygous losses by
uniparental disomy cannot be excluded. Moreover, loss of TP53BP1 and REV7 (also known as
MAD2L2) can partially restore HRR in BRCA1- or ATM-deficient cells, but not BRCA2-mutant
cell lines [184]. In our OS cohort, 35% and 8% show large-scale heterozygous- or subclonal
losses of TP53BP1 and REV7, respectively. However, in our samples BRCAness seems to stem
mainly from aberrations in HRR-genes other than BRCA1, and of the ten cases with disrupted
ATM, five have additional deletions in other HRR genes. The contribution of these known
PARP inhibitor resistance mechanisms in OS might therefore be minor.
Another concern is the efficacy of PARP inhibitors in the treatment of metastatic or recurrent
OS, since novel treatment approaches are generally tested in advanced disease stages first
(see section 1.2.3 on page 7). A functional HRR-machinery is required for the repair of DNA
damage induced by many currently used DNA-damaging chemotherapy agents and conse-
quently, refractory tumors which survived the current standard-of-care MAP-regimen might
only consist of subclones that are devoid of BRCAness properties or have acquired resistance
to PARP inhibitors [167, 183]. Since the study presented here is based on pretreatment
tumors, we cannot derive any information about the clonal composition of refractory tumors.
However, a study to investigate this issue is currently in progress. Regardless of the outcome,
PARP inhibitor treatment might still be a potential maintenance therapy candidate to sup-
port current chemotherapy regimens, since hyperadditive effects between PARP inhibition
and cisplatin chemotherapy have been demonstrated in several cancers [185]. Therefore
a reduction of chemotherapy dosages might be possible, which could greatly reduce side
effects.
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Figure 9 – Validated somatic mutation signatures and their presence in human cancer
genomes. A, The presence of mutational signatures across human cancer types is depicted, based
on a pan-cancer data set of 7'042 tumors. Probable mutation mechanisms are indicated. B, Each
signature is displayed according to the 96 mutation motifs including the trinucleotide context of
the mutated base. The contributions of substitutions to the mutational signatures are displayed in
different colors. The mutation types are on the horizontal axes, whereas vertical axes depict the
percentage of mutations attributed to a specific mutation type. All mutational signatures are displayed
on the basis of the trinucleotide frequency of the human genome. C, The workflow from somatic
mutations to mutation signatures is depicted. See text for more details. Adapted from Nik-Zainal et al
[157].
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Figure 10 – Mechanism of PARP inhibition. The role of PARP inhibitors in synthetic lethality.
Enzymes of the PARP family play a key part in the repair of DNA damage. Single-strand breaks occur
frequently during each cell cycle and can be repaired. In particular, PARP1 binds to single-strand
breaks in DNA and recruits other enzymes to repair the DNA damage through the base-excision
repair pathway. Failure to repair single-strand breaks can result in double-strand breaks during DNA
replication; thus, PARP inhibition can induce further DNA damage. In normal cells, double-strand
breaks can be repaired through homologous repair. BRCA1, BRCA2 and RAD51 are key components of
these homologous recombination repair pathways and therefore, BRCA-mutant tumors are inherently
deficient in DNA repair. This vulnerability forms the foundation for selective targeted synthetic lethal
therapy with PARP inhibitors in patients with BRCA-mutant breast cancer. The DNA damage that
occurs after inhibition of PARP activity cannot be adequately repaired and the alternative, low-fidelity
NHEJ repair pathway is engaged. This will eventually result in chromosomal instability, cell-cycle
arrest, and subsequent apoptotic cell death. As DNA-repair processes remain intact in noncancerous
cells, which generally retain at least one functional copy of both BRCA1 and BRCA2, PARP inhibition
is hypothesized to selectively kill cancer cells, sparing normal tissue. Abbreviation: UV; ultraviolet
irradiation; PARP, poly(ADP-ribose) polymerase; HRR, homologous recombination repair; NHEJ;
non-homologous end-joining, BER, base excision repair, APE1, Apurinic/apyrimidinic endonuclease 1.
Adapted from Sonnenblick et al [176].
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3.3 RET Germline Mutations and Susceptibility to Osteosarcoma
In an osteosarcoma cohort of 337 patients which we analyzed for germline mutations, we
found seven cases with bona fide pathogenic RET mutations and four cases with variants of
unknown clinical significance. By comparing these findings to the mutation frequency in the
normal population as compiled by the Exome Aggregation Consortium (ExAC) consortium
[186], we demonstrated that the cumulative odds of any American Thyroid Association (ATA)-
classified multiple endocrine neoplasia type 2 (MEN2) type A or familial MTC-predisposing
RET mutation were significantly higher in the OS cohort (odds ratio 9.12, 95% CI, 4.26
to 19.54, P<0.0001). RET germline mutations have been previously indicated in cancer
development, yet the connection to OS is, to the best of my knowledge, a new discovery.
3.3.1 What Is the Role of RET in Normal Development?
RET (rearranged during transfection) is a proto-oncogene, which encodes a single-pass
transmembrane receptor tyrosine kinase [187]. The RET protein consists of an extracellular
domain for ligand-binding, a hydrophobic transmembrane region, an intracellular tyrosine
kinase domain for downstream signalling [188], and a cadherin domain, supposedly for
cell-cell interactions (see figure 11 on page 127) [189]. The protein is required for normal
development of several cell types and processes, such as kidney induction, spermatogonial
stem cell maintenance, neural crest cell migration, and development and maintenance of
the central and peripheral nervous system [190]. Recently, RET was also implicated in the
survival, expansion and function of haematopoietic stem cells [191]. High conservation
between species from Drosophila melanogaster to primates underlines the relevance of RET
in these developmental processes. The ligands of RET belong to the group of glial cell
line-derived neurotrophic factor family ligands and promote the survival of certain neuron
populations during normal development. Abnormally high GFL expression has been correlated
with invasiveness and progression of pancreatic adenocarcinoma and oral cancer [192, 193].
Binding of the ligand to RET requires a co-receptor from a glial cell line-derived neurotrophic
factor (GLF) receptor-α family. Varying affinity between members of the ligand and co-
receptor families, as well as spatio-temporal expression patterns allow specific RET activation
during development and homeostasis of mature tissues [194]. Upon binding of the co-
receptor/ligand complex, the extracellular cysteines mediate the formation of RET dimers.
Subsequently, specific tyrosine residues in the cytoplasmic domain are autophosphorylated
which can then activate a plethora of downstream signaling cascades [190]. Multiple docking
sites for different signalling complexes at phosphotyrosines pY1062, pY1096 and others have
been described to stimulate RAS-MAPK, JAK-STAT3, and PI3K-AKT pathways [195, 196, 197]
in response to RET activation.
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3.3.2 What is the Role of RET in Cancer?
RET as a Somatic Cancer Driver
The transforming properties of RET were originally discovered in early experiments in which
DNA from human lymphoma cells was transfected into the mouse NIH-3T3 fibroblast cell
line, upon which RET was rearranged and activated [187]. Since RTK are involved in many
physiological processes, its role in tumorigenesis and tumor progression has been further
studied and demonstrated in many cancers. In humans, RET is located on chromosome
10q11.2 and consists of 53,325 bp and 21 exons. Early studies have shown that somatic
mutations in the gene can be the driving events in thyroid cancer development. In sporadic
medullary thyroid carcinoma, 30-50% of cases carry activating RET mutations [198]. The
most common mutation is the M918T methionine to threonine substitution in the kinase
domain, which can lead to decreased autoinhibition and increase of kinase activity and
ATP binding [199]. More recently, recurrent RET rearrangements have been described as
oncogenic drivers in papillary thyroid carcinoma [200], as well as in a smaller subset of non-
small-cell lung cancer (KIF5B-RET) [201]. Other frequently mutated RTK include ABL and
ALK in hematological cancers, and EGFR and HER-2 in non-small-cell lung cancer (NSCLC)
and breast cancer, respectively [202].
RET in Familial Cancer Syndromes
Germline mutations in RET with a loss of function effect can lead to a congenital disorder
called Hirschsprung's Disease (HSCR) disease, which is characterized by the absence of
enteric ganglions in the gut and blocked peristalsis (often leading to a congenital megacolon).
Causal alterations are dispersed over the whole gene but are mostly nonsense and missense
mutations, which lead to loss of RET signaling [203, 204]. These HSCR mutations have
been found to constitutively induce apoptosis in RET expressing cells, which can explain the
absence of the affected ganglion cells in the disease phenotype.
Gain-of-function mutations in RET can lead to multiple endocrine neoplasia type 2, which has
emerged as a paradigm for heritable activated oncogenes in cancer predisposition syndromes.
MEN2 is an autosomal dominant familial syndrome and predisposes patients to a spectrum
of endocrine tumors [205, 206]. The syndrome's genetic basis lies exclusively in germline
mutations in the RET oncogene. While these are mainly heterozygous missense variations, a
whole repertoire of these mutations has been described which leads to the distinction of three
MEN2 subtypes: MEN2A, MEN2B and familial medullary thyroid carcinoma (FMTC). These
subtypes, however, can show a wide variability in their phenotypes. MEN2A, the most common
subtype, manifests itself by MTC and often includes development of pheochromocytoma, a
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tumor of the adrenal gland. MEN2A mutations are mainly affecting extracellular cysteine
residues. Gain-of-function mutations in codons 609, 611, 618, 620, and 634 together
make up 98% of cases. Functional studies have shown that these mutations lead to a
ligand-independent dimerization and therefore constitutive activation and downstream-
signalling of RET [207]. MEN2B is characterized by mutations in the kinase domain (mostly
M918T), causing receptor autophosphorylation, which can drive MTC formation in mice
[208]. In addition, pheochromocytoma as well as developmental irregularities can occur
which, together with the generally early onset in infancy or early childhood, makes MEN2B
the clinically most severe subtype. Mutations causing FMTC can either affect the extracellular
cysteines or the kinase domain. Current data and guidelines by the ATA hint towards a
phenotypic continuum between MEN2A and FMTC [209]. Modifying variants have also been
described. When occurring in cis, such mutations can amplify deleterious mutations and
further complicate unequivocal genotype-phenotype correlations [210].
The distinction between HSRC-causing loss of function variants and MEN2-causing gain-
of-function variants is not always trivial. So-called Janus mutations can lead to both phe-
notypes by constitutively activating RET but simultaneously hindering protein maturation
and reducing the receptor expression on the cell membrane [211]. A publicly available
and comprehensive list of mutations is maintained by the University of Utah and can aid in
genotype/phenotype correlations, for both MEN2 and HSCR [212].
3.3.3 What Is the Potential Role of RET in Osteosarcoma?
As discussed previously, the function of RET as an oncogene is well known, yet a link of RET
germline mutations to OS has, to the best of my knowledge, not been previously described.
Generally, the role of RET in OS has not yet been extensively studied and thus not a lot is
known about its involvement in osteosarcomagenesis. A phosphoproteomic screening has
shown that RET and four other RTK are expressed and activated in the metastatic human OS
cell lines 143B and LM7. Subsequent functional genomic screens using small interfering RNA
(siRNA) demonstrated that RET contributes to the motility and colony forming phenotype of
LM7 cells [213]. However, the underlying mutation leading to its activation has not been
identified and the clinical significance and prevalence of these in vitro findings have not been
followed up.
We identified seven cases with bona fide pathogenic RET mutations in our analyzed cohort
of 337 OS patients. Like in MEN2, most of these mutations are located in the extracellular
domain of the protein (six of seven). Of the four additional RET variants with unknown
clinical significance, three mapped to the extracellular domain (see table S1 on page 95).
This extracellular domain of RET consists of a cysteine-rich region, which is located adjacent
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to the transmembrane portion of the protein, and a cadherin-like domain, which in turn
is made up of four cadherin-homology repeats [214]. Mutations in the RET cadherin-like
domains are common in HSCR and are thought to affect folding and membrane transport of
the protein [215]. Nevertheless, the functional consequences of these mutations in cancer
are not fully understood.
The cysteine-rich region dictates protein conformation and ligand binding. Amino acid sub-
stitutions of these cysteines lead to unpaired cysteine residues which can form intermolecular
disulfide-bonds and therefore GLF ligand-independent RET homodimers. This dimerization
results in constitutive RET signalling [190]. Alterations of this kind are found in virtually all
MEN2A cases and are also frequently found in FMTC. RET signalling is organized around
phosphotyrosines in the intracellular domain. Upon ligand binding and dimerization of RET
receptors, these residues are autophosphorylated and allow direct interaction with signalling
molecules such as SRC or STAT, or a broad range of adaptor proteins. This leads to the
activation of various downstream pathways, including RAS-MAPK, JAK-STAT, and PI3K-AKT
pathways. These cascades can promote cell growth, proliferation, survival and differentiation
[190]. Alongside the pathogenic variants and variants of unknown significance (VUS) in
RET, we identified a G691S polymorphism in 5 of the 11 cases (see figure S2 on page 90).
Functional studies have shown that RET-G691S leads to an increased oncogenic activity of the
S891A mutation and a trend towards earlier onset in patients. It has therefore been proposed
that in MEN the status of this polymorphism should be evaluated for more appropriate
follow-up decisions [216]. The validity of this observation in OS remains to be confirmed.
Particularly the activity of the PI3K/AKT pathway has been experimentally linked to the
MEN2 phenotype and it was shown in cell culture studies that the oncogenic potential of
the typical C634R MEN2 mutation is dependent on PI3K/AKT activation [217]. Interestingly,
high activity of the PI3K/AKT pathway has been implicated in genomic instability, which
constitutes a hallmark of osteosarcoma genomes. Phosphoinositide 3-kinase family kinases
(PI3K) and their target AKT get activated by RTK. Activated AKT protects cells from apoptosis
during the G2/M checkpoint transition in normal cell cycles. Since the G2 checkpoint normally
prevents cells with DNA damage from undergoing mitosis, dysregulation of AKT can result
in toleration and accumulation of DNA damage [218]. Findings in glioblastoma suggest
that AKT signalling might also actively promote genomic instability by interfering with the
recruitment of BRCA1, RAD51 and other DNA damage response proteins to the site of damage,
and thereby repressing the accurate repair of DNA lesions by HRR. In this case, DNA breaks
will be preferentially repaired by the low-fidelity NHEJ mechanism, which can result in
rearrangements [219]. Importantly, negative regulation of the PI3K/AKT pathway is mainly
achieved by PTEN in homeostasis [220] . This tumor suppressor gene is the second-most
mutated gene after P53 in solid tumor types and we have identified PTEN as a potential driver
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mutation in 16% of our sequenced osteosarcoma cases. An other study found PTEN deleted
in 43% of OS cases [100]. Furthermore, a transposon-based screen demonstrated that PTEN,
AKT2 and other PI3K/AKT pathway members can drive OS tumorigenesis in mice [221]. In
addition to deletions of PTEN, constitutive activation of RET as implied by the mutations in
our cohort might therefore represent an alternative mutational trajectory towards PI3K/AKT
activation and accumulation of genomic lesions in a subset of OS. This hypothesis is supported
by our observation that germline RET-mutated tumors result in genomically similar tumors
to sporadic OS in terms of mutation burden, mutation signatures and methylated regions.
Besides promoting genomic instability, typical RET MEN2 mutations have also been shown to
increase proliferation in cell line experiments [222]. It is thus conceivable that RET mutations
can contribute to OS tumorigenesis on both, an antiapoptotic level, i.e. by rendering the cell
unresponsive to DNA damage during the acquisition of genomic aberrations, and repression
of HRR as well as by directly increasing cell proliferation rates. Other modes of action
also seem possible. Activated RET is known to induce overexpression of the cell cycle
protein c-MET, which in turn has been demonstrated to transform human osteoblasts into
an OS phenotype [223, 224]. The exact mechanism with which RET mutations contribute
to osteosarcoma tumorigenesis remains to be elucidated. Experiments to establish direct
functional evidence between our observed RET mutations and PI3K/AKT activation in OS
still need to be conducted. However, in either case constitutively active RET signalling seems
to be emerging as a common denominator with clinical potential.
3.3.4 How Can The New Knowledge About Osteosarcoma as a RET-associated
Disease Benefit the Clinics?
By analyzing 337 osteosarcoma patients we identified seven patients with bona fide pathogenic
germline variants and additional four patients with RET germline variants of currently
unknown clinical significance, which corresponds to a frequency of 2% or 3.3%, respectively.
Even though this can unarguably be perceived as a rare finding in a rare tumor, our results
may still hold value for diagnosis and treatment of osteosarcoma, which shall be discussed
hereafter.
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Early Detection of At-Risk Patients
The frequency of germline RET mutations observed by us is similar to the frequency of
pathogenic germline TP53-mutations, as determined in a large study of 765 osteosarcoma
cases (3.1 %) [225], as well as to the frequency of germline TP53 mutations in early-onset
breast cancer patients (2%) [226]. For both cases, routine genetic testing has recently been
recommended [227]. Given the similar prevalence between these studies and our data and
genetic testing for RET mutations already being well established in clinics for MTC, it might
be warranted in OS patients as well, independent of family history.
Furthermore, the pathogenic RET germline mutations we described in the OS patients have
all been categorized as moderate by the ATA in respect of risk for developing MTC; for carriers
of these mutations thyroidectomy in childhood or young adulthood is advised [228]. It is
therefore possible that affected OS patients, if untreated, will develop thyroid carcinomas
later in life. With the improved survival outcome in OS due to introduction of chemotherapy
in the 1970s, it can be expected that more patients will eventually reach the age to develop
variable late-onset MTC caused by moderate risk RET mutations as we found in OS. Early
identification of these patients will allow adequate surveillance and treatment and enable
predictive testing of at-risk family members.
RET as a Therapeutic Target
RET is a tyrosine kinase and as such can be targeted with small molecule inhibitors. Current
RET-targeting drugs are compounds which were initially developed as inhibitors for other
tyrosine kinases but which, due to high sequence homology in the functionally important ATP-
binding and kinase motifs, are effective in decreasing RET activity as well (multikinase TKI).
So far, no RET specific inhibitors have been approved for clinical use. Even though clinical
data for unspecific inhibitors do show prolonged progression-free survival of metastatic or
unresectable MTC, their cross-reaction with other tyrosine kinases, such as the VEGF receptor,
can lead to a regression of normal blood vessels and associated thyroid dysfunction [229].
These adverse effects can prevent long-term treatment [198]. With non-small-cell lung
carcinoma recently being added to the portfolio of RET related cancers [230], agents which
target RET more specifically and efficiently are likely to emerge in the near future [231].
Since our data suggest that a subset of OS is caused by pathogenic germline RET mutations,
targeting of RET is a potential treatment option which should be investigated in more detail.
Even though no direct link between RET and OS existed so far, preliminary experiments
with TKI have been done, prompted by the observation that several RTK are activated in
OS. A study with seven OS cell lines and mouse xenografts suggest that the TKI sorafenib
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exerts apoptotic and antitumor activity [232]. Interestingly, the murine xenograft models
also showed a reduction in number and size of lung metastases upon sorafenib treatment. A
dose-escalation study which assessed the efficacy of regorafenib, another multikinase RET
inhibitor, against refractory advanced solid tumors showed preliminary evidence of antitumor
activity in an osteosarcoma patient [233]. However, trials involving more patients and the
integration of their RET mutation profile are needed to accrue more solid evidence. The
different proposed contributions of RET-mutations to tumorigenesis, and varying degrees of
intratumor heterogeneity might perturb therapeutic effects of RET inhibition. If constitutively
activated RET functions as an enabler of early genomic instability by inactivating DNA-
damage induced apoptosis and HRR repression, then treatment of OS with TKI at the stage
of recurrence or metastatic spread may be belated since the tumor has already accumulated
its transforming genomic aberrations. On the other hand, in tumors where dysfunctional
RET signalling does not only induce chromosomal instability but also contributes to cell
proliferation and metastatic spread at a later stage, targeting of RET might represent a new
avenue for OS therapy.
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Figure 11 – The RET protein and its connection to the PI3K-AKT signalling cascade.
RET signalling, either induced by ligand binding or activating mutations, is organized around phos-
photyrosines in the intracellular domain. These signaling hubs can interact with various downstream
pathways such as RAS-MAPK, JAK-STAT and PI3K-AKT. Phosphoinositide 3 -kinase family kinases
(PI3K) and their target AKT can be activated by various receptor tyrosine kinases (RTK), including
RET. Activation of the PI3K/AKT pathway by phosphorylation of AKT can protect cells from apoptosis
during G2/M checkpoint transitions, which can lead to accumulation and toleration of DNA damage.
AKT signalling can promote genomic instability by interfering with the recruitment of BRCA1, RAD51
and other DNA damage response proteins to the site of damage, thereby repressing the accurate repair
of DNA lesions by HRR. See text for more details. CLD; cadherin-like domain, TM; transmembrane
domain, CRD; cysteine-rich domain. Encircled Ps depict phosphorylation sites.
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3.4 General Conclusion and Outlook
In this work, we combined state of the art genomic analysis methods with an extensive
collection of pretherapeutic samples to gain a better understanding of the genomic landscape
of OS, which could lead to therapeutic approaches that complement current treatment
protocols. To this end we integrated data from SNP-based copy number arrays, gene panel-
, exome, and whole-genome sequencing as well as the specialized DNA-PET method for
detection of structural variations.
We identified recurrent rearrangements with breakpoints in intron 1 of TP53 to be highly
specific for OS. We demonstrated that these rearrangements lead to abrogated expression of
TP53 and that they represent the genetic basis for LFS in a family. Even though these findings
do not offer a direct therapeutic target, they may hold value as a diagnostic marker for both
OS and LFS, especially since in the future advanced long-read based sequencing techniques
are likely to be routinely used in diagnostics. Additional functional studies are needed to
elucidate the indicated transcription-dependent rearrangement mechanism we propose.
We further identified 12 driver genes which supplement the classical, TP53 and RB1 centric
model of osteosarcomagenesis. Mutational signature analyses suggest that the majority of OS
in our cohort are deficient in HRR (“BRCAness”). PARP inhibitors, which specifically target
HRR deficiency show promising treatment results in other malignant tumors and we show that
PARP inhibition significantly reduces viability in OS cell lines with BRCAness. Nevertheless,
the high intratumoral heterogeneity of OS complicates a clear correlation between the
mutations we identified in bulk tumors and the measured BRCAness. Multi-region or single
cell sequencing (once the latter technique has matured more) could help in establishing
clearer prognostic correlations. Also, the analyzed cohort consisted of pretherapeutic samples.
Thus, the degree of BRCAness and the accompanying predicted PARP inhibitor sensitivity of
refractory and metastatic tumors remain to be elucidated; an ongoing project is addressing
this limitation of the current data.
Based on the findings in an index case with a pathogenic germline RET, we analyzed sequenc-
ing data 337 of OS patients and discovered predisposing RET mutations, which occur with
a comparable frequency to germline TP53 mutations in OS and breast cancer. There are
ongoing collaborative efforts to create mouse models that reflect RET mutated OS. Therefore,
future functional studies will need to shed light on the consequences RET mutations have
on downstream signaling pathways such as PI3K/AKT. Such models will further allow the
assessment of the possibilities of TKI in the treatment of OS. The cost of sequencing has
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dramatically decreased in the past and will continue to do so in the future. This will enable
individual pathology departments as well as cooperative research consortia to sequence a
high number of OS and matching normal samples. It is therefore likely that more predisposing
germline mutations of similar frequency than the ones we describe in RET will surface.
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4 Materials and Methods
The methods described in this chapter have previously been published as parts of the presented
publications [129, 161]. For the reader's convenience and clarity, some of the methods are
addressed again and extended below.
4.1 DNA-PET Sequencing of Osteosarcoma
4.1.1 OS Patient Samples for DNA-PET Sequencing
For initial analysis of recurrent structural variations in OS, DNA of four pretreatment OS
tumors and paired normal blood was obtained from the Biopathology Center (BPC) of the
Childrens Oncology Group (COG). The COG cooperative group includes medical centers in
the United States, Canada, Mexico, Australia, New Zealand and countries in Europe.
4.1.2 DNA-PET Library Construction and Sequencing
DNA-PET library construction from 1 to 4 kb fragments of genomic DNA was performed for OS
DNA samples from the Children’s oncology group, where enough DNA was available. Library
construction was adapted from the protocol described by Hillmer et al [234]. 5-10 µg of
genomic tumor DNA was randomly fragmented using HydroShear (Genomic Solutions, USA)
and end-repaired using the DNA End-Repair kit (Epicentre Biotechnologies, USA). Long Mate
Pair LMP CAP adaptors (Applied Biosystems, USA) were ligated to both ends. This adapter is
missing the 5'phosphate on the shorter oligonucleotide and therefore the ligation product
carries one nick in each strand. DNA constructs were size-separated on an agarose gel and
1-4 Kb fragments were selected and extracted (yielding in 150-500 ng) for further ligation
with the biotinylated internal adapter. By a nick translation using DNA polymerase I, the nick
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Figure 12 – DNA-PET sequencing library preparation. 5-10 µg genomic DNA (blue) was
fragmented to a target size of 1-4kb and end-repaired. Long Mate Pair LMP CAP adaptors, which
are missing a 5'phosphate (upper gray box), are ligated. After size-selection on an agarose gel the
biotinylated internal adapter (red fragment) is ligated. The nick in the ligation product is pushed
inwards using DNA polymerase I and The DNA-PET construct is released by T7 exonuclease and S1
nuclease digestion. The sequencing adapters P1 and P2 (green and yellow, respectively) are ligated
and the final library (lower gray box) is PCR amplified, size-selected using polyacrylamide gel (PAGE)
and sequenced. The reads are mapped to the human genome and discordant reads analyzed using
a dedicated bioinformatics pipeline to identify SV candidates. Figure adapted from UC Santa Cruz
[235].
was pushed from the LMP CAP adaptor in 5'direction into the genomic DNA fragment. The
construct was digested by T7 exonuclease and S1 nuclease resulting in a cut at the nick position
and release of the DNA PET constructs. SOLiD sequencing adaptors (Applied Biosystems,
USA) were ligated to the PET constructs, which were then amplified for 15 cycles by PCR
using the SOLiD PCR primers (Applied Biosystems, USA) and the final 225-425 bp libraries
was extracted from a polyacrylamide gel. High throughput sequencing was performed
on SOLiD sequencers (v3plus and v4) according to the manufacturer’s recommendation
(Applied Biosystems, USA). The resulting PET reads were mapped to the National Center for
Biotechnology Information (NCBI) human reference genome build 37 (hg19).
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4.1.3 Bioinformatics Workflow for SV Detection
Sequencing, mapping and data analysis were performed as described by Hillmer et al [234],
with refined bioinformatics filtering as described by Nagarajan et al [236]. The short reads
were aligned to the NCBI human reference genome build 37 (hg19) using Bioscope (Life
Technologies).
Since not enough constitutional DNA was available to generate DNA-PET libraries, potential
somatic SV were filtered out by subtracting any SV identified by paired-end sequencing in
an additional 29 unrelated normal individuals (20 individuals analysed by DNA-PET and
9 individuals analyzed by other paired-end sequencing protocols. Sequence context and -
homology of rearrangement partners were assessed by expert visual inspection to exclude false
positive results. Somatic SV calls were validated by PCR and Sanger sequencing. Candidate
SV selected for further analysis were validated to be somatic by breakpoint PCR in the paired
normal sample.
4.2 Dual-Color Break-Apart FISH Assay for Detection of TP53 Re-
arrangements In Osteosarcoma
The BAC clones RP11-1081A10 and RP11-107F4 (BACPAC, Children’s Hospital Oakland
Research Institute, USA) were selected for the TP53 break-apart assay (see table 1 on page
133 for details). 1.5µg of each BAC clone was labelled by nick translation (Nick Translation Kit,
Abbott Laboratories, USA) for 15 mins at 15◦C according to the manufacturer's instructions,
using red or green fluorescently labelled dUTP nucleotides, respectively (Enzo Life Sciences,
Switzerland). Labeled probes were precipitated with salmon sperm DNA and 3M sodium
acetate (NaAc) (10% v/v) at -20◦C and resuspended in nuclease-free H2O. The probes were
heated for 4 hours at 37◦C to ensure complete dissolving. The in situ hybridization was
performed according to routine protocols. Tumors were considered to have a rearrangement
in TP53 when at least 10% of cells showed clearly separated green and red hybridization
signals (= FISH positive/break-apart).
BAC Clone Labelling Start Coordinate End Coordinate
RP11-1081A10 red dUTP chr17:7420240 chr17:7589389
RP11-107F4 green dUTP chr17:7627095 chr17:7785964
Table 1 – Fluorophore labelling and genomic coordinates (NCBI human reference
genome build 37 / hg19) of BAC clones as used for break-apart FISH for detection
of TP53 rearrangements.
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4.3 Methylation- and Copy Number Arrays of Osteosarcoma
4.3.1 Copy Number Arrays
Genome-wide CytoScan HD Arrays (Affymetrix, CA, USA) were performed according to
the manufacturer’s instructions using 250 ng of genomic DNA from each tumor sample.
To evaluate copy number variations, data was processed using the Nexus Copy Number
software (Version 7.0, BioDiscovery, USA) with integrated algorithms for segmentation and
normalization. Copy number alterations were called using the SNP-FASST2 algorithm with
a significance threshold of 1.0E−14, a maximum contiguous probe spacing of 1 Mbp, and a
minimum number of 3 probes per segment. For LOH regions, a minimum length of 500 KB
was required.
4.3.2 Methylation Arrays and Differential Methylation Analysis
250 ng of DNA were used on an Infinium Methylation EPIC BeadChip (Illumina, USA).
Differential methylation analysis between tumors was performed in R using the Chip Analysis
Methylation Pipeline for Illumina HumanMethylation450 and EPIC chips (ChAMP version
1.11.1) [237]. The data was normalized by beta-mixture quantile normalization (BMIQ)
and methylation variable positions were segmented into biologically relevant differentially
methylated regions using the Probe Lasso algorithm [238].
4.4 TP53 Breakpoint Identification in a LFS Family
4.4.1 Custom Sequence Capture for TP53 Breakpoint Identification In a LFS
Family by Paired-End Sequencing
The TP53-containing region chr17:7,520,000 - 7,680,000 (NCBI build 37) was defined for a
custom sequence capture (SeqCap EZ Choice, Roche NimbleGen Inc.). Repetitive regions
are usually excluded for sequence capture assays but since most of the observed breakpoints
in OS were in LINE sequences, we forced the inclusion of the repetitive sequences of the
intron 1 region of TP53 (chr17:7,579,941 - 7,590,694). Illumina sequencing libraries were
constructed and capturing was performed according to the manufacturer’s recommendations
and the library was sequenced on an Illumina HiSeq 2000 by 2x50 bases. Reads were mapped
to the human reference genome (NCBI build 37) by BWA and read-pairs where one read
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Breakpoint Name Sequence Forward Sequence Reverse
LFS-BP1 CTCAAAAGGCCATCAAAAGG GTATGGTGGCCTGTTCCTGT
LFS-BP2 GGCTGCTGGGAGTTGTAGTC AGCTATCTTGACCCCACACG
LFS-BP1-wt CCCGAATAGCTGGGATTACA GCAAGTGCACAGGAAGATGA
LFS-BP2-wt GGAGGAATCCTGCATTGTGT CAGGCTTCAGACCTGTCTCC
POLR2A positive control GCTGCTGGACGTGAGTATGA AGTTCCAACAATGGCTACCG
Table 2 – PCR primer pairs as used for validation of TP53 breakpoint candidates in a Li-
Fraumeni Family.
mapped to the TP53 target region and the paired read mapped outside of that region were
identified by custom scripts. Reads of similar mapping patterns were clustered together as
described earlier in [234] and prioritized for validation by PCR and Sanger sequencing based
on cluster size (number of paired-reads with similar mapping patterns).
4.4.2 Sanger Sequencing Validation of TP53 Rearrangements In a LFS Family
Identified TP53 breakpoints were screened by PCR in all LFS family members of whom DNA
was available. Validation PCR with 120 ng DNA template were conducted using Jumpstart
REDAccuTaq LA DNA Polymerase (Sigma-Aldrich) following manufacturer’s instructions.
Where sample was insufficient, the genomic DNA was amplified using REPLI-g Mini Kit
(Qiagen) and 3 µl diluted amplification product were used as template for validation PCR.
PCR were performed using the following cycling conditions: 3 min at 94◦C, (20 s at 94◦C, 30
s at 58◦C, 2 min at 68◦C )x15, (20 s at 94◦C , 30 s at 55◦C , 2 min at 68◦C )x20, 5 min at
68◦C. For primer sequences see table 2 on page 135.
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Figure 13 – Workflow of Custom Sequence Capture and Bioinformatics Pipeline for
TP53 intron 1 breakpoint identification in a LFS Family. Custom capture of the TP53 region
and its rearrangement partners, based on biotinylated RNA probes, is depicted on the left. Captured
fragments, including wildtype TP53 and chimeric fragments are sequenced using conventional paired-
end sequencing. The custom-built bioinformatics workflow is displayed on the right. Full-length
reads were trimmed to 40bp to increase mapping probability on chimeric regions, and clustered
according to their mapping patterns using an in-house developed pipeline. Read IDs contributing
to candidate SV are extracted and the full-length read sequence retrieved. Breakpoint contexts are
recreated using de-novo assembly. Validation was carried out using breakpoint PCR and subsequent
Sanger sequencing.
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4.5 RT-qPCR Expression Analysis of TP53 in LFS Family Samples
RNA was isolated from PAXgene Blood RNA Tubes using the PAXgene Blood miRNA kit
(Qiagen). RNA from fresh frozen tumor H2, and RNA from a tumor derived cell line, P13,
were isolated using RNAeasy Mini kit (Qiagen). The one step qRT-PCR was carried out
using QuantiTect Probe radiotherapy (RT)-PCR kit (Qiagen), with a total of 50 ng RNA
per PCR. The TaqMan primer/probe set (Life Technologies) was used for TP53 full length
(HS01034249) and the PrimeTime primer/probe set (Integrated DNA Technologies Inc.) for
transcripts encoding for ∆133p53 and ∆160p53 were designed using sequences from Marcel
and colleagues [141]. qRT-PCR were performed on a Bio-Rad CFX device. Cq values were
normalized against GAPDH as ∆Cq and displayed relative to normal blood control as ∆∆Cq
as fold-change (2−∆∆Cq).
4.6 Whole-Exome and Whole-Genome Sequencing of Osteosar-
coma
4.6.1 DNA and RNA Extractions
DNA and RNA was extracted from fresh-frozen tumor samples using a TissueLyser (Qiagen,
Germany) and the AllPrep DNA/RNA Micro or Mini Kit (Qiagen, Germany) according to the
manufacturer’s instructions. RNA was incubated with RNAse-Free DNase (Qiagen, Germany)
according to the manufacturer’s instructions. Constitutive DNA was extracted from whole
blood using QIAamp DNA blood mini kit (Qiagen Germany). DNA was eluted in elution
buffer (Qiagen, Germany) and RNA was eluted in nuclease-free H2O (Ambion / Thermo
Fisher Scientific, USA). Quality of both RNA and DNA was assessed by Nanodrop and 2100
Bioanalyzer (Agilent Technologies, USA).
4.6.2 Library Preparation for Illumina Whole-Exome Sequencing
Exome enrichment was performed using the SureSelect target capture kit (version 4, Agilent
Technologies, USA). Samples were quantified using the Qubit system (Invitrogen, USA) and
sequencing libraries constructed from 1µg DNA. Samples were sequenced using the Illumina
HiSeq 2000 platform as paired 100-bp reads with Chemistry version 3.0, with the aim of
target coverage of 100x for the blood DNA and 200x for the tumors.
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4.6.3 Bioinformatics Pipeline for Illumina Whole-Exome Sequencing of 31 OS
Exomes
Bioinformatic processing of Illumina sequencing data was performed on a Linux server
running Ubuntu, or a cluster system running CentOS with the Univa Grid Engine scheduler.
The below workflow is visualized in figure 14 on page 140.
Initial quality control of base-called fastq-files was performed using FastQC [239] to assess
base quality, sequencing adapter contamination, and kmer enrichment, amongst other indica-
tors. If necessary CutAdapt [240] was used to trim off low quality bases or to remove adapters.
Reads were mapped with Stampy [241] version 1.0.12 onto the Human Reference Genome
(GRCh37d5/hg19) and PCR duplicates were removed using Picard. Resulting Sequence
Alignment/Map format (SAM) files were converted to the binary binary Alignment/Map
format (BAM) format and indexed using SAMtools [242]. SNV and small insertion/deletion
(InDel) were called with the Platypus variant caller [243] version 0.5, using the bam files
of tumor-normal pairs together to ensure comparable calls at every locus. Variants were
only called if they were assigned a sufficiently high posterior probability (phred score >20).
Variants with an assigned PASS quality flag were used for further analysed. Variants called
with an allele bias flag were also included to increase sensitivity for potentially subclonal
mutations. Finally, for selected variants, we made sure that the automatic call matched the
data by expert visual inspection of the mapped reads onto the reference genome using the
standard integrated genomic viewer [244] and its read direction colouring scheme. Somatic
mutations were identified by comparison of matched constitutional and tumor samples.
Variant annotation for both somatic and germline variants was performed by ANNOVAR
[245], using hg19 reference genome and 2014 versions of standard databases and functional
prediction programs. To reduce false-positive calls, we excluded duplicated genomic regions
(>90% homology) from the analysis and variants within regions with low mappability
scores. Variants were annotated with ANNOVAR Refseq gene model using dbSNP(135); 1,000
genomes project allele frequencies (October 2014), 6,500 exome-sequencing project allele
frequencies, University of Santa Cruz (UCSC) segmental duplication scores and UCSC 46
species conservation scores and predictions of functional importance from SIFT, PolyPhen2
and MutationTaster.
For the analysis of mutation burden and mutation spectra, we applied the following exclusion
filters to somatic variants: (i) presence in a segmental duplication region or a region with
mapability score <0.5; (ii) variant is present in any read from the paired normal sample; (iii)
fewer than 10 reads in total at the variant site in the normal sample; (iv) fewer than 8 reads
in total in the tumor; (v) fewer than three variants in the tumor; variant allele frequency <5%
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in the tumor; and (vi) presence of variant in public databases (Exome Variant Server, 1,000
genomes project and Complete Genomics 69 reference genomes) at a frequency of >2%.
Variants identified in constitutional DNA from any of the other local, non-cancer sequencing
projects (for example, 29 million variants across 284 samples from the Oxford-Illumina
WGS500 consortium) were discarded as being more likely based on a systematic error in our
sequencing pipeline than on a genuine somatic mutation.
4.7 Bioinformatics Pipeline for Illumina Whole Exome Sequenc-
ing of OS Cases with RET Germline Mutations
The pipeline for Whole Exome Sequencing was as described in section 4.6.3 on page 138,
with the following deviations: Reads were mapped to the human hs37d5 reference genome
using BWA [246] version 0.7.12-r1039. Where available, reads from whole genomes and
exomes were pooled for Platypus SNV and small InDel calling. Annotation was performed
using ANNOVAR (release date version 2016-02-01) with the hg19 reference genome and
2015 versions of standard databases and functional prediction programs. In addition to
databases described in section 4.6.3 on page 138, ANNOVAR was used to also annotate the
variants with the ExAC database of variant frequencies.
4.7.1 Mutation Spectra, Somatic Signatures and Analysis of Mutation Burden
For each tumor with exome sequencing or whole-genome sequencing data available, mutation
burden in terms of somatic SNV frequencies were calculated and the deviation of their spectra
from the background (determined across all samples) was assessed using χ2-test (df=5).
The trinucleotide spectrum was normalized according to 3-mer frequencies in the reference
exome (Agilent SureSelect version 4). Somatic mutation signatures were inferred using the
R package SomaticSignatures [247, 248], in which a mutation spectrum was decomposed
with a non-negative matrix factorization algorithm. The decomposition was performed for
prior sets of 2, 3 ,4, 5, 6 and 10. The optimal number of signatures was manually chosen
based on the maximum differentiation between the signatures. The signature analysis was
repeated 10 times with the same results obtained after each run.
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Figure 14 – Bioinformatics pipeline workflow for quality control, mutation calling and
annotation of Illumina exome-sequencing data. Input data (gray trapezoid) in form of
base-called fastq files were quality checked using fastqc and trimmed by CutAdapt based on base
quality or adapter sequences present in the reads. Reads were mapped to the Human Reference
Genome (GRCh37d5/hg19) by Stampy and BWA-MEM, PCR duplicates removed and the bam files
indexed. Platypus variant caller was used to identify SNV and small InDel which were assigned a
PASS or AllelBias quality flag. Variant annotation for both germline and somatic variants was done
with ANNOVAR. Somatic signatures and spectra were calculated using R.
4.7.2 Illumina Targeted Re-Sequencing
Biological replication was carried out using 1 µg of DNA from 92 additional tumors and
Illumina MiSeq re-sequencing to an average depth of 480x. The custom Nimblegen target
enrichment kit was used to capture all exons of 30 genes (that is, 13 main OS drivers and
their 17 interaction partners; see table 3 on page 141), and a ∼20-kb region encompassing
the TP53 gene Repetitive elements and other sequence features of the desired capture region
allowed a probe coverage of 92%. Read mapping, filtering and variant calling was done with
the Stampy-Platypus pipeline using the same setting as described above for Whole Exome
Sequencing.
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Gene Symbol Description Chromosome Position
APC APC, WNT signaling pathway regulator chr5 112043201-112181936
ATRX ATRX, chromatin remodeler chrX 76760355-77041755
CCND1 cyclin D1 chr11 69455872-69469242
CDKN1A cyclin dependent kinase inhibitor 1A chr6 36644236-36655116
CDKN2A cyclin dependent kinase inhibitor 2A chr9 21967750-21994490
EP300 E1A binding protein p300 chr22 41488613-41576081
ERBB4 erb-b2 receptor tyrosine kinase 4 chr2 212240441-213403352
FANCA Fanconi anemia complementation group
A
chr16 89803958-89883065
FAS Fas cell surface death receptor chr10 90750315-90776818
LIMCH1 LIM and calponin homology domains 1 chr4 41361623-41702061
MDC1 mediator of DNA damage checkpoint 1 chr6 30667583-30685458
MUTYH mutY DNA glycosylase chr1 45794913-45806142
MYCN v-myc avian myelocytomatosis viral onco-
gene neuroblastoma derived homolog
chr2 16080559-16087129
NUMA1 nuclear mitotic apparatus protein 1 chr11 71713909-71791739
PPP2R3B protein phosphatase 2 regulatory subunit
B”beta
chrX 294667-347690
PTEN phosphatase and tensin homolog chr10 89623194-89731687
PTENP1 phosphatase and tensin homolog pseudo-
gene 1
chr9 33673501-33677418
PTPRZ1 protein tyrosine phosphatase, receptor
type Z1
chr7 121513158-121702090
RB1 RB transcriptional corepressor 1 chr13 48877882-49056026
RECQL4 RecQ like helicase 4 chr8 145736666-145743210
RET ret proto-oncogene chr10 43572516-43625797
RREB1 ras responsive element binding protein 1 chr6 7107829-7252213
RUNX1 runt related transcription factor 1 chr21 36160097-36421595
RUNX2 runt related transcription factor 2 chr6 45296053-45518819
RUNX3 runt related transcription factor 3 chr1 25226001-25291501
SFPQ splicing factor proline and glutamine rich chr1 35641978-35658746
STAT3 signal transducer and activator of tran-
scription 3
chr17 40465342-40540513
TP53 tumor protein p53 chr17 7571719-7590868
TTN titin chr2 179390716-179672150
ZNF276 zinc finger protein 276 chr16 89786775-89807332
Table 3 – Genes included in the custom target capture sequencing for biological repli-
cation of osteosarcoma sequencing. Based on results from an exome sequencing of 31 OS cases
the genes listed above were used for re-sequencing of a replication cohort consisting of 92 additional
tumors. Sequencing is further described on page 140. Genomic coordinates given are referring to the
Human Reference Genome (hg19).
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4.7.3 Illumina Whole Genome Sequencing of OS Cases with RET Germline
Mutations
DNA samples were quantified using the Qubit system (Invitrogen, USA ) and sequencing
libraries constructed from 0.5 µg of DNA. Samples were sequenced using the Illumina
HiSeq 2000 or 4000 platform as paired-end 100-bp reads with Chemistry version 3.0. A
minimum target coverage of 15x was aimed for. Quality control, removal of PCR duplicates
and Stampy/BWA mapping was done using the bioinformatics pipeline used for exome
sequencing which was described in section 4.6.3 on page 138.
4.7.4 Classification of RET Mutations
Mutation Classification by ATA Guidelines
The correlation between mutations and HSCR/MEN can be complex. Therefore, the American
thyroid association has released detailed treatment guidelines for thyroid cancer based on RET
mutations [209]. Described mutations are classified into the risk levels ATA-A (lowest risk)
to ATA-D (highest risk). Independent of symptoms, prophylactic thyroidectomy is generally
recommended before the age of 5 for carriers of mutations of class ATA-A to ATA-C, and
before age 1 for carriers of class ATA-D mutations (mostly MEN2B).
Mutation Classification Based on American College of Medical Genetics and Genomics
(ACMG)
The ACMG has developed standards for the interpretation of germline sequence variants
[249], which are widely used by geneticists in clinical settings. The ACMG recommends
the classification of variants into the groups ’pathogenic’, ’likely pathogenic’, uncertain
significance’, ’likely benign’, and ’benign’. This classification is based on a broad spectrum of
possible evidence, such as population data, in silico predictions, functional data, segregation
data in affected families, and de novo occurrence. These criteria are combined according to a
matrix which then leads to the classification of a variant into the above groups. Depending
on the nature and strength of the observations, the evidence can further be classified into
supporting, moderate, strong, or very strong evidence for pathogenicity or benignity. So shall,
for example, the fact that a suspected disease causing variant is found de novo in a patient
be classified as ’moderate pathogenic’ evidence, until maternity and paternity is confirmed,
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upon which the evidence can be reclassified as ‘strong pathogenic’ It should be noted that the
ACMG guidelines have been developed for the interpretation of germline variants. Somatic
mutations, as found in cancer cells, introduce several additional layers of complexity, such as
tumor heterogeneity and -purity of the sample.
4.7.5 Structural Variant Detection From Conventional Whole Genome Sequenc-
ing
Structural variants were predicted from whole-genome sequencing data using Breakdancer
[250] version 1.4.5 and the Human Reference Genome GRCh37d5. Candidate rearrangements
which were present in a normal control genome, or mapping to any decoy chromosome or
having less than 6 supporting reads were removed.
4.8 RNA-Sequencing of Osteosarcoma
4.8.1 Library Preparation and Sequencing
Ribosomal RNA was depleted from total RNA using the Ribo-Zero rRNA Removal Kit (Illumina,
USA), and subsequently converted to cDNA. The cDNA was end-repaired, A-tailed and adapter-
ligated. The resulting libraries were size-selected and quality was assessed. The finalized
libraries were paired-end sequenced with 75-bp reads on an Illumina HiSeq 4000 over one
lane of a flow cell.
4.8.2 Fusion Gene Prediction from RNA Sequencing Data
Base-called fastq files were quality-assessed by FastQC [239]. For each sample, 45 million
reads were used for analysis. Fusion gene predictions were performed with Fusioncatcher
software [251] version 0.99a with the ensembl v84 database and EricScript [252] version
0.5.5 with the provided ensembl database for human transcripts. To reduce false-positives,
candidates were only included for further analysis if they were predicted by both prediction
tools, or if at least one of the rearrangement partners included a bona fide OS driver gene or
a tyrosine kinase.
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